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Aims of this thesis
This thesis describes studies that all strive towards ‘Knowledge-based treatment of uveal 
melanoma’ and involves three different yet related topics. 
The first part of this thesis analyzes the role of the tumor microenvironment and of malig-
nant development of blood vessels in uveal melanoma and potential treatments. 
The second part explores future treatment options in uveal melanoma by development and 
identification of specific targets for treatment. 
The third part focuses on the evaluation of potential cancer treatments and explores dif-
ferent molecular mechanisms that play a role in uveal melanoma growth and dissemination.
Uveal melanoma
Ocular melanoma accounts for only 5% of all melanomas and arises in four ocular tissues, 
namely the uveal tract, conjunctiva, eyelid, and orbit. Uveal melanoma (UM) is the most 
common of the ocular melanomas (85 %) with an annual incidence of seven cases per million 
adults per year in Caucasian populations, and develops in the uvea which consist of the iris, 
ciliary body and choroid. Most melanocytic tumors of the uveal tract arise in the choroid 
(80 %), which is one of the most capillary-rich tissues of the body 1. Symptoms of a uveal 
melanoma include blurred vision, flashing lights and seeing shadows. Often, there are no 
symptoms, and therefore 30 % of the tumors is only discovered during routine examination 2.
Although much progress has been made in the last decades in the local treatment of uveal 
melanoma, prognosis is still poor. Uveal melanoma often is a deadly disease, with a 5-year 
mortality ranging from 26% to 32% 3. Uveal melanoma spreads hematogeneously, mainly to 
the liver 4. In case of metastases, life expectancy is merely a few months (2-6 months) 5.
Mechanisms involved in uveal melanoma development are largely unknown. Uveal mela-
noma is approximately 20 to 30 times more common in white people compared to black and 
Asian people 6. In addition, light skin color and light iris color are established risk factors 7,8. 
Still, unlike cutaneous sun-related malignancies, ultraviolet light exposure does not appear 
to be a consistent riskfactor in uveal melanoma 9
Other known risk factors related to survival are histologic cell type, tumor diameter, tumor 
location, age, and gender 10. Loss of chromosome 3 is one of the most significant predictors 
for uveal melanoma-related death 11,12. In addition, concurrent loss of chromosome 1p and 
6q and additional copies of 8q and 6p have also been shown to be potentially implicated in 
uveal melanoma survival 13,14. Furthermore, a gene expression-based molecular classification 
has been described 15,16. Tumors with a class 2 molecular “signature” are at high risk for the 
development of metastatic disease compared to tumors with a class 1 “signature”.
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Treatment of metastatic and primary uveal melanoma
Regarding metastatic uveal melanoma, current available treatments include chemotherapy, 
intra-hepatic arterial liver perfusion, chemoembolization and local resection 17-19. Although 
some individual successes have been described using these treatments, unfortunately, the 
overall survival can as yet only be prolonged with a few months 20. 
In case of primary UM, several treatment options are available. For tumors with a promi-
nence of more than 10 mm (or 8.0 mm near the disc), enucleation is often the first choice 
of treatment. Small to medium-sized tumors with a prominence of less than 10 mm can 
be treated with proton beam therapy, stereotactic irradiation, or (plaque) brachytherapy, 
occasionally in combination with transpupillary thermo therapy (sandwich therapy) 21-23,23-25. 
Radiation therapy results in destruction of the intraocular tumor, either through direct dam-
age to a cell’s DNA, which blocks cell division, or through damage to capillary endothelium, 
affecting the tumor’s blood supply 26-28. Brachytherapy is a highly successful treatment, 
achieving local tumor control of UM in 90-97% of the cases 29,30. Unfortunately, radiation 
therapy is also associated with a range of complications, including hemorrhages into the tu-
mor or the vitreous, cataract, optic neuropathy, and most commonly, radiation retinopathy. 
Radiation retinopathy 
Radiation retinopathy is a slowly-progressive, delayed-onset disease of retinal blood vessels 
due to changes in the structure and permeability of retinal vessels 31-33, and has been described 
to occur in up to 63% of eyes after plaque radiation treatment 34-37. On average, the onset of 
radiation retinopathy occurs at 26 months after radioactive plaque therapy 38. 
Ophthalmoscopic and fluorescein-angiographic findings characteristic of radiation reti-
nopathy include macular changes such as macular edema, capillary non-perfusion, cotton 
wool spots, capillary telangiectasia, retinal neovascularization, micro aneurysms, retinal 
hemorrhages, intraretinal exudation, and neuronal changes: disc edema, disc pallor, optic 
atrophy, and neovascularization of the disk 31 (Figure 1). 
Clinically, these signs are often identical to the findings seen in diabetic retinopathy. The 
threshold for radiation retinopathy depends on the total dose, the volume of irradiated retina, 
the fractionation scheme, and individual factors. In general, a greater total dose results in 
earlier, more severe and more pronounced radiation retinopathy 39. In spite of radiation dose 
reduction during the last decade, vision loss after therapy remains extensive, particularly 
vision loss due to macular edema. In one follow-up study, out of 31 uveal melanoma patients 
with a moderate to good vision ( ≥ 20/60 or 0.3) before radiation treatment, 5 years later, 







Angiogenesis and anti-angiogenic therapy
Retinal ischemia and leaking vessels are the two most relevant factors in radiation retinopa-
thy. It has been observed that 55% of eyes, that underwent enucleation after plaque radia-
tion for treatment failure, demonstrate vascular anomalies 34. As yet, there is no effective 
treatment to reverse visual loss from ischemic maculopathy due to capillary nonperfusion 
31. However, several anti-angiogenic agents have been used to resolve macular edema and 
prevent neovascularization. Corticosteroids such as triamcinolone acetonide (TA) have been 
shown to improve vision for a few months in patients with macular edema associated with 
diabetic retinopathy 40-43 and in patients with exudative age-related macular degeneration 
(ARMD) 44. In addition, a recent study reported a temporary positive effect of intravitreal 
TA injections in a group of 31 patients with radiation maculopathy 45. Vascular endothelial 
growth factor (VEGF) is a pro-angiogenic factor that has a crucial role in the formation of 
new vessels and most likely contributes to the pathogenesis of radiation retinopathy. Hence 
anti-angiogenic treatments that target VEGF, such as bevacizumab and ranibizumab, are 
also used for radiation retinopathy. Anti-angiogenic treatments are further discussed in 
(Chapter 3)
Angiogenesis is an important process in both radiation retinopathy and tumor progression. 
Besides the supply of oxygen and nutrients, tumor-associated vessels promote metastasis by 
facilitating tumor cell entry into the circulation 46. Unquestionably, this phenomenon plays 
a role in uveal melanoma, which metastasizes almost completely hematogenously 4,5. Several 
studies have shown that in uveal melanoma a high vascular density and ingrowth of tumor 
Figure 1. Radiation retinopathy due to Ruthenium brachytherapy of a choroidal melanoma.
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cells into the lumen of tumor blood vessels or into a scleral vessel is associated with poor 
survival 47-49. Furthermore, uveal melanoma cells are capable of forming a second microcircu-
lation consisting of “looping” patterns of extracellular matrix independent of angiogenesis, 
called vasculogenic mimicry 50. The potential to target tumor vessels has been investigated 
for these past decades in several malignancies and mainly focuses on the key mediator of 
angiogenesis, which is VEGF. Tumor angiogenesis, the role of VEGF, and anti-angiogenic 
therapy in cancer and particularly uveal melanoma is further reviewed in Chapter 3.
Targeted therapy
Cancer growth depends on many different mechanisms, such as cell proliferation, angiogen-
esis etc. as described earlier. The combination of different treatments will probably render 
tumor therapy successful in the future. However, two main obstacles have to be overcome; 
a specific and effective drug-delivery, and early detection of (micro) metastases. In uveal 
melanoma, the general accepted hypothesis is that the tumor remains dormant in the bone 
marrow and liver until becoming clinically detectable in the liver 51. Identification and 
inhibition of such micrometastases will prevent the occurrence of ‘full-blown’ metastatic 
disease and possibly improve survival in uveal melanoma patients. Effective drug-delivery 
that induces apoptosis and targets angiogenesis and cell signalling through uveal melanoma-
specific ligands would be beneficial. 
Other approaches may be immunological. Exploration of (cutaneous) melanoma-derived 
autoantigens and cell surface receptors has revealed potential targets in uveal melanoma. 
Currently, the most specific uveal melanoma markers include S-100 (specific for a protein 
derived from bovine brain cross-reacting with melanoma and melanocytes), HBM45 (spe-
cific for gp100) and A103, (recognizes the Melan-A/Mart-1 protein) 52-54. Sadly, most of these 
receptors do not exhibit specificity for uveal melanoma and are also expressed by mela-
nocytes or possibly other neural crest-derived cells, and treatment could cause significant 
side-effects.
Proliferation pathway
What do we know regarding the development and growth of a primary uveal melanoma? 
Although cutaneous melanoma and uveal melanoma share the same embryonic origin, 
no similarities can be found regarding mutations that regulate proliferation and cause loss 
of cell cycle control. Activation of the MAPK pathway in cutaneous melanoma occurs for 







mutations have been demonstrated in uveal melanoma, though relatively uncommon and 
are therefore less relevant in this disease 57. 
Recently, mutations in uveal melanoma tissue were identified in the GNAQ and GNA11 
genes which are located on chromosome 9 and 19, respectively. GNAQ and GNA11 encode 
for Gαq-type subunits of the heterotrimeric G-protein. Mutations of glutamine encoding 
codon 209 and (less frequently) R183 can result in constitutive G-protein activation which 
mediates intracellular signals and activates the RAS-RAF-MEK-ERK or the classical 
mitogen-activated protein kinase (MAPK) pathway 58. MAPK activation is crucial in the 
development of melanocytic neoplasia and constitutive activation of this pathway has been 
associated with many different types of cancer 59,60. Mutations in the GNAQ gene were shown 
to be common in primary UM (45%) and in UM metastases (22%) 61. GNA11 mutations were 
present in 32% of primary UM and 57% of UM metastases 62,63. Cellular components that 
couple GNAQ/GNA11 to MAPK signaling are most likely the effectors IP3, Src tyrosine 
kinase 64 and PKC 65.
Src and kinase inhibitors
Src is one of the longest known proto-oncogenes and is named after its viral counterpart 
v-Src, which was first described by Peyton Rous almost 100 years ago 66,67. Since then, expres-
sion and involvement of Src has been demonstrated in several malignancies implicating four 
‘hallmarks’ of cancer; proliferation, angiogenesis, cell survival and migration 66,68,69.
Increased Src signalling correlates with decreased E-cadherin expression and decreased 
cell-cell adhesion 70,71. In addition, downstream substrates of Src seem to act largely in paral-
lel to increase cell proliferation and survival 67. Furthermore, Src activation is associated with 
increased expression of proangiogenic cytokines such as VEGF, and thus tumor angiogenesis 
72,73. 
Interestingly, several commercially-available pharmacologic agents are able to inhibit Src. 
Dasatinib for instance is a small-molecule inhibitor taken orally that has been demonstrated 
to inhibit proliferation in several malignancies in vitro 74,75 (Figure 2). Like most tyrosine 
kinase inhibitors, dasatinib also variably inhibits other (receptor) tyrosine kinases such as, 
BCR-ABL, c-KIT, PDGFR, and ephrin A2 74,76. 
Outline
The first part of this thesis, Chapter 2 and 3, describes the literature regarding tumor an-
giogenesis, the role of vascular endothelial growth factor as key mediator of vessel growth, 
and the potential of anti-angiogenic therapies that are approved for treatment of several 
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malignancies or may be used in the future. Implications and studies involving uveal mela-
noma are highlighted in particular. In the second part, Chapter 4, tumor angiogenesis in 
uveal melanoma is experimentally analyzed. We demonstrate the involvement of hypoxia 
and the HIF-1α pathway in the induction of VEGF expression in uveal melanoma cell lines 
and cultures. In addition, we describe the association of high VEGF expression in sera of 
patients and the presence of uveal melanoma related metastases. In Chapter 5, we analyze the 
effect of two frequently used anti-angiogenic intraocular drugs for the treatment of radiation 
retinopathy caused by irradiation of uveal melanoma. Since local recurrences develop in 
some cases, the possibility that there are still living uveal melanoma cells present in eyes 
treated with radiotherapy cannot be excluded 77. We found that triamcinolone acetonide 
and anecortave acetate do not stimulate uveal melanoma cell growth in vitro, and therefore 
most likely will not give rise to recurrences. On the contrary, we demonstrate in Chapter 6, 
that bevacizumab induces intraocular tumor growth in mice. Although bevacizumab did 
not stimulate UM cell proliferation in vitro, VEGF expression via the HIF-1α pathway was 
induced, resulting in a ‘pseudohypoxic’ condition. This phenomenon has been described 
in other tumor types and may be the consequence of tumor adaptive or evasive resistance.
Part III describes the search for specific uveal melanoma ligands to be used for targeted 
therapy or early identification of micrometastases. Somatostatin receptor subtype 2 (SSTR2) 
for instance is expressed in several tumors, and synthetic radiolabelled antagonists like 
octreotide and octreotate are already being used as diagnostic or therapeutic agents for 
gastroenteropancreatic and neuroendocrine tumors 78-81. Although uveal melanoma cells 
and somatostatin-producing cells both originate from the neural crest, a low expression of 
SSTR2 was found in primary uveal melanoma specimens and in uveal melanoma cell lines. 
Furthermore, SSTR2 expression was not associated with tumor-free survival or any known 
prognostic factor (Chapter 7).
Figure 2. Dasatinib treatment (right) inhibits Src kinase-related lysate activity in metastatic uveal tissue 







On the contrary, we describe in Chapter 8 the identification of uveal melanoma-specific 
peptides (UMAPs) by in vitro panning using phage peptide libraries. Additionally, synthetic 
constructed peptides were shown to successfully internalize targeted UM cells.
In the final chapters of this thesis, the findings of all experiments are summarized and 
future implications and treatment options are discussed.
Finally, part IV describes the implication of the classical mitogen-activated protein kinase 
(MAPK) pathway in uveal melanoma. In Chapter 9, we identify Src as a determinant of 
ERK1/2 activation and show that Src expression and kinase activity together with ERK1/2 
activation is reduced in UM metastases cell lines compared to primary UM cells. In addi-
tion, we demonstrate in Chapter 10 the inhibition of MAPK activation via Src using the Src 
kinase inhibitor Dasatinib. Growth arrest was achieved in 60% of the tested UM cultures 
and the potential of growth inhibition may be predicted by MAPK and Src kinase activity. 
Furthermore, the sensitive cell cultures predominantly displayed monosomy 3 and, in a large 
set of UM samples, Src expression level was significantly associated with monosomy 3. 
In summary, knowledge of side effects of current intraocular treatments prevents recur-
rences and may protect the uveal melanoma-containing eye, and hence preserve vision.
Pre-clinical evaluation of treatment efficacy and safety based on tumor physiology renders 
the possibility of new treatment options to treat and/or prevent metastases.
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2.1 Uveal melanoma and angiogenesis
Tumor cells may leave the enclosure of the eye by intravascular spreading, by outgrowth 
through the trabecular meshwork or by migrating along blood vessels or nerves. Seddon 
et al. determined that in uveal melanoma the 10-year mortality without extraocular exten-
sion was 31%, and with extraocular extension 75% 1. Recent studies looked at tumor cell 
ingrowth in blood vessels within the tumor, and in the sclera, and observed a strong correla-
tion between any ingrowth of tumor cells into blood vessels and poor survival 2,3. Extraocular 
extension was correlated with the grade of malignancy of the tumor itself, such as the pres-
ence of monosomy 3. The presence of intravascular tumor cells was strongly correlated to 
intrascleral invasion. These data indicate the important role of blood vessels in the clinical 
course of uveal melanoma.
The amount of blood vessels is also related to prognosis: when looking at areas with a high 
MVD, one can identify so-called “hot spots” of vascular density 4-6, which in some studies 
showed a correlation with death. Mäkitie et al. studied vessel density in a group of 134 uveal 
melanomas, using the CD34 monoclonal antibody to identify blood vessels: a high MVD 
was associated with the presence of epithelioid cells, a high largest basal tumor diameter and 
tumor height, and a decreased survival 7. In addition, a high MVD was associated with an 
increased density of TAM 8.
Turning on angiogenesis, known as the angiogenic switch, is an important early event 
in tumor growth, including uveal melanoma. Angiogenesis often occurs as a response to 
intra-tumoral hypoxia, which leads to an upregulation of the transcription factor HIF-1α 
and expression of its target gene VEGF. In many types of cancer, intra-tumoral hypoxia, 
overexpression of HIF-1α, and increased microvascular density are found to be associated 
with tumor progression and poor prognosis 9,10. Fluorescein angiography shows that the 
formation of new vessels is an early feature that discriminates between uveal melanoma 
and choroidal nevi. The main uveal melanoma blood vessels are connected to the choroidal 
and not the retinal vasculature, and fluorescein angiography may thus show a dual circula-
tion. Uveal melanoma blood vessels may lack endothelial cells, and their walls are extremely 
thin while their lining often shows disruptions when tumor cells penetrate into the vessel 
lumen 11.The presence of new vessels is critical for tumor growth, as diffusion of oxygen and 
nutrients becomes limited when tumor size increases 12.Tumor blood vessels are considered 
to arise as an outgrowth of the local vascular bed (angiogenesis). But what determines the 
growth of new blood vessels in uveal melanoma?
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2.2. VEGF and regulation of angiogenesis
VEGF is one of the most important angiogenic factors, with a potent vasopermeability func-
tion. Uveal melanoma cell lines produce VEGF as well as Platelet-Derived Growth Factor 
(PDGF) 13,14. VEGF is present in the vitreous and aqueous of uveal melanoma-containing 
eyes, and has prognostic value 15-17. While increased levels of VEGF have been reported in 
uveal melanoma eyes, with significant VEGF production by stromal cells and tumor cells. 
However, immunohistochemical studies do not show a universal picture: some studies us-
ing immunohistochemistry observed VEGF expression in at least 25% of uveal melanomas 
18-21, while others reported a lack of VEGF expression in uveal melanoma 22-24. The variable 
expression patterns of VEGF protein and mRNA reported in uveal melanoma 15,16 most 
likely reflect variations in fixation, tissue-processing techniques and antibody specificity (for 
example, to VEGF splice variants). Epigenetic mechanisms may also be involved in VEGF 
overexpression in ocular melanomas 19.
Missotten and others observed a correlation between VEGF levels in the aqueous humor 
and an increased basal tumor diameter, as well as with ciliary body involvement 177. Patients 
with uveal melanoma metastases often have increased levels of VEGF in their serum (Fig 1) 
25.
While tumor cells may be the source of VEGF, other ocular sources of VEGF may include 
retinal Müller cells or neurons overlying the tumor, RPE cells disrupted during tumor growth, 
or macrophages inside or outside the tumor (see below). Vinores and others observed that 
Figure 1. Concentration of serum VEGF-A in (metastatic) UM patients and controls. 
Concentration of serum VEGF-A in the control group, and in patients with and without metastatic uveal 
melanoma. P-values (Mann–Whitney test) between the different groups are indicated in the graph. Each box 
shows the median, quartiles (box length is the interquartile range) and whiskers represent the 90th and 10th 
percentiles. Reproduced with permission from “Regulation of VEGF-A in uveal melanoma”, by El Filali et al. 







eyes containing a uveal melanoma expressed VEGF in ganglion cells, in vessel walls within 
the inner retina, and in the RPE, ciliary body and iris 20. Analysis of frozen tumor sections 
revealed expression of VEGF mRNA in quite a large number of tumors, while short-term 
cultured primary uveal melanoma cells or uveal melanoma cell lines often expressed and 
produced VEGF (Fig. 2) 25,26. Exposure of cultured tumor cells to hypoxia greatly induced 
the production of VEGF, and this may also play an important role in tumor angiogenesis. 
Similar to the situation in other solid tumors, outgrowth of uveal melanoma combined with 
limited oxygen diffusion probably leads to local areas of tumor ischemia, and thus hypoxia. 
This hypoxia subsequently induces HIF-1α, which stimulates VEGF production by oxygen-
deprived tumor cells and tumor-associated macrophages. Ocular studies using a retinal laser 
photocoagulation model showed that macrophages directly stimulate angiogenesis, since 
a reduction of choroidal neovascularisation took place when macrophages were removed 
prior to laser treatment 27.
A similar situation may occur in uveal melanoma metastases, which may remain dormant 
for many years. It may well be that dormancy depends on the (temporary) lack of vasculari-
sation in metastases. Preventing angiogenesis may be a useful therapy in this phase of the 
disease 28. What triggers the metastatic cells to become active, often many years after enucle-
ation of the melanoma-containing eye, remains elusive, but it may be that local macrophage 
accumulation plays a stimulatory role.
That hypoxia may influence malignant tumor-cell behaviour is well-illustrated by in vitro 
work by Victor et al., using the MUM2B uveal melanoma cell line. Exposure of these cells to 
Figure 2. VEGF-A mRNA expression in primary UM cell cultures following exposure to hypoxia.
The amount of VEGF-A mRNA expression was measured with quantitative real-time RT-PCR in primary 
UM cell cultures (cultures 1–5) under normoxic (black) and hypoxic (gray) conditions after 24 h. Expression 
is demonstrated in normalized fold. Reproduced with permission from “Regulation of VEGF-A in uveal 
melanoma”, by El Filali et al. (2010) via Copyright Clearance Center.
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an hypoxic environment induced several changes in RNA expression including upregulation 
of CXCR4, angiopoietin-related protein, pyrovate dehydrokinase 1, integrin β8 and others, 
and increased tumor-cell migration, invasion and adhesion 29. Cells transfected with siRNA 
directed against HIF-1α did not show an increase in any of these characteristics, suggesting 
that HIF-1α-mediated processes were involved.
2.3 Uveal melanoma and matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that can 
degrade most extracellular (ECM) components. Secreted and transmembrane MMPs play a 
major role in tumor invasion and metastasis, and are important in angiogenesis, inflamma-
tion, apoptosis, cell-surface protein-shedding, release and activation of ECM-sequestered 
growth factors such as Transforming Growth Factor (TGF)-β and Fibroblast Growth Fac-
tor (FGF)-2, and signal transduction 30,31. MMPs are generally constitutively expressed at 
low levels, and production is tightly regulated at the level of transcription as well as post-
transcription by cytokines, growth factors and hormones, and by changes in cell–cell and 
cell–ECM interactions. MMPs are mostly secreted in latent (proMMP) forms and activated 
in the extracellular space by serine proteases such as plasmin, urokinase plasminogen activa-
tor (uPA) or by other MMPs, including membrane-type (MT)-MMPs. EMMPRIN (CD147, 
extracellular MMP inducing protein) can induce MMP production by stromal cells such as 
fibroblasts and endothelial cells, and can regulate VEGF and MMP production in tumor an-
giogenesis 32. Tissue Inhibitors of MMPs (TIMPs) may modulate MMP activity, and regulate 
cell proliferation, angiogenesis, and apoptosis.
In uveal melanoma, MMPs have been implicated in both angiogenesis and vasculogenic 
mimicry due to their ability to degrade vascular basement membranes as well as to activate 
growth factors such as VEGF and TGFβ 33-36. MMP-2, -9 and MT1-MMP have been reported 
to facilitate tumor angiogenesis, cell migration, and invasion 30,37,38. Consistent with these 
observations, (latent and active) heterogeneous MMP-1, -2, -9 and MT1-MMP expression 
has been observed in uveal melanomas, including on the tumor vasculature 39 (Fig. 3). 
In primary uveal melanoma, the presence of VEGF-A and MMP-9 is associated with 
metastasis formation 40. Heterogeneous EMMPRIN expression was observed on primary 
uveal melanomas, in association with MMP-expressing fibroblasts, particularly at tumor 
edges (Fig. 4). Melanomas with a mixed and epithelioid morphology generally expressed 
higher levels of EMMPRIN, assessed with immunohistochemistry. In vitro studies showed 
that EMMPRIN-expressing uveal melanoma cells co-cultured with choroidal fibroblasts can 
induce fibroblast MMP-2 production and activation.
In uveal melanoma, immunohistochemistry, gene array, and in vitro studies collectively 







Figure 3. Immunoperoxidase labelling of MMP-1, -2 and -9 in uveal melanoma. A and B. 
Tumor cells immunolabelled for MMP-1, although not at the tumor-sceral interface (TSI). B. Tumor cells 
are also seen within a blood vessel (bv) C and D. Blood vessels (bv) show strong MMP-2 immunostaining, 
with little or no MMP-2 immunostaining of tumor cells. E and F. MMP-9 immunostaining of tumor cells and 
vasculature within uveal melanoma. As seen in E, the pattern of MMP-9 immunostaining appears similar to 
the extravascular matrix patterns seen with PAS staining. An MMP-9 positive intravascular leukocyte is also 
visible in F. (TSI – tumor-scleral interface; bv – blood vessel; hematoxylin counterstain).
Figure 4. Co-immunolabelling for MMP-2 and EMMPRIN (CD147) in uveal melanoma, visualized using 
confocal microscopy. A and B.
Stromal cells (presumptive fibroblasts; arrowheads) near the tumour edge show strong MMP-2 
immunostaining (green). Tumor cells (M) display distinct cell-surface EMMPRIN immunostaining (red); (bv 
– blood vessel).
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with tumor invasion and vasculogenic mimicry 33,39,41. MMPs can mediate formation of the 
laminin-rich matrix via cleavage of laminin 5γ2 to form pro-migratory fragments 42,43. Block-
ing MMP activity in vitro using chemically-modified tetracyclines inhibits laminin 5γ cleav-
age, and downregulates MMP-2, -9, MT1-MMP, VEGF-C, VE-cadherin and TIE-1, inhibit-
ing vasculogenic mimicry 43. Gene-expression profiling of different phases of oncogenesis 
in uveal melanoma shows TIMP-3 (an MMP-inhibitor) downregulation during progression 
from melanocyte to metastasis 41. TIMP-3 immunoreactivity was also decreased in more 
aggressive, epithelioid/mixed uveal melanomas 39. Clinically, uveal melanoma expression of 
MMP-2 and -9 is associated with a higher incidence of metastatic disease, and patients with 
tumors expressing low levels of the MMP inhibitors TIMP-1 and -2 showed a worse survival 
44,45. As not only tumor cells but also macrophages can produce MMPs, inflammatory cyto-
kines and VEGF, they too are important for the (further) induction of local inflammation as 
well as angiogenesis. 
2.4 Angiogenesis and treatment
Anti-angiogenic therapy is currently being trialed for many types of cancer. With regard 
to uveal melanoma, several potential areas for the use of anti-angiogenic therapy can be 
identified: growth inhibition of an intraocular melanoma, growth inhibition of metastases, 
and treatment of side effects of ocular irradiation, i.e. radiation retinopathy. As treatment of 
intraocular tumors with different types of irradiation leads not only to inhibition of tumor 
growth but also to shrinkage of the tumor, additional treatment with angiogenesis inhibitors 
may not be needed. On the other hand, one might consider treatments with fewer side effects 
than irradiation, and that might include a combination of anti-angiogenic agents with local 
chemotherapy or immunotherapy. Attacking blood vessels too early may not be such a good 
idea, as this might stop the local distribution of chemotherapy. Treating suspicious large 
nevi with anti-angiogenic treatments might be an option, as an early change to malignancy 
includes the development of intra-tumoral blood vessels. However, closing blood vessels 
may have an unwanted effect related to reduced oxygen distribution and local hypoxia, 
selecting outgrowth of tumor cells that are more resistant to hypoxia and that have become 
less sensitive to irradiation. In addition, temporary vessel closure may be followed by local 
hypoxia, resulting in more vessel growth instead of less. Finally, primary uveal melanoma 
and metastases not only contain blood vessels but also extravascular channels. This addi-
tional tumor microcirculation (vasculogenic mimicry) provides a route for alternative fluid 
movement and perfusion within solid tumors, and in vitro, does not appear to be targeted by 
agents specific for vascular endothelial cells such as endostatin 46.
With regard to metastasis, one looks for therapies that may stimulate tumor-cell dormancy. 







have not developed their full vascularisation. We do not know whether systemic treatment 
with angiogenic inhibitors will help patients who have clinically significant liver metastases. 
El Filali and others observed that patients with uveal melanoma metastases often have in-
creased levels of serum VEGF (Fig. 5) 25. The first results from experimental studies of VEGF 
inhibitors to prevent the growth of metastases in mice are promising 47. Using bevacizumab, 
metastases outgrowth in the liver could be partially inhibited in a mouse model, using B16 
cells as well as human uveal melanoma cells. As combination treatments of anti-angiogenic 
and chemotherapy are nowadays recognized treatments of various types of cancer metas-
tases, the first trials for the treatment of uveal melanoma metastases will probably soon be 
underway. It is unfortunate, that growth inhibition by anti-angiogenic agents is often only 
temporarily, and combination therapies should be sought.
The third area where anti-angiogenic agents can be applied is in the treatment of radiation 
retinopathy, which may occur after irradiation of an intraocular or orbital tumor. Radiation 
retinopathy is a complication of radiation therapy and intraocular VEGF-A expression was 
shown to be particularly high in eyes developing secondary iris and retinal neovascularisa-
tion after receiving local radiotherapy 15,17,48. Several case histories or small series of cases have 
already been reported, with variable results.
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For several decades, targeting of tumor- related vessels has been regarded as a potential anti-
cancer therapy. Such anti-angiogenic therapy is based on the assumption that a tumor cannot 
grow beyond the limits of diffusion (about 1– 2 mm) of oxygen and nutrients from capillaries, 
unless angiogenesis takes place. Vascular endothelial growth factor (VEGF) plays a key role 
in angiogenesis, regulating vasopermeability as well as the proliferation and migration of en-
dothelial cells. In several types of cancer (colon carcinoma, soft tissue sarcomas and gastric 
cancer), serum VEGF levels are a marker for disease stage and an indicator of metastasis. 
VEGF levels are significantly elevated in uveal mela noma patients with metastatic disease 
compared to patients without metastases. Anti-angiogenic therapy, such as bevacizumab, 
is currently used for the treatment of metastases of several malignan cies. Anti-angiogenic 
therapy has not yet been tested for the treatment of primary uveal melanoma or related 
metastatic disease. Clinicians, however, have a broad experience with anti-angiogenic agents 
in patients with uveal melanoma by treating the complications of radiation therapy. We will 
discuss tumor angiogenic processes and related molecular pathways in uveal melanoma. 
The role of VEGF and the potential use of current commercially and experimentally avail-
able anti-angiogenic drugs for the treatment of primary uveal melanoma and/or metastatic 
disease will be explained below. 
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The targeting of tumor-related vessels has been investigated for several decades. The funda-
mental belief that a tumor cannot grow beyond the limits of diffusion (about 1– 2 mm) of 
oxygen and nutrients from blood vessels has been advocated since the 1970s. Dr. J. Folkman 
has played a pivotal role, describing the molecular aspects of tumor angiogenesis and also 
predicting anti-angiogenic therapy. Furthermore, he demon strated the importance of a po-
tent tumor blood supply for the growth of metastases 1. In uveal melanoma, metastasis occurs 
exclusively via the hematogenous route,emphasizing the importance of tumor vasculature 2. 
Criscuolo et al.3 were the first to describe the occurrence of vascular perme ability increas-
ing factor in malignant glioma, which we currently know as vascular endothelial growth 
factor (VEGF). The VEGF-A isotype, referred to as VEGF in this review, plays a key role 
in angiogenesis, regulating vasopermeability as well as the proliferation and migration of 
endothelial cells 4. In several tumors (e.g. colon carcinoma, soft tissue sarcomas and gas-
tric cancer), serum VEGF levels have been found to be a marker of disease stage and an 
indicator of metastasis 5-7. In uveal melanoma, VEGF expression in sera of patients with a 
primary tumor, cannot pre dict survival. Nevertheless, serum VEGF levels are significantly 
higher in uveal mel anoma patients with metastatic disease compared to patients without 
such spread 8,9. 
In 2004, bevacizumab, the first angiogenesis inhibitor that targets VEGF, was devel oped, 
approved and licensed for intravenous infusion in the treatment of colorectal carcinoma 10. 
Bevacizumab is also used for the treatment of metastases from sev eral other malignancies, 
including renal and lung cancer 11,12 and is under investi gation for other primary tumors (e.g. 
pancreas cancer and cutaneous melanoma) 13,14. However, not all results are positive. It has 
been reported that VEGF inhibitors elicit tumor adaptation and increased lymphatic and 
distant metastasis in patients with pancreatic neuroendocrine carcinoma and glioblastoma- 
bearing mice 15. In uveal melanoma, antiangiogenesis therapy has not yet been used for the 
treatment of primary uveal melanoma or related metastatic disease. Still, there has been 
extensive research into the effect of anti-angiogenic agents such as bevacizumab on uveal 
mela noma cells and animal models 16 (el Filali et al., submitted). Serendipitously, clini cians 
already have a broad experience with anti-angiogenic agents in patients with uveal mela-
noma as a result of treating the complications of radiation therapy of the primary tumor. 
The role of VEGF as key mediator in tumor angiogenesis and as a main treatment target 
will be addressed as well as several other anti-angiogenic drugs for future treat ment of pri-
mary uveal melanoma and/or metastatic disease. 
Tumor Angiogenesis in Uveal Melanoma 









Microvessel density of uveal melanoma was studied by immunohistochemistry and has 
been found to correlate strongly with the risk of metastatic death 17. Microvessel density was 
shown to be locally induced and not evenly distributed in the whole tumor 18,19. In subsequent 
studies, specific ‘hot spots’ of vascular density have been shown to correlate with uveal mela-
noma- related metastatic death 20. 
Extracellular Matrix Patterns and Vasculogenic Mimicry 
Several extracellular matrix patterns have been described in uveal melanoma. When so- 
called closed loops and networks are present, they predict a worse 10- year prob ability of 
melanoma- specific survival (loops: 0.45 vs. 0.83; two- sided p < 0.0001, and networks: 
0.41 vs. 0.72, two- sided p < 0.0001) 21. Moreover, these patterns are also shown in uveal 
melanoma- related metastases and are described as ‘vascu logenic mimicry’. This concept 
proposes the formation of fluid- conducting channels by tumor cells independent of local 
vascular outgrowth, without endothelium 22. Vasculogenic mimicry has also been identified 
in several other malignancies and shown to be associated with aggressive tumor behavior 23. 
The increased diffusion surface that these channels offer could allow continued growth of 
uveal melanoma. 
Vasculature and Metastatic Disease 
For metastases to occur, uveal melanoma cells must detach from the primary tumor and 
invade surrounding tissues to enter a nearby blood vessel, after which the cell can circulate 
systemically to a new location. A strong association has been observed between tumor cell 
ingrowth into blood vessels and extraocular extension, which is known to indicate a poor 
survival probability 24,25. To form a metastatic tumor, the circulating malignant cells must 
exit the circulation and enter an organ, which in case of uveal melanoma is usually the liver 
26,27. The predominance of liver metas tasis cannot be explained solely by blood circulation 
because the lungs are the first organ that uveal melanoma cells encounter. There must be 
a preferential microenvi ronment in which uveal melanoma cells proliferate more easily or 
quickly. Expression of insulin growth factor-1 receptor (IGF- 1R) in uveal melanoma offers 
a possible explanation for the bad prognosis 28. IGF-1, the ligand for IGF-1R, leads to phos-
phorylation of IGF-1R, which in turn activates key signal molecules involved in cell prolif-
eration 29. IGF-1 is mainly produced by the liver and may explain the pref erential growth of 
hepatic metastasis from uveal melanoma 29. Besides a favorable microenvironment, the new 
location must provide a good blood supply. Interestingly, IGF-1 has been shown to stimulate 
secretion of VEGF in retinal pigment epithelial cells and possibly IGF-1 signaling is also 
involved in tumor angiogenesis in hepatic metastases from uveal melanoma 30. 
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Molecular Mediators of Angiogenesis 
Uveal melanoma is characterized by slow progression and periods of dormancy, both of the 
primary tumor and of metastases. It has been suggested that this dormancy is associated 
with an avascular phase, in which a conversion to the angiogenic phenotype has yet to be 
established. This conversion, which is known as the ‘angiogenic switch’, is due to an altera-
tion in the balance of inhibitory and stimulatory factors 31. Folkman hypothesized that one 
important stimulatory factor, called tumor angiogenic factor, induces the tumor to convert 
to such an angiogenic phenotype. VEGF was later iden tified as one of the most potent tumor 
angiogenic factor molecules, which acts as the central mediator of tumor angiogenesis by 
regulating vasopermeability and the pro liferation and migration of endothelial cells 4. 
Another group of enzymes that has been implicated in tumor angiogenesis and the as-
sociated tissue remodeling is the family of metalloproteinases (MMPs) 32. The major MMPs 
involved in tumor angiogenesis are MMP- 2, - 9, and - 14 33. The sur vival rate of patients 
with MMP- 2- and MMP- 9- positive uveal melanomas is worse than that of patients with 
MMP- 2- and MMP- 9- negative melanomas (31– 27 vs. 85%, p < 0.05) 34. Epidermal growth 
factor (EGF) and its receptor (EGFR) also have an established role in tumorigenesis. EGF(R) 
is a potent proangiogenic factor able to induce migration of endothelial cells and regulate 
the production of angiogenic factors in tumor cells, such as VEGF, basic fibroblast growth 
factor and angiopoi etin 35. Other common angiogenic factors detected in tumors are platelet- 
derived growth factor, hepatocyte growth factor, and IGF family members 36. In uveal mel-
anoma, several of these proangiogenic factors have been analyzed. Boyd et al. 37, for example, 
demonstrated uveal melanoma cell expression of basic fibroblast growth factor at the protein 
level by immunohistochemistry and by RT- PCR in almost all tested samples (89%), espe-
cially around microvasculature. Expression of the recep tors for hepatocyte growth factor and 
IGF are bad prognostic factors in uveal mela noma as described earlier 28. 
The Role of Vascular Endothelial Growth Factor 
Structure 
VEGF- α, also termed VEGF- A or VEGF, is a member of the VEGF platelet- derived growth 
factor family that also comprises placenta growth factor 38. VEGF exists in a range of isoforms 
due to alternative splicing of the RNA: VEGF121, VEGF165 (the predominant form), VEGF189, 
and VEGF206 
39. VEGF proteins are available to cells by at least two different mechanisms: (1) 
as freely diffusible proteins (VEGF121, VEGF165), or (2) after protease activation and cleavage 
of protein bound to heparin (VEGF189, VEGF206) 
40. 
The effects of VEGF are mainly mediated through binding to VEGF receptor 1 (Flt 1) and 
VEGF receptor 2 (KDR), both of which are expressed on vascular endothelial cells as well 







are transmembrane tyrosine kinase receptors that become active upon ligand binding and 
thereby trigger signal transduction pathways that are involved in angiogenesis. VEGF recep-
tor 3 (Flt- 4) is mainly involved in VEGF- C- and VEGF- D-mediated lymphangiogenesis 42. 
Genetics 
The human VEGF gene has been assigned to chromosome 6p21.3 43. Chromosome 6p gain 
in uveal melanoma has been reported in several studies and includes the VEGF locus 44,45. A 
correlation between copy number changes in the 6p region and the expression of VEGF in 
uveal melanoma has not yet been established 46. Moreover, abnormalities of chromosome 6 
have been associated with a better survival in uveal melanoma patients, which seems to be in 
conflict with metastasis- promoting tumor angiogenesis 47. Unfortunately, in this study, loss 
of 6q and gain of 6p were combined as one factor, thus limiting the evaluation of the role of 
6p unclear. 
Regulation 
Several factors have been shown to participate in the regulation of VEGF expres sion. How-
ever, hypoxia is the best known factor and VEGF mRNA expression can be induced reversibly 
by exposure to low oxygen levels in many cell types 48. The key regulator of hypoxia- induced 
VEGF is the transcription factor hypoxia- inducible factor (HIF)- 1α 49. Under hypoxic con-
ditions, HIF- 1α is stabilized and drives the expression of a large cluster of genes including 
VEGF and erythropoietin 50. In tumors with significant necrosis, the expression of VEGF is 
mostly upregulated in the ischemic tumor cells adjacent to the necrotic areas 51. 
Several cytokines or growth factors, such as EGF, platelet- derived growth factor, trans-
forming growth factor β, interleukin 6, interleukin 1 and IGF-1, are also known to upregulate 
VEGF expression in several normal cells, including retinal pigment epi thelial cells, and in 
tumor cells 4,30,52. Uveal melanomas that overexpress one of these cytokines/growth factors 
or the receptors for these ligands might generate auto crine signaling that promotes tumor 
growth and tumor vascularization. Blocking IGFR with picropodophyllin in mice with 
induced choroidal neovascularization reduced VEGF levels and vessel formation 53. In 
addition, picropodophyllin has been shown to inhibit uveal melanoma growth in vivo in 
uveal melanoma xenografts 54. Furthermore, VEGF expression has been demonstrated to 
be increased in asso ciation with specific genetic events such as loss of tumor suppressor 
genes or activation of oncogenes. The von Hippel- Lindau tumor suppressor gene has been 
implicated in the regulation of VEGF gene expression 55. Loss of von Hippel- Lindau protein 
func tion results in constitutive activation of HIF- 1α and thus VEGF expression 56,57. 
Oncogenic mutations or amplification of ras and overexpression of v- Src have also been 
shown to upregulate VEGF 58. Interestingly, we have demonstrated high Src activation in 
uveal melanoma that is associated with a constitutive activation of the mitogen- activated 
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protein kinase (MAPK) pathway and correlated with a bad prog nosis 59 (el Filali et al., sub-
mitted). 
Biological Function 
VEGF is known to be involved in several different aspects of angiogenesis. After bind ing 
of VEGF to the VEGFR- 1 and - 2, several proteins are activated including focal adhesion 
kinase, PI3K and Src. These downstream kinases promote vascular perme ability, endo-
thelial cell proliferation, migration and survival [60]. Originally, VEGF was referred to as 
vascular permeability factor 61. A rapid increase in vascular per meability occurs when the 
microvasculature is exposed acutely to any number of vas cular permeabilizing factors, like 
VEGF, allowing the diffusion of trophic substances to adjacent tumor cells. VEGF promotes 
proliferation of endothelial cells through induction of the Raf- MEK- MAPK pathway and 
the formation of the endothelial lin ing of tumor vessels by attracting circulating endothelial 
cells. VEGF also activates focal adhesion kinase and the PI3- kinase- Akt pathway, induc-
ing subsequent migra tion of endothelial cells expressing VEGFR- 2 60. In addition, VEGF 
is involved in cell survival (via PI3- kinase/Akt activation and antiapoptotic proteins) and 
monocyte activation, the description of which is beyond the scope of this chapter 62,63. 
Expression and Implication of Vascular Endothelial Growth Factor in Uveal 
Melanoma 
VEGF induction has been extensively demonstrated in a range of malignancies, includ-
ing lung, breast, and gastrointestinal tract tumors 64-66. In the eye, VEGF gene and protein 
expression are observed in ocular tissues, primarily in the retina and retinal pigment epithe-
lium, and are particularly upregulated in retinopathies that are associ ated with angiogenic 
proliferation 67. The first study that investigated VEGF gene expression in uveal melanoma 
applied RT- PCR to 7 uveal melanoma cell lines 68. Subsequently, Sheidow et al. 69 showed 
VEGF immunostaining in uveal melanoma samples of enucleated eyes, but did not find any 
correlation between the occurrence of metastatic disease and the amount of VEGF expres-
sion in uveal melanoma tissue. 
Using immunohistochemistry, Boyd et al. 70 showed only a moderate staining of VEGF 
in uveal melanoma samples (22%; n = 50). On the contrary, all uveal mela nomas tested 
expressed VEGF mRNA (n = 20). Another publication by the same investigators describes 
elevated VEGF concentrations (up to 21.6 ng/ml) in vitreous and anterior chamber fluids of 
eyes with uveal melanoma compared to samples from healthy eyes (<0.96 ng/ml). Remark-
ably, the highest VEGF levels were found in fluids of eyes that had been treated with radia-
tion 37. In studies by Missotten et al. and others, elevated VEGF in the aqueous humor of eyes 
with uveal melanoma was confirmed and found to be correlated with largest basal tumor 
diameter and tumor height. In situ analysis further demonstrated that both the tumor cells 







in uveal melanoma and found that hypoxia massively induces HIF- 1α and VEGF in uveal 
melanoma cell lines and primary tumor cell cultures. On the contrary and as expected, TSP-
1, an anti-angiogenic factor, was downregulated when uveal melanoma cells were exposed 
to ischemic conditions (fig. 1). VEGF expression in primary uveal melanoma samples (n 
= 27) was variable (range of expression 0.04– 9.55 normalized fold), and demonstrated no 
correlation with specific histological markers or prog nosis. Upregulation of VEGF in uveal 
Figure 1. VEGF and TSP-1 mRNA expression in primary uveal melanoma cell cultures. 
The amount of VEGF (black) and TSP-1 (gray) mRNA expression was measured with quantita tive real- time 
RT- PCR in pri mary uveal melanoma cell cultures (cultures 1– 5) under normoxic (1% O2) and hypoxic (20% 
O2) conditions after 24 h. Expression is demonstrated in normalized fold. 
Figure 2. Concentration of serum VEGF- A in (metastatic) uveal melanoma patients and controls.
Concentration of serum VEGF- A in the control group (n = 50), and in patients with (n = 20) and with out 
metastatic (n = 74) uveal melanoma. p values (Mann-Whitney test) between the different groups are indicated 
in the graph. Each box shows the median, quartiles (box length is the interquartile range) and whiskers 
represent the 90th and 10th percentiles (from el Filali et al. [9]). UM = Uveal melanoma; MM = metastatic 
melanoma. 
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melanoma cell lines, in response to hypoxia, did not increase cell proliferation 9. The ability 
to modulate expression of VEGF by uveal melanoma cells may provide the tumor with the 
opportunity to initiate vascu larization. Whether VEGF is essential for tumor angiogenesis 
should be analyzed in vivo, in a model resembling the tumor environment including para-
crine signaling of endothelial cells. 
In several tumors (e.g. colon carcinoma, soft tissue sarcomas and gastric cancer), serum 
VEGF levels have been found to be a marker of disease stage and an indicator of metastases 
5,6,72. Until recently, lactate dehydrogenase and alkaline phosphatase were the most indicative 
serum markers for metastatic disease in uveal melanoma, in combination with liver ultra-
sonography 73,74. Elevated serum osteopontin, melanoma- inhibitory activity and S- 100β 
levels showed a correlation with metastatic uveal melanoma to the liver in some studies 75,76. 
However, serum markers that indicate micrometastases at an early stage would be clinically 
preferable. In contrast to the immunohistochemical study of Sheidow et al. 69, several studies 
have observed VEGF expression in melanoma cell lines to be correlated with development 
of experi mental metastasis 77,78. In uveal melanoma, we found no difference in the amount of 
VEGF in sera of uveal melanoma patients compared to healthy people. However, VEGF lev-
els are significantly raised in uveal melanoma patients with metastases com pared with those 
without metastic disease (p < 0.001) (fig. 2). The same finding has recently been confirmed in 
other studies 79. In addition, using a uveal melanoma mouse model, VEGF serum levels were 
increased in the presence of hepatic micro-metastases in hypoxic regions of the liver 80. Also, 
Barak et al. demonstrated a significant increase of VEGF in sera of uveal melanoma patients 
after the occurrence of metastases; however, wide inter-patient variance prevents the use of 
a single VEGF serum level to be used as a marker for metastatic disease 8. 
Approved Anti-Angiogenic Treatment in Cancer 
In the last two decades, most of the anticancer angiogenic treatments have focused on 
VEGF/VEGFR and EGF/EGFR, since these factors play such an important role in tumor 
angiogenesis. There are several other anti-angiogenic drugs that have been approved for the 
treatment of several different tumors (table 1). The four main meth ods used to block VEGF 
or any other angiogenic factors are: 
1. neutralizing monoclonal antibodies against the factor or its receptor: bevacizumab, cetux-
imab, panitumumab, trastuzumab, ranibizumab; 
2. small molecule tyrosine kinase inhibitors (TKIs) of receptors: sorafenib, sunitinib, erlo-
tinib; 
3. soluble receptors which act as decoy receptors: VEGF- Trap; 







Due to the complexity of angiogenesis, as reviewed in the section on tumor angio genesis, 
it is obvious that there may be several indirect ways to inhibit vessel growth besides the 
direct blocking of angiogenic factors. Temsirolimus (Torisel®), for instance, is an mTOR 
inhibitor that has direct antitumor activity by arresting cells in the G1 phase of the cell cycle 
and increasing apoptosis, but that also suppresses HIF- 1α transcription levels in tumor cells, 
thus reducing VEGF expression and angiogenesis 81. Bortezomib (Velcade®) is a proteasome 
inhibitor that has been shown to inhibit VEGF, IGF-1, and angiopoietin by an unknown 
mechanism in multiple myeloma 82. Thalidomide (Thalomid®) has been unpopular since the 
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1960s when its severe teratogenic effects were unknown and its use resulted in malforma-
tions of the extremities in unborn children of pregnant users. Nevertheless, thalidomide 
(or its derivative lenalidomide, introduced in 2004) has recently been shown to have potent 
anti-angiogenic properties, such as decreasing vascular density and successfully blocking 
angiogenic factors such as basic fibroblast growth factor, and VEGF and it is now under in-
vestigation for suppressing tumor angiogenesis 83. Other approved and established drugs that 
have been found to exert anti-angiogenic activity include doxycycline and celecoxcib 84,85. 
Additionally, multiple other agents targeting tumor angiogenesis in several differ ent ways 
are still in (pre- )clinical investigation and should provide more treatment options in the 
future. 
Anti- VEGF antibodies (bevacizumab) and TKIs (sunitinib and sorafinib) will be high-
lighted in the next section. 
Anti-Angiogenic Therapy in Uveal Melanoma 
At this time, no anti-angiogenic drugs are used clinically for the treatment of uveal melanoma 
or its metastases. Intravitreal use of bevacizumab in three cases of uveal melanoma who were 
wrongfully diagnosed as choroidal neovascularizations did not demonstrate inhibition of 
tumor growth 86. 
With regard to the primary tumor, the current treatment includes enucleation, local resec-
tion and radiotherapy, either by brachytherapy (iodine or ruthenium), stereot actic or proton 
beam irradiation 87-90. Radiotherapy achieves local tumor control in up to 97% of all treated 
eyes, and can therefore be regarded as being very effective 91,92. One could therefore argue 
whether other therapies, such as anti-angiogenic drugs, are necessary. First of all, not all 
tumors can be irradiated: contraindications for irradiation are a tumor height of more than 
10.0 mm (or 8.0 mm near the disk), a tumor diameter of more than 16.0 mm (although in the 
case of proton beam irradia tion, larger tumors can be treated), when the tumor is not clearly 
defined by echog raphy, is diffuse or multifocal, when there is neovascular or secondary 
glaucoma and in case of extrascleral extension 87,90. In addition, radiation therapy can lead 
to radiation retinopathy, a delayed- onset complication characterized by retinal ischemia, 
neovascularization and leaking vessels 93,94. Ultimately, radiation retinopathy can result in a 
severe decrease of visual acuity in the ‘preserved’ tumor-containing eye. 
Anti-Angiogenic Treatment of Radiation Retinopathy 
In eyes with uveal melanoma, bevacizumab is frequently utilized for the treatment of ra-
diation retinopathy. Radiation retinopathy has been described in up to 63% of eyes after 







neovascularization in radiation retinopathy demonstrates a decrease of macular edema and 
an improvement of visual acuity 97-99. 
Other anti- VEGF agents besides bevacizumab have been widely used in ophthal mology 
this last decade in the treatment of age- related macular degeneration, dia betic macular ede-
ma and neovascular glaucoma. Pegaptanib (Macugen), an aptamer that only binds VEGF165, 
was the first drug to receive approval for the treatment of macular degeneration. Although 
this drug is hardly used for any ocular pathology, one case study describes improved visual 
acuity after treatment with pegaptanib in a patient with proliferative radiation retinopathy 
100. Ranibizumab (Lucentis) is a recombinant humanized immunoglobulin monoclonal 
antibody fragment especially designed for intraocular use and is approved in many coun-
tries. The efficacy and safety of ranibizumab were evaluated in several randomized trials 
involving more than 1,000 patients with neovascular age- related macular degeneration and 
was shown to significantly maintain (90%) and improve (33%) visual acuity after 24 months 
101. In addition, treatment with ranibizumab also improved visual acuity in 4 of 5 patients 
with radiation maculopathy 102. VEGF- Trap is a soluble protein that acts as a VEGF decoy 
receptor, and is currently undergoing phase 3 testing for age- related macular degeneration 
as well as for metastatic melanoma treatment 103. 
Anti-Angiogenic Therapy for Uveal Melanoma Metastasis 
Almost 50% of all uveal melanoma patients eventually develop metastatic disease, with the 
current 5- year uveal melanoma- related mortality ranging from 26 to 32% 27. Life expectancy 
in the case of uveal melanoma- related metastatic disease ranges from 2 to 6 months since 
hardly any effective treatment is currently available; chemo therapy and local resection only 
prolong survival by a few months 104. A number of anti-angiogenic agents may be of clinical 
use. 
Bevacizumab 
Yang et al. studied the effect of bevacizumab on the growth inhibition and num ber of hepatic 
micrometastases in an ocular melanoma mouse model, in which B16 melanoma cells were 
inoculated subchoroidally 16. Bevacizumab was administered by intraperitoneal injection 
(starting dose: 50 or 250 μg/100 μl). Bevacizumab suppressed primary ocular melanoma 
growth and the formation of hepatic micrometastases in a dose- dependent manner (p < 
0.01). In addition, bevacizumab significantly reduced the level of VEGF in the culture media 
of two human uveal melanoma cell lines. 
In contrast, we found a rather unexpected effect of bevacizumab on uveal mela noma. Our 
mouse model consisted of B16 melanoma cells which were placed into the anterior chamber 
of the eye and bevacizumab (10 times the equivalent human dose, 20 μg/4 μl; equivalent 
human dose, 2 μg/4 μl) or a mock injection were given intraocularly. In vivo acceleration of 
intraocular tumor growth was observed in the eyes treated with bevacizumab, although it did 
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not influence B16 or uveal melanoma cell proliferation in vitro. Remarkably, bevacizumab 
did increase mRNA VEGF melanoma expression and HIF- 1α stabilization in vitro. This was 
especially seen under hypoxic conditions. Only after treatment with bevacizumab did we 
observe anterior chamber and tumor hemor rhages in murine eyes, emphasizing increased 
microvascular permeability, possibly due to induced VEGF expression. This ‘pseudohypoxic’ 
phenomenon has been described in other tumors and may be the consequence of a tumor 
adaptive or evasive response. It will be further elaborated in the following section (el Filali 
et al., submitted). 
Sorafenib 
Sorafenib, which inhibits VEGFR, has been tested in a xenograft model in which uveal 
melanoma cell line 92.1 was injected subcutaneously. Mangiameli et al. demon strated in-
hibition of tumor growth (p < 0.0035) and fewer metastases after sorafenib treatment (33 
vs. 60%) 105. In patients with metastatic cutaneous melanoma, monotherapy with sorafenib 
has demonstrated hardly any antitumor activity 106. Recently, the final results of a phase 3 
trial, which compared treatment of metastatic (not including uveal) melanoma patients (n = 
823) with carboplatin, paclitaxel and with either sorafenib (SCP) or a placebo (CP), did not 
demonstrate a difference in overall survival: the median over all survival for the SCP group 
was 11.1 months (95% CI 10.3– 12.3) and for the CP group 11.3 months (95% CI 9.7– 12.3) 
(ASCO meeting 2010, abstract number 8511). 
Sunitinib 
Sunitinib is another TKI which inhibits VEGFR 107. There is not much preclinical evidence 
for antitumor activity in uveal melanoma. Still, a clinical benefit in advanced metastatic 
melanoma patients has recently been observed in a phase 2 trial analyz ing the effect of 
sunitinib monotherapy. Three patients (8.3%) demonstrated a partial response, with a mean 
duration of 6.5 months. Nine had stable disease (25%), with a mean duration of 4.1 months 
(range: 3– 8.2 months), and 17 had progressive disease (47.2%) (ASCO meeting 2010, abstract 
number 8518). Although uveal melanoma is the most common intraocular tumor in adults 
(0.7/100,000 per year), it is still a relatively rare form of cancer. Conducting a good clinical 
trial in such a population is therefore quite challenging. There are ongoing and recruiting 
trials investigating bevacizumab, sorafenib and sunitinib as a single agent or in combination 
with other regimes. Most studies are focused on cutane ous metastatic melanoma. Fortu-
nately, trials currently also include uveal melanoma patients and some of them even enroll 
only patients with ocular melanoma- related metastasis (clinicaltrials.gov). Hopefully this 







Adverse Effects of Anti-Angiogenic Therapy 
Vascular Endothelial Growth Factor Inhibitors 
Clinical experience with predominantly bevacizumab has revealed that anti- VEGF therapy 
often prolongs overall survival of cancer patients by a few months, without really curing 
metastatic disease 108. It has been proposed these past few years that VEGF inhibitors may 
actually promote tumorigenesis and metastatic dissemination on the long run 15,109. Recently, 
the FDA has prohibited the use of bevacizumab (monotherapy) for metastatic breast cancer 
patients. When we observed tumor accel eration after treatment with bevacizumab in our 
mouse model, we also analyzed the effect on human uveal melanoma cells. In vitro treatment 
with bevacizumab induced VEGF mRNA expression in uveal melanoma cells. Moreover, we 
observed that this upregulation involved the HIF- 1α pathway (el Filali et al., submitted). 
VEGF inhibitors seem to elicit similar effects as described earlier for ischemic conditions 
that induce VEGF expression in uveal melanoma cells through the HIF- 1α pathway. The 
paradox of VEGF upregulation upon anti- VEGF treatment has been dubbed ‘pseudohy-
poxia’ and has been described before in other tumor studies. In mice bearing intracerebral 
glioma, it has been demonstrated that anti- VEGF treatment with pegaptanib (Macugen) 
increases GLUT- 1 expression (glucose transporter also upregulated by HIF- 1α) 51. This 
‘pseudohypoxia’ has also been shown to increase tumorigenesis in other types of cancer cells. 
Treatment of mice with pancreatic neuroendocrine tumors with anti-VEGFR also resulted 
in an initial response of tumor stasis followed by tumor recur rence. The relapsing tumor 
expressed higher levels of mRNAs of proangiogenic factors and demonstrated several hy-
poxic regions 110. Furthermore, treated mice developed more invasive tumors and metastatic 
lesions, all characterized by hypoxic regions 15. 
Ischemic conditions caused by anti- VEGF treatment can also lead to recruitment of vari-
ous bone marrow- derived cells that have angiogenic capacities. Proangiogenic monocytes 
induce vessel growth by expression of several cytokines and angiogenic factors. In mice 
bearing glioblastoma multiforme tumors treated with bevacizumab, the stabilization of 
HIF- 1α has been demonstrated to promote angiogenesis by inducing recruitment of mature 
F4/80+ macrophages 11,112. Additionally, a clin ical study suggests that hypoxia determines 
survival outcome in patients treated with bevacizumab for glioblastoma multiforme 113. Since 
it has previously been shown that malignant uveal melanoma tumors in patients with a poor 
survival contain many macrophages, this mechanism is especially relevant 114. Moreover, we 
may be observing in our experiments resistance of the tumor cells, after an initial response 
phase, to adapt or evade therapy by inducing mechanisms that reduce dependence on 
neovascularization, leading to changed tumor proliferation. The ‘pseudohypoxic’ conditions 
could be responsible for selection of more malig nant tumor cells, which are less sensitive 
to anti-angiogenic treatment and switch on other malignant pathways that result in prolif-
eration, migration and invasion. Besides angiogenesis and vascular permeability, VEGF has 
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been shown to activate the ras/ raf pathway through activation of the tyrosine kinase VEGF 
receptors and the down stream MAPKs 115,116. MAPK- driven proliferation has been shown to 
play an important role in uveal melanoma growth through upstream Src signaling 59. 
Tyrosine Kinase Inhibitors 
TKI side effects are related to their nonspecific nature 117. In order to be able to pre dict treat-
ment outcome, one should know the effect of TKIs on the different pathways and how these 
pathways may interact. Sorafenib treatment of cutaneous melanoma patients may have been 
disappointing because the combined effect on all inhibited kinases turned out to be negative 
for tumor inhibition 118. Although the capacity of TKIs to target multiple kinases is interesting 
because of its wide application in several different malignancies, it also results in many ‘off- 
target’ effects demonstrated in several clinical trials. For example, hand- foot skin reactions, 
fatigue, stomatitis, diarrhea, hair color changes, myelosuppression, and thyroid dysfunction 
are frequently associated with TKI treatment. In addition, the low effectiveness of available 
TKIs requires higher doses. Unfortunately, higher doses are in turn associated with increased 
blockade of nontarget kinases due to low selectivity, again resulting in toxicity. The off- target 
effects of TKIs have also limited their use in combination with chemotherapeutic drugs due 
to overlapping toxicity profiles. Recently, treatment with sunitinib and sorafenib has been 
associated with cardiovascular toxicity as an adverse event 119. These limitations have led to 
the development of more selective and potent anti- VEGFR TKIs 120. 
Conclusion 
Uveal melanoma remains a highly lethal tumor, which results in metastatic disease in almost 
50% of all patients despite adequate primary tumor treatment. It is there fore important to 
investigate different treatment options to be used in curative or preventive therapy of uveal 
melanoma- related metastatic disease. Tumor angiogen esis has been demonstrated to be of 
great importance in tumor growth and dissemi nation. In addition, tumor vessel formation 
is also complex and extensive, involving various molecular mediators and pathways. Anti-
angiogenic therapy has focused on VEGF, which has been implicated in uveal melanoma 
angiogenesis. Unfortunately, experimental and clinical trials using anti- VEGF monotherapy 
have been disappoint ing. In addition, VEGF inhibitors may actually promote tumorigenesis 
and metastatic dissemination. The key to effective treatment is good patient and tumor selec-
tion. The inhibition of protein activity by small molecules appears to be a promising approach 
for several types of malignancies. For example, imatinib has been analyzed for treatment of 
uveal melanoma- related metastases in a clinical trial, based on c- Kit overexpression and the 
in vitro response of cell lines with c- Kit expression to imatinib mesylate 121. Treatment with 







upregulation in the patients in the trial because patients had been treated irrespective of their 
c- Kit tumor status 122,123. This could also be the case with anti-angiogenic therapies in which 
patients are treated irrespective of the angiogenic profile and VEGF/VEGFR expression of 
their uveal melanoma and/or metastases. We demonstrated that angiogenesis and especially 
VEGF expression can easily be modulated by the uveal melanoma cells themselves, either 
by tumor microenvironment or due to VEGF inhibitors. In addition, structures identified as 
vasculogenic mimicry may provide uveal melanoma with an alternative tumor circulation. 
Therefore, one could still question whether tumor angiogenesis and the angiogenic switch 
are necessary for uveal melanoma growth and malignant dissemination. They may merely be 
a consequence of tumor growth. 
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Purpose: Blood vessels are important constituents of intraocular uveal melanoma (UM), but 
whether angiogenesis is regulated by environmental factors such as ischemia, or by genetic 
mechanisms is not known. We examined regulation of the pro-angiogenic factor Vascular 
Endothelial Growth Factor (VEGF-A).
Material & Methods: Cell lines and primary tumours was tested for expression of VEGF-A, 
under normoxic and hypoxic conditions, using quantitative PCR, ELISA, WST-1 viability, 
and in-cell Western experiments. VEGF-A serum levels were determined by ELISA.
Results: Hypoxia induced HIF-1α and VEGF-A in UM cell lines and primary tumour 
cultures. Hypoxia did not influence proliferation. VEGF-A expression in primary tumours 
was variable, demonstrating no correlation with specific histological markers or prognosis. 
However, VEGF-A levels were significantly raised in UM patients with metastases compared 
with those without metastases (p<0.001).
Conclusion: VEGF-A expression by UM cells is mainly controlled by hypoxia and involves 
the HIF-1α pathway, thus indicating an important role for the tumour cell environment. 
Metastases led to increased serum VEGF-A levels, indicating that VEGF-A may be involved 
in the growth of metastases.
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Introduction
Uveal melanoma (UM), although rare, is the most common primary intraocular tumour, 
with an annual incidence of 0.7/100.000 in the adult Western population 1. Angiogenesis is 
an important mediator in tumour progression, as a tumour depends on its blood supply for 
oxygen and nutrients. Without a functional vasculature, tumour growth cannot proceed be-
yond the limits of perfusion. The formation of a ‘tumour-associated vasculature’ is a process 
referred to as tumour angiogenesis. 
Angiogenesis research has identified many pro- and anti-angiogenic factors that regulate 
tumour angiogenesis. One of the major groups of cytokines influencing adult angiogenesis is 
the vascular endothelial growth factor family (VEGF). VEGF-A is known to cause increased 
vascular permeability, endothelial cell growth, angiogenesis, and monocyte activation. 
Expression of the VEGF-A gene and protein occurs in ocular tissues, especially the retina 
and retinal pigment epithelium, and has been shown to be up-regulated in retinopathies of 
the eye that are associated with angiogenic proliferation 2. Many tumours such as e.g. brain 
malignancies and breast cancer are known to produce VEGF-A 3,4. In previous studies by 
Boyd and later by Missotten and others, it was demonstrated that VEGF-A concentrations 
were increased in the aqueous humour of eyes with uveal melanoma 5,6 Furthermore, in situ 
hybridization showed that both the tumour as well as the retina were sources of VEGF-A.
However, it is still unknown whether VEGF-A in UM is induced by ischemic conditions 
or is produced continuously as part of tumour progression, for example, due to selection of 
specific UM cells that express a high amount of VEGF-A. In general, the key regulator of 
hypoxia-induced angiogenesis is the transcription factor Hypoxia-Inducible Factor (HIF)-
1α.We previously demonstrated that several UM cell lines express VEGF-A in vitro, indicat-
ing a possible role in UM angiogenesis and proliferation7. Accidentally, while performing in 
vitro experiments with UM cells in our laboratory, one UM cell culture was not harvested 
before (as intended), but after the weekend. During that time, cells had proliferated and filled 
the culture well. Assessment of that culture showed a very high VEGF-A protein level. An 
explanation for this phenomenon might be lack of nutrients, or lack of oxygen supply to the 
multilayered cells, and this led us to explore the effect of hypoxia on VEGF-A expression by 
uveal melanoma cells.
We subsequently analyzed several UM tumour cell lines and primary UM tumour cell 
cultures for expression of VEGF-A under normoxic (20 % O2) and hypoxic conditions (1 % 
O2) to answer the question whether the angiogenic factors are continuously turned on in 
UM, or whether these angiogenic factors are still under hypoxic and thus environmental 
regulation.
Besides the supply of oxygen and nutrients, tumour-associated vessels promote metastasis 
by facilitating tumour cell entry into the circulation8. Undeniably, this plays a role in uveal 







melanoma patients, up to 50% eventually die due to metastatic disease 9,10. Several studies 
have shown that the presence of areas with a high local vascular density as well as ingrowth 
of tumour cells into the lumen of tumour blood vessels or into scleral vessels in UM is as-
sociated with poor survival11-13. Since VEGF-A plays a pivotal role in tumour angiogenesis, 
regardless of the way in which it is regulated, the presence of a high amount of this factor in 
the primary UM could possibly be used as a prognostic marker for the presence of UM and/
or formation of metastatic disease. 
We determined whether VEGF-A in the sera of patients is related to prognostic markers, 
the development of metastatic disease and UM-related death, and whether it discriminates 
between patients with and without metastases.
Material and Methods
UM cell lines 
Nine UM cell lines were cultured under either normoxic (20% O2 ) or hypoxic (1% O2 ) con-
ditions (HERAcell 240 CO2 Incubator, Thermo Fisher Scientific Inc, USA). Mel 202, Mel 
285, Mel290, Mel270, 92.1 and OCM-1 were all primary tumour-derived cell lines, while 
OMM1, OMM2.3 and OMM2.5 were metastases-derived cell lines. OCM-1 was provided 
by dr. J. Kan-Mitchell (Karmanos Cancer Institute, Detroit, MI), Mel202, Mel270, Mel285, 
Mel290, OMM2.5 and OMM2.3 by dr. B. Ksander (Schepens Eye Research Institute, Boston, 
MA), OMM1 by dr. G.P.M. Luyten (Erasmus University Medical Center, Rotterdam, the 
Netherlands) and 92.1 was established in our laboratory 14-18. All cell lines were cultured in 
Dulbecco’s Modified Eagle’s Medium (RPMI) supplemented with 10% fetal calf serum and 
1% penicillin/streptomycin (GIBCO, Life Technologies, Paisley, UK). The cells were passaged 
once or twice a week using trypsin (0.05%).
Patient tumour material and cell cultures
Informed consent was obtained prior to enucleation and the study was performed according 
to the tenets of the Declaration of Helsinki. Diagnosis was made based on histopathology of 
the tumour samples. Fresh tumour tissue, obtained immediately after enucleation of the eye, 
was frozen in liquid nitrogen-cooled isopentane for cryopreservation (cryosections) or used 
to isolate RNA and to develop a cell culture.
Five primary tumour cell tissues were cultured in Amniochrome® Pro Medium (Lonza 
Group Ltd, Basel, Switzerland) and passaged maximally once or twice before exposing the 
cells to different conditions using a normal and a hypoxic chamber: normoxia (20% O2, 5% 
CO2 , 37°C) or hypoxia (1% O2 , 5% CO2, 37°C).
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Quantitative PCR 
Expression of VEGF-A mRNA expression was analyzed by reverse transcriptase-polymerase 
chain reaction (qPCR). RNA was isolated using an Rneasy® Mini Kit (Qiagen, Valencia, 
USA). RNA samples were stored at -80°C until further processing. Approximately 1 μg of 
RNA per sample was reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad, 
Hercules, USA). The 20μl solutions obtained this way were diluted by adding sterile water 
until the volume reached a total of 100 μl. Using 96-well plates, 2 μl of this solution was 
added to a 15 μl solution of iQ SYBR Green Supermix, forward and reverse primers (10μM 
solutions) for beta-actine (β-ACTIN), ribosomal protein S11 (RPS-11) VEGF-A, (Table 1) and 
sterile water (volume ratio respectively 10:1:1:8). 
A quantitative PCR analysis (IQ5 PCR System; Bio-rad) of the samples for gene expression 
was then performed. The PCR reaction settings were 95°C for 3 minutes, then 40 cycles at 
95°C for 30 seconds and 60°C for 30 seconds, then 95°C for 1 minute and 60°C for 1 minute. 
To correct the sample-to-sample variation when determining gene expression, an accepted 
method is to select a cellular housekeeping gene that serves as an endogenous control, against 
which the target gene expression levels can be normalized 19. RPS-11 is a housekeeping gene 
that has recently been introduced to normalize gene expression in UM cells7,20. β-Actin is 
a relatively stable cytoskeletal protein generally thought to be present at a constant level in 
cells, regardless of experimental treatment or technical procedure 21.
Cell proliferation and cytotoxicity 
Cell death was determined by trypan blue dye-exclusion using a Bürker counting chamber. 
In addition, cell proliferation was measured by mitochondrial function using the water-
soluble tetrazolium salt (WST-1) assay (Roche Diagnostics, Indianapolis, IN), as previously 
described 22. In short, 96-well plates were filled with 1200 uveal melanoma cells per well, 
filled with regular medium (control), and either placed in a normoxic (20% O2, 5% CO2 , 
37°C) or hypoxic (1% O2, 5 % CO2 , 37°C) chamber (HERAcell 240 CO2 Incubator, Thermo 
Fisher Scientific Inc, USA). Absorbance was measured at 450nm (n=8) on a multiwell spec-
trophotometer (Perkin Elmer, Wellesley, MA). 
Table 1. Primer sequences of the genes studied in the qPCR assay 
Primer Gene Forward primer (5’-3’) Reverse primer (5’-3’)
Endogenous controls RPS11 AAGCAGCCGACCATCTTTCA CGGGAGCTTCTCCTTGCC 
β-ACTIN CGGGACCTGACTGACTACCTC CTCCTTAATGTCACGCACGATTT 
Genes under study VEGF-A GCCCTTGCCTTGCTGCTCTACC GTGATGATTCTGCCTCCTCCTTC 
Primer sequences of the control and studied genes that were used in qPCR assay to determine level of 







Patient and controls for serum samples
Serum samples were obtained from 74 consecutive patients (38 males, 36 females) with the 
diagnosis intraocular UM, enucleated at the Leiden University Medical Center from 1992 to 
2000. Serum was collected prior to enucleation, and was stored at -80°C until analysis. At 
that time, none of the patients had liver metastases on ultrasonographic images of the liver. 
Tumours were classified histopathologically: in 59 out of 74 cases, the UM was located in 
the choroid (79.7%), in six cases in the ciliary body (8.1%), in nine cases in both the choroid 
and the ciliary body (12.2%). Mean age at the time of enucleation was 66.0 years (SD 12.5).
As a control, serum was obtained from 50 healthy individuals (26 male, 24 female), who 
voluntarily donated blood for this occasion. Mean age of the healthy individuals was 63.4 
years (SD 12). Control sera were also frozen at -80°C until analysis. The study was performed 
according to the Declaration of Helsinki, and with the agreement of the local Medical Ethical 
Committee. 
At the time of diagnosis of metastases, 20 samples were collected. Fourteen patients had 
primarily been treated with ruthenium irradiation, six with enucleation. All patients had 
liver metastases, confirmed by liver ultrasonographic images. In 14 cases, liver metastases 
were confirmed by fine needle aspiration biopsies (FNAB) and histopathology. Mean time 
between diagnosis and metastases was 2.6 years (0.01 – 7.90 year). The mean time between 
development of clinical metastases and melanoma-related death was 1.1 year (0.21 - 3.20 
year).
For the determination of lactic dehydrogenase (LD), aspartate aminotransferase (ASAT), 
alanine aminotransferase (ALAT), alkaline phosphatise (AP) and γ-glutamyl transpeptidase 
( γGT), standardized tests were used (Roche Diagnostics, Mannheim, Germany). The detec-
tion limits and upper normal limits of these tests are mentioned in Table 2.
VEGF-A protein expression 
VEGF-A protein concentrations in the supernatant of cell cultures were determined using 
commercial solid phase sandwich enzyme-linked immunosorbent assays (VEGF-A: human 
VEGF ELISA immunoassay Kit, Biosource, Camarillo, USA.). The VEGF-A concentration 
in sera of patients were measured using the same assay. The lowest measurable concentration 
was 5 pg/ml with an intra-assay coefficient of variation (CV) of 4.7 % and an inter-assay CV 
of 8.1%. The upper normal limit is 600 pg/ml according to the manufacturer (Table 2).
HIF-1α In-cell Western experiment
Phosphorylation and activation of HIF-1α was determined by an in-cell Western im-
munofluorescent assay 23,24. Briefly, cells were grown to approximately 70% confluency in 
a microtiter plate (NUNC, Roberts, WI, USA) and either placed in a normoxic (20% O2, 
5% CO2 , 37°C) or hypoxic (1% O2, 5 % CO2 , 37°C) chamber (HERAcell 240 CO2 Incubator, 
Thermo Fisher Scientific Inc, USA) for 24 hours. For binding assays, medium was replaced 
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with Fixing Solution (3.7% formaldehyde in 1X PBS) for 20 minutes at room temperature to 
immediately fix the cells. Subsequently, cells were washed four times with Triton Washing 
Solution (1xPBS+0.1% TritonX-100). Cells were blocked in Odyssey Blocking Buffer for 1.5 
hours, then incubated with HIF-1α antibody (Bethyl laboratories INC Montgomery, TX, 
USA)) (1:1000) for 2 hours. After washing the cells five times with Tween Washing Solution 
(1x PBS + 0.1% Tween-20), plates were incubated with the second antibody IRDye® 800CW 
(1:800) and for normalization of cell number, the 700nm-channel DRAQ5 (1:2000) and Sap-
phire700 (1:1000) were used (all three from LI-COR Biosciences, Lincoln NB, USA).
Washing steps were repeated and the plate was scanned on an Odyssey infrared scanner 
(LI-COR Biosciences, Lincoln NB, USA). Data were acquired using the scanner software, 
exported to Excel (Microsoft, Redmond, WA, USA), and analyzed by GraphPad Prism 
(GraphPad Software, San Diego, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 sofware (SPSS Inc. Chicago, Illinois, 
USA). An independent t-test was performed to detect a possible association of VEGF-A in 
primary UM samples (data normally distributed) and the presence of metastatic disease. 
Median concentrations of serum values and expression data between the tested groups 
were compared using non-parametric tests (Mann-Whitney or Kruskal-Wallis), because of 
small sample size and categorical scale. Overall survival were estimated by the Kaplan Meier 
method and log-rank test. P < 0.05 was considered statistically significant.
Results
VEGF-A mRNA expression in UM cell lines and primary tumour cell cultures
We analyzed whether VEGF-A is continuously secreted in UM or is regulated by hypoxia. 
VEGF-A mRNA was determined in nine UM cell lines and five primary UM tumour cell 
cultures. All cell lines expressed VEGF-A, but at variable levels. Ischemic conditions had 
Table 2. Detection limits and UNL for serum tests
Detection limit Upper normal limit
LD, U/L 1 450
AP, U/L 1 120
ASAT, U/L 1 40
ALAT, U/L 1 45
γ-GT, U/L 1 F: 35 / M:50
VEGF-A, pg/ml, 5 600







a major time-dependent effect on VEGF-A expression in all nine cell lines with a VEGF-A 
induction of 5.8-fold difference (normalized expression under hypoxia/ normalized expres-
sion under normoxia after 24 hours), compared to normoxic conditions (range; 1.5 to 9.8 fold 
difference, shown for six cell lines in Figure 1). Cell lines created from primary tumours and 
from metastases behaved similarly. 
As cell lines may have been modified during culture, we also tested short-term cultured 
primary UM (Figure 2). These cultures also showed hypoxia-stimulated expression of 
VEGF-A, with an induction of 4.2-fold difference, compared to normoxia (range; 2.0-7.2-
fold difference). 
VEGF-A protein expression 
To assess whether mRNA expression of UM cells resulted in the production of protein, we 
analyzed VEGF-A protein expression under either hypoxic or normoxic conditions in UM 
cell lines and primary tumour cell cultures using an ELISA on culture supernatant. All UM 
cell lines and cell cultures produced VEGF-A, but clear differences were observed in the 
amounts. Assessment of culture supernatant showed that UM cell lines under normoxia and 
hypoxia had a median VEGF-A protein expression (sum of amount of VEGF-A/ four time 
points) of 41 pg/ml (range 0-202 pg/ml) and 77 pg/ml (range 0-418 pg/ml), respectively. 
Hypoxic conditions induced VEGF-A protein expression in the same time-dependent man-
ner as observed for mRNA expression (Figure 3). 
Basic VEGF-A protein expression in the primary tumour cell cultures was significantly 
higher than seen in the UM cell lines (normoxia: median of 174 pg/ml after 24 hours). As 
seen with UM cell lines, hypoxia induced VEGF-A protein expression in primary tumour 
cell cultures (hypoxia: median of 328 pg/ml) with a 2.7-fold difference (range 1.4-4.5-fold 
difference, Figure 4).
HIF-1α in-cell Western on UM cell lines
The key regulator of VEGF-A under hypoxic circumstances is HIF-1α. To test whether the 
VEGF-A expression alterations are regulated by the HIF-1α pathway as expected under 
hypoxic circumstances, an in-cell Western experiment was performed on UM cell lines. 
Hypoxia induced expression of HIF-1α in all UM cell lines (mean HIF-1α expression under 
normoxia: 0.9 density light units; hypoxia: 2.2 density light units), with a mean increase by a 
factor 4 (range 1.9-8.1) compared to normoxic conditions (Figure 5).
Cell proliferation and cell death
As hypoxia stimulates endothelial cell proliferation, we considered the option that hypoxia 
might be involved in stimulation of tumour growth and performed a viability assay to inves-
tigate this possibility. Surprisingly, though VEGF-A expression is induced under ischemic 
conditions, the WST-1 assay demonstrated a reduced cell proliferation rate under hypoxia in 
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Figure 1. VEGF-A mRNA expression in UM cell lines. 
The amount of VEGF-A mRNA expression was measured with qPCR in UM cell lines under normoxic (black) 
and hypoxic (gray) exposure after four different time intervals (3, 6, 24 and 48 hours). Normalized expression 
is shown with a maximum of 2.0- or 6.0-fold on the y-axis.
Figure 2. VEGF-A mRNA expression in primary UM cell cultures. 
The amount of VEGF-A mRNA expression was measured with qPCR in primary UM cell cultures (cultures 








Figure 3. VEGF-A protein expression in UM cell lines. 
The amount of VEGF-A protein expression measured with ELISA in supernatants of UM cell lines under 
normoxic (black) and hypoxic (gray) exposure after four different time intervals (3, 6, 24 and 48 hours). 
Expression is demonstrated in amount of protein (pg/ml) with a maximum of 150 or 300 pg/ml.
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Figure 4. VEGF-A protein expression in primary UM cell cultures.
The amount of VEGF-A protein expression measured with ELISA in supernatants of primary UM cell cultures 
(cultures 1-5) under normoxic (black) and hypoxic (gray) exposure after 24 hours. Expression is demonstrated 
in amount of protein (pg/ml).
Figure 5. HIF-1α expression in UM cell lines. 
Expression of HIF-1α was measured in UM cell lines using in-cell Western assay under normoxic (black) 
and hypoxic (gray) exposure during 24 hours. Expression is demonstrated in normalized integrated intensity 








all nine UM cell lines (Figure 6). Hypoxia had no toxic effect on UM cells up to 11 days, as 
there were no differences in the percentages of dead cells between the different conditions 
measured by the Bürker counting chamber (data not shown).
Short-term cultures obtained from primary UM (n = 5) showed similar proliferation rates 
under either hypoxia or normoxia up to three days in culture. After three days, proliferation 
rates and toxicity varied considerably between cultures. However, no differences in prolifera-
tion rate between the different environments (normoxia and hypoxia) were observed (data 
not shown). 
VEGF-A mRNA expression in primary tumour tissue
We evaluated whether expression of VEGF-A had any prognostic value, by determining 
expression by qPCR analysis in 27 samples of primary UM tumour tissues and compar-
ing the data to clinical parameters. Some samples showed almost no expression (0.04-fold 
Figure 6. Cell proliferation of UM cell lines. 
The proliferation rate of UM cell lines measured by WST-1 viability assay under normoxic (solid line) 
and hypoxic (dashed line) exposure after four different time intervals (4, 6, 8 and 11 days). Proliferation is 
measured by viability of the cells at each time point, and is expressed in absorbance (optical density, OD).
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normalized mean), while others demonstrated up to approximately 10 times normalized 
expression (9.55-fold normalized mean). We looked for a possible association of VEGF-A 
expression with histopathological characteristics of the tumour, but no association was ob-
served (Table 3). An independent t-test analysis of VEGF-A and the presence of metastatic 
disease was performed. No association between VEGF-A expression and the occurrence of 
metastasis (p= 0.14) could be demonstrated. Further analysis with the Kaplan Meier method 








  choroid 16 (59) 1.01
choroid + ciliary body 11 (40) 2.67
   
Cell type  
  Mixed 18 (67) 1.79 P*=0.191
  Epithelioid  5 (19) 1.02
  Spindle  4 (15) 4.06
   
Bruch’s membrane P†=0.834
  Intact  6 (22) 2.41
  Broken 17 (63) 1.91
  not known  4 (15) 1.73
   
Scleral ingrowth P†=0.399
  No  3 (11) 1.70
  Yes 23 (85) 2.50
  Episcleral  1 (4) 0.49 (1 value)
Tumour diameter P†=0.457
≤ 10 mm  8 (30) 1.45
> 10 mm 19 (70) 2.01
Tumour prominence P†=0.136
≤ 5 mm  9 (33) 0.99
> 5 mm 18 (67) 2.58
Levels of expression were compared with histological tumor characteristics.







and log-rank test did not show a relation between VEGF-A expression and metastases-free 
survival (p=0.76, mean follow-up of 57 months; range: 8-206 months)”.
Prognostic value of serum VEGF-A at the time of enucleation
Previously, VEGF-A was shown to be present in the aqueous humour of enucleated eyes 
with uveal melanoma, and a high concentration was correlated with a bad prognosis 6. We 
investigated whether the level of VEGF-A in serum at the time of enucleation for UM was 
of prognostic significance. VEGF-A was measured in sera of 74 UM patients and showed 
a median value of 183 pg/ml, while this was 167 pg/ml in the serum of 50 control persons 
(Figure 7), which difference was not significant (P=0.28). We also compared VEGF-A levels 
with histopathological characteristics of the tumour. No significant relations were observed 
(data not shown). 
VEGF-A in serum of patients with metastatic disease 
We also investigated the possibility of using VEGF-A serum levels to discriminate between 
UM patients with and without metastasis. VEGF-A was measured in the serum of 20 patients 
with metastatic UM and compared to serum levels of 74 patients with UM without metasta-
ses and 50 controls. Six of 20 patients with metastases (30%) had a VEGF-A level above the 
upper normal limit (UNL, the maximum level of VEGF-A in healthy individuals, Table 4) 
with a median concentration of 351 pg/ml, while only 7 out of 74 (9%) melanoma patients 
without metastases and 4 out of 50 (8%) controls had an amount of VEGF-A above the UNL. 
Figure 7. Concentration of serum VEGF-A in (metastatic) UM patients and controls.
Concentration of serum VEGF-A in the control group, and in patients with and without metastatic uveal 
melanoma. P-values (Mann-Whitney test) between the different groups are indicated in the graph. Each box 
shows the median, quartiles (box length is the interquartile range) and whiskers represent the 90th and 10th 
percentiles.
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The difference in VEGF-A concentration between patients with and without metastases was 
highly significant (Mann-Whitney, p < 0.001) (Figure 7).
Discussion
Tumour angiogenesis is important for tumour growth and metastatic potential. Both mi-
crovessel density as well as specific extracellular matrix patterns contribute independently 
to prognosis and survival in patients with UM 11,12. The clinical course of many cases of UM 
is slow and it has been suggested that dormancy is associated with an avascular phase. The 
conversion to proliferation could be associated with a change to an angiogenic phenotype, 
both with regard to the intra-ocular tumour as well as to metastases. This conversion, which 
is known as the ‘angiogenic switch’, is due to an alteration in the balance of inhibitory and 
stimulatory factors such that vessel growth is favoured 25,26. 
The process of angiogenesis is initiated when cells within the tumour respond to hypoxia 
by increasing their production of pro-angiogenic factors. We studied several UM tumour 
cell lines and primary UM tumour cell cultures under normoxic and hypoxic environments 
to analyze whether expression of the pro-angiogenic factor VEGF-A is regulated by tumour 
microenvironmental conditions or other mechanisms. All cell lines and primary tumour 
cultures expressed VEGF-A, as described before 5,6,27. Additionally, hypoxia had a major 
inducing effect on VEGF-A mRNA and protein expression. We can therefore conclude that 
ischemic conditions greatly contribute to the induction of the pro-angiogenic factor VEGF-
A in UM. HIF-1α is thought to be the most important initiator of hypoxia-induced VEGF-A 
expression 28. We observed that also in UM, expression of HIF-1α was induced under hypoxic 
conditions. Still, accumulating evidence indicates that HIF-independent pathways can also 
control angiogenesis 26. As many cell lines had a basic VEGF-A production: the two routes 
may be additive. In addition, VEGF-A may not only be produced by UM cells, but also 
by infiltrating cells: UMs often contain macrophages, and these are known to also produce 
VEGF. As hypoxia is known to induce macrophage migration into the hypoxic areas, induc-
tion of VEGF by hypoxic tumour cells may at the same time stimulate the influx of VEGF-
producing macrophages 29. Moreover, it is known that numerous other HIF-1α target genes 
Table 4. Amount of VEGF-A in sera above the detection limit and upper normal limit (UNL) for sera 
from healthy control subjects and patients with UM with or without metastases.
Group N > UNL. (%) Median VEGF-A (pg/ml) Range
Controls (n = 50) 4 (8) 168.6 5.3 – 846
Uveal melanoma patients (n=74) 7 (9) 183.2 4.8 – 821







besides VEGF-A can modulate angiogenesis by promoting the mitogenic and migratory 
activities of endothelial cells 28.
Although hypoxia considerably induced VEGF-A expression in cell lines and primary 
cell cultures, cell proliferation rates did not increase. Moreover, UM cell proliferation was 
significantly reduced under hypoxic conditions in comparison to UM cells in a normoxic 
environment. This indicates that VEGF-A protein does not independently increase uveal 
melanoma growth through a possible feedback loop. Whether VEGF-A protein is essential 
for formation of new functioning vasculature will be analyzed in a three-dimensional in 
vitro model and in a mouse UM melanoma model.
Apart from which mechanisms regulate VEGF-A in UM, several studies have observed 
VEGF expression to be correlated with development of experimental metastasis 30-32. On 
the contrary, Sheidow et. al. found no correlation between VEGF immunoreactivity in 
uveal melanoma samples of enucleated eyes and the occurrence of metastatic disease 33 . 
We compared VEGF-A mRNA expression in 27 uveal melanoma samples with clinical and 
prognostic data for metastatic disease and found no relation (Table 3). Additional t-test and 
survival analysis of the data demonstrated no association between VEGF-A expression and 
formation of metastasis. Because of the small number of samples used and in some cases 
short follow-up, these findings may not be conclusive. That the primary tumour samples 
showed a great variation in VEGF-A mRNA expression, may be due to sampling bias, as 
some tumour samples may have originated from ischemic regions, and some of the samples 
from fully oxygenated areas. It has been demonstrated that analysis of UM paraffin sections 
showed genetic heterogeneity 34. Determination of VEGF-A mRNA expression in a sample 
obtained from primary uveal melanoma may therefore not be representative of the whole 
tumour due to this heterogeneous distribution. To avoid such a sampling bias, examination 
of the amount of VEGF-A protein in sera of UM patients can be an alternative. In several 
tumours, e.g. colon carcinoma, soft tissue sarcomas and gastric cancer, serum VEGF-A levels 
have been found to be a marker of disease stage and an indicator of metastases 35-37. Until 
now, lactate dehydrogenase (LD) and alkaline phosphatase (AP) are the most indicative 
serum markers for metastatic disease in UM, in combination with liver ultrasonography 
38,39. Elevated serum osteopontin, melanoma-inhibitory activity (MIA) and S-100beta levels 
showed a correlation with metastatic UM to the liver in some studies 40,41. However, serum 
markers that indicate micrometastases at an early stage would be clinically preferable. When 
we indeed determined the amount of VEGF-A in sera of UM patients, we observed that 
VEGF-A levels were not increased at the time of enucleation and that only patients with 
manifest metastases had high VEGF-A serum levels (Fig. 7). A similar study was recently 
presented with the same results by Barak et al. 42 . Thus, although we found no correlation 
between VEGF-A expression by the primary tumor and histologic parameters, VEGF-A 
levels were significantly higher in patients with metastatic disease. It may be that the size 
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of the hypoxic areas (the ‘small’ eye versus the ‘large’ liver) influences the VEGF-A levels in 
the blood.”
Further research is necessary to determine whether VEGF-A levels increase prior to 
clinical recognition of UM metastases and whether this marker can be used for screening 
purposes.
In conclusion, we observe a basic as well as a hypoxia-induced expression of HIF-1α and 
VEGF-A mRNA and protein expression by UM cells. The basic expression is variable, espe-
cially in biopsies taken from UM in enucleated eyes, but in all cell lines and primary tumour 
UM cell cultures, VEGF-A expression was increased by hypoxia. Most likely, the variation 
between biopsies is due to different degrees of ischemia in different tumour areas. The high 
amounts of VEGF-A in the sera of patients with UM metastases suggests that VEGF-A plays 
a role in the growth of metastases, and the use of VEGF-A inhibiting agents should therefore 
be considered. 
Acknowledgements








 1. Egan, K. M., Seddon, J. M., Glynn, R. J., Gragoudas, E. S., and Albert, D. M. Epidemiologic aspects of 
uveal melanoma. Surv.Ophthalmol. 1988. 32:239-251.
 2. Witmer, A. N., Vrensen, G. F., Van Noorden, C. J., and Schlingemann, R. O. Vascular endothelial 
growth factors and angiogenesis in eye disease. Prog.Retin.Eye Res. 2003. 22:1-29.
 3. Gasparini, G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000. 
5 Suppl 1:37-44.
 4. Machein, M. R. and Plate, K. H. Role of VEGF in developmental angiogenesis and in tumor angiogenesis 
in the brain. Cancer Treat.Res. 2004. 117:191-218.
 5. Boyd, S. R., Tan, D., Bunce, C., Gittos, A., Neale, M. H., Hungerford, J. L., Charnock-Jones, S., and 
Cree, I. A. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal 
melanoma: identification of a potential therapeutic window. Br.J.Ophthalmol. 2002. 86:448-452.
 6. Missotten, G. S., Notting, I. C., Schlingemann, R. O., Zijlmans, H. J., Lau, C., Eilers, P. H., Keunen, J. 
E., and Jager, M. J. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch.Ophthal-
mol. 2006. 124:1428-1434.
 7. el, Filali M., Homminga, I., Maat, W., van, d., V, and Jager, M. J. Triamcinolone acetonide and anecor-
tave acetate do not stimulate uveal melanoma cell growth. Mol.Vis. 2008. 14:1752-1759.
 8. Papetti, M. and Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis. Am.J.Physiol 
Cell Physiol 2002. 282:C947-C970.
 9. Augsburger, J. J., Correa, Z. M., Freire, J., and Brady, L. W. Long-term survival in choroidal and ciliary 
body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998. 105:1670-
1678.
 10. Kujala, E., Makitie, T., and Kivela, T. Very long-term prognosis of patients with malignant uveal mela-
noma. Invest Ophthalmol.Vis.Sci. 2003. 44:4651-4659.
 11. Foss, A. J., Alexander, R. A., Jefferies, L. W., Hungerford, J. L., Harris, A. L., and Lightman, S. Microves-
sel count predicts survival in uveal melanoma. Cancer Res. 1996. 56:2900-2903.
 12. Makitie, T., Summanen, P., Tarkkanen, A., and Kivela, T. Microvascular density in predicting survival 
of patients with choroidal and ciliary body melanoma. Invest Ophthalmol.Vis.Sci. 1999. 40:2471-2480.
 13. Ly, L., Odish, O., de Wolff-Rouendaal, D., Missotten, G., Luyten, G., and Jager, M. Intravascular pres-
ence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey. Invest Ophthalmol.
Vis.Sci. 2009.
 14. Chen, P. W., Murray, T. G., Salgaller, M. L., and Ksander, B. R. Expression of MAGE genes in ocular 
melanoma cell lines. J.Immunother. 1997. 20:265-275.
 15. De Waard-Siebinga, I., Blom, D. J., Griffioen, M., Schrier, P. I., Hoogendoorn, E., Beverstock, G., 
Danen, E. H., and Jager, M. J. Establishment and characterization of an uveal-melanoma cell line. 
Int.J.Cancer 1995. 62:155-161.
 16. Kan-Mitchell, J., Mitchell, M. S., Rao, N., and Liggett, P. E. Characterization of uveal melanoma cell 
lines that grow as xenografts in rabbit eyes. Invest Ophthalmol.Vis.Sci. 1989. 30:829-834.
 17. Luyten, G. P., Naus, N. C., Mooy, C. M., Hagemeijer, A., Kan-Mitchell, J., van, D. E., Vuzevski, V., 
de Jong, P. T., and Luider, T. M. Establishment and characterization of primary and metastatic uveal 
melanoma cell lines. Int.J.Cancer 1996. 66:380-387.
 18. Verbik, D. J., Murray, T. G., Tran, J. M., and Ksander, B. R. Melanomas that develop within the eye 
inhibit lymphocyte proliferation. Int.J.Cancer 1997. 73:470-478.
 19. Bustin, S. A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain 
reaction assays. J.Mol.Endocrinol. 2000. 25:169-193.
Regulation of VEGF-A in uveal melanoma 81
 20. Zuidervaart, W., van, d., V, Hurks, M. H., van Nieuwpoort, F. A., Out-Luiting, C. J., Singh, A. D., 
Frants, R. R., Jager, M. J., and Gruis, N. A. Gene expression profiling identifies tumour markers poten-
tially playing a role in uveal melanoma development. Br.J.Cancer 2003. 89:1914-1919.
 21. Gilsbach, R., Kouta, M., Bonisch, H., and Bruss, M. Comparison of in vitro and in vivo reference genes 
for internal standardization of real-time PCR data. Biotechniques 2006. 40:173-177.
 22. Narayanan, R., Kenney, M. C., Kamjoo, S., Trinh, T. H., Seigel, G. M., Resende, G. P., and Kupper-
mann, B. D. Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest 
Ophthalmol.Vis.Sci. 2005. 46:304-309.
 23. Chen, H., Kovar, J., Sissons, S., Cox, K., Matter, W., Chadwell, F., Luan, P., Vlahos, C. J., Schutz-
Geschwender, A., and Olive, D. M. A cell-based immunocytochemical assay for monitoring kinase 
signaling pathways and drug efficacy. Anal.Biochem. 2005. 338:136-142.
 24. Kovar, J. L., Johnson, M. A., Volcheck, W. M., Chen, J., and Simpson, M. A. Hyaluronidase expression 
induces prostate tumor metastasis in an orthotopic mouse model. Am.J.Pathol. 2006. 169:1415-1426.
 25. Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell 2000. 100:57-70.
 26. Bergers, G. and Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat.Rev.Cancer 2003. 3:401-
410.
 27. Ijland, S. A., Jager, M. J., Heijdra, B. M., Westphal, J. R., and Peek, R. Expression of angiogenic and 
immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999. 9:445-450.
 28. Mizukami, Y., Kohgo, Y., and Chung, D. C. Hypoxia inducible factor-1 independent pathways in tumor 
angiogenesis. Clin.Cancer Res. 2007. 13:5670-5674.
 29. Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Mantovani, A., and Marme, D. Migration of human 
monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor 
flt-1. Blood 1996. 87:3336-3343.
 30. Potgens, A. J., Lubsen, N. H., van Altena, M. C., Schoenmakers, J. G., Ruiter, D. J., and de Waal, R. 
M. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines 
xenografted to nude mice. Am.J.Pathol. 1995. 146:197-209.
 31. Claffey, K. P., Brown, L. F., del Aguila, L. F., Tognazzi, K., Yeo, K. T., Manseau, E. J., and Dvorak, 
H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells 
increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996. 56:172-181.
 32. Westphal, J. R., van’t Hullenaar, R. G., van der Laak, J. A., Cornelissen, I. M., Schalkwijk, L. J., van 
Muijen, G. N., Wesseling, P., de Wilde, P. C., Ruiter, D. J., and de Waal, R. M. Vascular density in 
melanoma xenografts correlates with vascular permeability factor expression but not with metastatic 
potential. Br.J.Cancer 1997. 76:561-570.
 33. Sheidow, T. G., Hooper, P. L., Crukley, C., Young, J., and Heathcote, J. G. Expression of vascular endo-
thelial growth factor in uveal melanoma and its correlation with metastasis. Br.J.Ophthalmol. 2000. 
84:750-756.
 34. Maat, W., Jordanova, E. S., van Zelderen-Bhola, S. L., Barthen, E. R., Wessels, H. W., Schalij-Delfos, N. 
E., and Jager, M. J. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for 
prognostication based on fine-needle aspiration biopsies. Arch.Pathol.Lab Med. 2007. 131:91-96.
 35. Karayiannakis, A. J., Syrigos, K. N., Polychronidis, A., Zbar, A., Kouraklis, G., Simopoulos, C., and 
Karatzas, G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathologi-
cal variables, patient survival, and tumor surgery. Ann.Surg. 2002. 236:37-42.
 36. Hayes, A. J., Mostyn-Jones, A., Koban, M. U., A’Hern, R., Burton, P., and Thomas, J. M. Serum vascular 







 37. Celen, O., Kahraman, I., Yildirim, E., and Berberoglu, U. Correlation of vascular endothelial growth 
factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma 
2004. 51:293-299.
 38. Eskelin, S., Pyrhonen, S., Summanen, P., Prause, J. U., and Kivela, T. Screening for metastatic malignant 
melanoma of the uvea revisited. Cancer 1999. 85:1151-1159.
 39. Kaiserman, I., Amer, R., and Pe’er, J. Liver function tests in metastatic uveal melanoma. Am.J.Ophthalmol. 
2004. 137:236-243.
 40. Barak, V., Frenkel, S., Kalickman, I., Maniotis, A. J., Folberg, R., and Pe’er, J. Serum markers to detect 
metastatic uveal melanoma. Anticancer Res. 2007. 27:1897-1900.
 41. Missotten, G. S., Korse, C. M., van Dehn, C., Linders, T. C., Keunen, J. E., Jager, M. J., and Bonfrer, J. 
M. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A compari-
son with liver function tests. Tumour.Biol. 2007. 28:63-69.
 42.  Barak V, Frenkel S, Kalickman I, Pe’erJ. VEGF serum levels as a new marker for metastic uveal mela-
noma. Presented at the International Congress of Ocular Oncology, Cambridge, UK; 2009.
Chapter 5
Bevacizumab and intraocular 
tumors: an intriguing paradox 
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Purpose. Bevacizumab, a humanized monoclonal antibody to Vascular Endothelial Growth 
Factor-A (VEGF-A), was originally developed as an anti-tumor treatment. In ocular oncol-
ogy, it is being used to treat macular edema due to radiation retinopathy, but it may also be 
useful for the treatment of primary uveal melanoma (UM) or its metastases. We determined 
the effect of bevacizumab on the growth of B16F10 cells inside the eye and on B16F10 and 
UM cells cultured in vitro. 
Methods. B16F10 melanoma cells were placed into the anterior chamber of the eye of C57Bl/6 
mice and tumor growth was monitored after injection of different doses of bevacizumab or 
mock injection. In addition, the effect of bevacizumab on in vitro growth of B16F10 and 
human UM cells and on the expression of VEGF-A, GLUT-1, and HIF-1α was evaluated. 
Results. Following intraocular injection of bevacizumab into murine B16 tumor-containing 
eyes, an acceleration of tumor growth was observed, with the occurrence of anterior cham-
ber hemorrhages. Bevacizumab did not affect proliferation of B16F10 cells in vitro, while it 
inhibited UM cell proliferation. Expression analysis demonstrated that addition of bevaci-
zumab under hypoxic conditions induced VEGF-A, GLUT-1 and HIF-1α in B16F10 cells as 
well as in UM cell lines and two of four primary UM tumor cultures. 
Conclusion. In contrast with expectations, intraocular injection of bevacizumab stimulated 
B16F10 melanoma growth in murine eyes. In vitro exposure of B16 and human UM cells 
to bevacizumab led to paradoxical VEGF-A upregulation. The use of VEGF inhibitors for 
treatment of macular edema (due to radiation retinopathy) after irradiation of UM should be 
considered carefully, because of the possible adverse effects on residual UM cells.
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Introduction
Uveal melanoma (UM) is the most common primary intraocular tumor in adults with an an-
nual incidence of 7-10 cases per million per year. Current treatments of UM depend on several 
clinical factors and include enucleation, radiotherapy (plaque, proton beam or stereotactic 
irradiation), transpupillary thermotherapy (TTT) and local resection 1-7. Radiotherapy using 
a radioactive plaque is a highly successful therapy, achieving local tumor control of UM in 
up to 97% of treated cases 8-10. However, radiation therapy may lead to radiation retinopathy, 
a slowly progressive, delayed-onset disease of retinal blood vessels characterized by retinal 
ischemia, neovascularization and leaking vessels 11-13. Radiation retinopathy has been de-
scribed in up to 63% of eyes after plaque radiation treatment 14-17. Vascular endothelial growth 
factor (VEGF)-A, a strong pro-angiogenic factor, most likely contributes to its pathogenesis: 
it has been shown that VEGF-A can be produced by retinal tissue as well as hypoxic UM cells 
18,19. Intravitreal bevacizumab (a humanized monoclonal antibody to VEGF-A) has been used 
to treat numerous ophthalmologic disorders involving ischemia and neovascularization, 
including radiation retinopathy. Several studies demonstrate a decrease of macular edema 
in radiation retinopathy and improvement of visual acuity after intravitreal bevacizumab 
treatment 20-26. 
Another indication for using bevacizumab might be the treatment of the tumor itself and 
its metastases. Bevacizumab has been approved for treatment of metastases of several malig-
nancies, including colorectal, renal, and lung cancers 27-29, and is still under investigation for 
numerous other primary tumors and metastatic disease, e.g. of breast and pancreas cancer 
and cutaneous melanoma 30-32. Despite the good primary tumor control achieved by current 
treatment options, estimates of 5-year UM-related mortality range from 26% to 32% 33,34, and 
up to 50% of all UM patients may eventually die due to metastatic disease 35,36. 
Blood vessels in primary UM can facilitate tumor cell entry into the circulation, resulting 
in metastatic disease 37. Yang et al. studied the systemic treatment of metastatic disease of 
UM with bevacizumab in mice and demonstrated a reduction in the number of metastases 
38. There are no studies describing a possible treatment with intravitreal VEGF inhibitors for 
primary uveal melanoma. It has been proposed that patients who develop clinical metasta-
ses from UM often harbour micrometastases for years which will most likely resemble the 
primary UM cell genotype 39. Also, following radiation therapy of an intraocular melanoma, 
viable UM cells may remain, and these might be influenced by intraocular treatment with 
intravitreal bevacizumab. While bevacizumab might be a useful drug to attack uveal mela-
noma, several studies have been published describing unexpected effects of bevacizumab 
on tumor cells, resulting in tumor recurrences and therapy resistance 40,41. We therefore 
investigated the effect of bevacizumab on intraocular tumor growth of the murine B16F10 







on the proliferation of this B16F10 cell line, on UM cell lines in vitro, and on primary UM 
cell cultures 42. 
Material and Methods
In vivo experiments
Male C57BL/6jico mice, 8 weeks old, were obtained from Charles River (Lille, France). The 
mice were housed under Specific Pathogen Free (SPF) conditions and cared for in accor-
dance with the guidelines of the University Committee for the Humane Care of Laboratory 
animals, NIH guidelines on laboratory animal welfare, and the ARVO statement for the Use 
of Animals in Ophthalmic and Vision Research. All research protocols were approved by 
the local Committee for Animal Welfare (DEC), LUMC, Leiden, The Netherlands. B16F10 
melanoma cells were injected into the anterior chamber of the mice as described previously 
43. In short, mice were anesthesized intraperitoneally using Xylazine (Rompun 2%, Bayer, 
Leverkussen, Germany) and Ketamine Hydrochloride (Aescoket; Aesculaap bv, Boxtel, 
The Netherlands; ratio 1:1). A sterile 30 G needle was used to make a paracentesis at the 
corneoscleral junction, parallel and anterior to the iris. A fused silica capillary (200 μm 
outer diameter (OD), 100 μm inner diameter (ID) was fitted into a union (VALCO, Vici 
AG international, Schenkon, Switzerland). The capillary and the union were mounted onto 
a 0.1 ml Hamilton syringe. The capillary, loaded with B16F10 melanoma cells (2.5. 104 cells/ 
4 μL (approximate volume of anterior chamber of murine eye), was inserted through the 
paracentesis in the cornea, and the tumor cells were deposited into the anterior chamber. 
Mice were separated into three groups (n=7 per group) and the experiment was performed 
twice; the first group received a low dose of bevacizumab (equivalent human dose; 2µg/ 4 
µl), the second group received a high dose (10 times the equivalent human dose; 20 µg/ 4 
µl) of bevacizumab; a control group was injected with a mock injection with 4 µl phosphate-
buffered saline (PBS). 
The eyes were examined three times a week using a dissecting microscope to monitor tumor 
growth. Tumor volume was recorded as the percentage of anterior chamber occupied with 
tumor. Mice were sacrificed by cervical dislocation when the tumor occupied 80-100% of the 
anterior chamber. Afterwards, all murine eyes were fixed in 10% neutral-buffered formalin 
for 48 hours and embedded in paraffin. Serial sections of 4μm were prepared, mounted on 
glass slides and stained with hematoxylin and eosin. The number of vessels and their location 
were evaluated in every tumor-containing eye of one experiments (n=7 per group).
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Cell lines and primary tumor cell cultures
The B16F10 melanoma cell line was cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Invitrogen, CA), supplemented with 10% fetal calf serum (FCS), glutamine and 
2% penicillin/ streptomycin. Cells were incubated at (37°C, 5 % CO2). When cultures showed 
70% confluency, the cells were harvested and used for inoculation or in vitro experiments.
Two UM cell lines and four primary UM cell cultures were cultured under either nor-
moxic (20% O2 ) or hypoxic (1% O2;  during experiments) conditions (HERAcell 240 CO2 
Incubator, Thermo Fisher Scientific Inc, USA). Mel285 is a primary tumor-derived cell line, 
while OMM2.3 is a metastasis-derived cell line. Mel285, and OMM2.3 were provided by dr. B. 
Ksander (Schepens Eye Research Institute, Boston, MA) 44,45. Four primary cell cultures were 
established in our laboratory. UM cell lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10 % fetal calf serum and 1% penicillin/streptomycin 
(GIBCO, Life Technologies, Paisley, UK). The cells were passaged once or twice a week using 
trypsin (0.05%). Fresh tumor tissues, obtained immediately after enucleation of the eye, were 
cultured in Amniochrome® Pro Medium (Lonza Group Ltd, Basel, Switzerland) and passaged 
maximally once or twice before experiments.
Cell proliferation 
Cell proliferation was measured by mitochondrial function using the water-soluble tetrazo-
lium salt (WST-1) assay (Roche Diagnostics, Indianapolis, IN, USA), as previously described 
46. In short, 96-well plates were filled with 1200 cells per well, filled with regular medium 
(control) or bevacizumab solutions (three doses, see ‘bevacizumab treatment’ on the next 
page), and either placed in a normoxic (20% O2, 5% CO2 , 37°C) or hypoxic (1% O2, 5 % CO2 , 
37°C) chamber to mimic in vivo ischemia (HERAcell 240 CO2 Incubator, Thermo Fisher 
Scientific Inc, USA). Proliferation was measured on days 1, 2, and 3 (B16F10) or 1, 3, and 
6 (human cell lines and primary cultures) by adding 10ul WST-reagent to 8 wells (8 wells 
without reagent for background absorbance). Absorbance was measured at 450nm (n=8) on 
a multiwell spectrophotometer (Perkin lmer, Wellesley, MA). 
Quantitative PCR 
To analyze VEGF-A mRNA expression after treatment with bevacizumab, reverse transcrip-
tase in combination with quantitative PCR experiments were performed, as described before 
19,47. In short, RNA was isolated using an Rneasy® Mini Kit (Qiagen, Valencia, USA) and RNA 
samples were reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA, USA). Using 96-well plates, a solution of sample cDNA, iQ SYBR Green Supermix, 
forward and reverse primers for beta-actine (β-ACTIN), ribosomal protein S11 (RPS-11), 
VEGF-A and sterile water was prepared. Primer sequences were used as described previ-
ously and are summarized in Table 1 [19,48]. A quantitative analysis of the samples was then 







The PCR reaction settings were 95°C for 3 minutes, 40 cycles at 95°C for 30 seconds and 
60°C for 30 seconds, followed by 95°C for 1 minute, and 60°C for 1 minute. To correct the 
sample-to-sample variation, several cellular housekeeping genes were selected using Genorm 
software (Center for Medical Genetics, Ghent, Belgium), and these served as an endogenous 
control against which the target-gene expression levels were normalized (normalized expres-
sion of treated cells/ normalized expression of control cells after 24 hours) 47-49. 
VEGF-A protein expression 
The VEGF-A protein concentration was measured in the supernatant of the B16F10 cell cul-
ture using a commercial sandwich enzyme-linked immunosorbent assay (mouse VEGF-A 
ELISA, Arcus Biologicals, Modena, Italy). The lowest measurable concentration was 4.5 pg/
ml.
HIF-1α in-cell Western experiment
To determine if bevacizumab influences VEGF-A expression in UM cells through the HIF-1α 
pathway, phosphorylation and activation of HIF-1α were analysed using an in-cell Western 
immunofluorescent assay as described before 19,50,51. Briefly, 96-well plates were filled with 
600 melanoma cells per well, filled with regular medium (control) or bevacizumab solutions 
(three doses, see ‘bevacizumab treatment’ on the next page), and placed in a hypoxic (1% O2, 
5 % CO2 , 37°C) chamber (HERAcell 240 CO2 Incubator, Thermo Fisher Scientific Inc, USA) 
for 24 hours, to mimic hypoxic in vivo conditions and stimulate VEGF-A expression. Cells 
were fixed and permeabilized for 1.5 hours before incubation with HIF-1α antibody (Bethyl 
laboratories INC Montgomery, TX, USA (1:1000 for 2 hours)) in Odyssey Blocking Buffer. 
After washing, plates were incubated with the secondary antibody Goat anti-Rabbit IRDye® 
800CW (1:800); for determining the cell number, DRAQ5 (1:2000) and Sapphire700 (1:1000) 
were used (all three from LI-COR Biosciences, Lincoln NB, USA). The plate was scanned 
on an Odyssey infrared scanner, HIF-1α at the 800nm channel and DRAQ5 at the 700nm 
channel (LI-COR Biosciences, Lincoln NB, USA). Data were acquired using the scanner 
software, exported to Excel (Microsoft, Redmond, WA, USA), and analyzed by GraphPad 
Prism (GraphPad Software, San Diego, CA, USA).
Table 1. Primer sequences of the genes studied in the qPCR assay 
Primer Gene Forward primer (5’-3’) Reverse primer (5’-3’)
Endogenous 
controls 
RPS11 AAGCAGCCGACCATCTTTCA CGGGAGCTTCTCCTTGCC 
β-ACTIN CGGGACCTGACTGACTACCTC CTCCTTAATGTCACGCACGATTT 
Genes under study 
VEGF-A GCCCTTGCCTTGCTGCTCTACC GTGATGATTCTGCCTCCTCCTTC 
GLUT-1 CCCGCTTCCTGCTCATCAACC GCCGACTCTCTTCCTTCATCTCC
Primer sequences of the control and studied genes that were used in qPCR assay to determine level of 
expression in UM cell lines.
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Bevacizumab treatment
Several bevacizumab (Avastin®, Roche Pharma, Germany) solutions were used to investigate 
treatment options in vitro and in vivo. 
In vitro uveal melanoma cells
To treat UM cell cultures, bevacizumab was dissolved in medium to obtain solutions of 1.25 
mg/ 5.46 ml (generally used intraocular human dose), 12.5 mg/5.46 ml (10 times the normal 
dose) or 25 mg/5.46 ml (20 times the normal dose) per well. As control, we used culture 
medium.
In vivo mice experiments
Equivalent mouse doses were calculated according to human and mouse intraocular volume: 
as 1.25 mg bevacizumab is used to inject the human eye with a mean volume of 5.46 ml, we 
used 2µg (first group; equivalent human dose) or 20 µg (second group 10 times equivalent 
human dose) to inject a murine eye with a mean volume of 9.60 µl. The third group received 
a mock injection with PBS as previously described. Injections were performed on days 2, 6, 
and 10 after tumor cell inoculation (not all mice received an injection on day ten since some 
of them were already sacrificed). 
Statistical analysis
Statistical analysis was performed with Graphpad Prism software (GraphPad Software, Inc., 
La Jolla, CA). Overall survival of mice was estimated by the Kaplan-Meier method and log-
rank test. One-way ANOVA and the Bonferonni test were used to analyze for significant 
differencences in cell proliferation and HIF-1α activation of treated and untreated cells. P < 
0.05 was considered statistically significant.
Results
Intraocular tumor growth in a B16F10 eye tumor mouse model 
As VEGF-A inhibitors are being used to treat many different types of cancer metastases, we 
wondered whether they can be used to inhibit intraocular tumor growth. After intraocular 
inoculation of B16F10 melanoma cells into the anterior chamber of C57Bl/6 mice, two dif-
ferent doses of bevacizumab or medium were injected intraocularly on days 2, 6 and 10. 
Each group consisted of seven mice, and the experiment was performed twice. A summary 
of the results of the two experiments is shown in Figure 1. Whereas inhibition of tumor 
and vessel growth was expected, an acceleration of intraocular tumor growth was observed 
in eyes treated with both doses of bevacizumab. Treated mice had to be sacrificed earlier 







anterior chamber and tumor hemorrhages were observed in the eyes that had been treated 
with bevacizumab but not in untreated eyes (Figure 2). 
B16F10 murine melanoma cell line: in vitro experiments
In vitro cell proliferation
As the in vivo results showed the opposite effects of what was expected, we studied the 
effect of bevacizumab on tumor cell proliferation under normoxia and hypoxia. Addition 
of bevacizumab to B16F10 cells in vitro did not effect proliferation of tumor cells cultured 
in normoxic conditions, while a dose-dependent decrease in proliferation was noticed after 
treatment with bevacizumab under normoxic conditions (Figure 3). 
In vitro VEGF-A mRNA expression 
As intraocular and intratumoral hemorrhages were visible in eyes receiving bevacizumab, 
we wondered whether the anti-VEGF-A treatment with bevacizumab had a paradoxical 
stimulatory effect on VEGF-A gene expression. Indeed, bevacizumab induced VEGF-A 
mRNA expression in a dose-dependent manner when cells were cultured under hypoxic 
Figure 1. Acceleration of intraocular tumor growth in mice after treatment with bevacizumab. 
After placement of B16F10 melanoma cells in the eye of C57Bl/6 mice, bevacizumab was injected intraocularly 
to try to inhibit intraocular tumor growth. Following three bevacizumab injections on days 2, 6 and 10, a 
significant acceleration of intraocular tumor growth occurred compared to the control group (AVA1 versus 
control p = 0.007, and AVA10 versus control p = 0.06 ). Growth was recorded as the percentage of anterior 
chamber occupied with tumor, and mice were sacrificed when the tumor occupied 80-100% of the anterior 
chamber. The curves are the pooled data from two experiments, with 14 (two times 7) mice in each of the three 
groups.
AVA1= equivalent human dose: 2 μg/ 4 µl; AVA10= 10 times the equivalent human dose: 20 μg/ 4 μl; CO= 
control group: 4 µl mock PBS injection.
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Figure 2. Anterior chamber hemorrhages in murine eyes treated with bevacizumab. 
Anterior chamber hemorrhage as seen in a murine tumor eye treated with bevacizumab (right) in contrast to 
an untreated eye (left).
Figure 3. A high dose of bevacizumab inhibits proliferation of B16F10 cells under hypoxic conditions. 
Bevacizumab was added to B16F10 cells in vitro under normoxic (top) and hypoxic (bottom) circumstances 
and proliferation was measured by water-soluble tetrazolium salt assay on days one, two and three after the 
addition of bevacizumab. Cell density is expressed in absorbance (optical density). A high dose of bevacizumab 







conditions. Under normoxia, baseline VEGF-A expression is relatively high but not affected 
by bevacizumab treatment (Figure 4).
In contrast to mRNA expression, in vitro treatment of B16F10 cells with the human 
equivalent dose of bevacizumab led to a lower VEGF protein expression after 3 or 6 days of 
culture (Figure 4). We hypothesize that the high concentration of bevacizumab effectively 
bound the produced VEGF-A, thus making it unavailable for binding in the immuno assay.
Figure 4. Bevacizumab induces vascular endothelial growth factor A mRNA expression in B16F10 cells 
under hypoxic conditions.
The effect of bevacizumab on VEGF-A expression in B16F10 cells was determined using qPCR analysis (top) 
and ELISA (bottom). The amount of VEGF-A mRNA expression was measured with qPCR under normoxic 
(black) and hypoxic (gray) conditions after 24 hours with different doses bevacizumab treatment. Expression 
is demonstrated in normalized fold. VEGF-A mRNA expression increased in a dose-dependent manner after 
treatment with bevacizumab, when cells were cultured under hypoxic conditions. 
An ELISA was used to measure the amount of VEGF-A protein in the supernatant of UM cell lines after 
hypoxic exposure for 24 hours. Shown is the amount of VEGF-A protein (pg/ml). Paradoxically, the amount of 
produced protein is reduced in the presence of bevacizumab. 
AVA1= equivalent human dose: 1.25 mg/5.46 ml; AVA10= 10 times the equivalent human dose: 12.5 mg/ 5.46 
ml; AVA20= 20 times the equivalent human dose: 25 mg/ 5.46 ml; CO= control group: culture medium.
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Histologic and in vivo observation of tumor-inoculated murine eyes
Based on the in vitro results, the acceleration of tumor growth in vivo could not be due to 
a direct proliferative effect, but possibly due to formation of new vessels after induction of 
VEGF-A. After sacrificing the mice, all eyes were enucleated and stained with haematoxylin 
and eosin to evaluate the amount of vessels and their location in the tumor. No apparent 
differences were present in the amount of vessels in the presence or absence of bevacizumab 
treatment (data not shown). 
Involvement of HIF-1α pathway
As the new working hypothesis was that the observed intraocular tumor growth after bevaci-
zumab was due to an increased production of VEGF-A, one might expect an upregulation of 
the pathways involved in VEGF-A induction. To investigate whether the increased VEGF-A 
mRNA expression after exposure to bevacizumab involved HIF-1α, an in-cell Western as-
say was performed. Under already hypoxic conditions, treatment with 10 times the human 
equivalent of bevacizumab induced an increase of HIF-1α protein in B16F10 melanoma cells 
in comparison to the control (Figure 5). 
To further confirm involvement of HIF-1α, GLUT-1 expression was measured as a deter-
minant of HIF-1α transcriptional activity. Gene expression analysis showed an induction of 
Figure 5. Bevacizumab induces HIF-1α activation and GLUT-1 mRNA expression in B16F10 cells under 
hypoxic conditions.
Expression of HIF-1α was measured in B16F10 cells using an in-cell Western assay after cell exposure to 
hypoxic conditions for 24 hours. Expression is demonstrated in normalized integrated intensity ((HIF-1α/ cell 
count)*100). A significant induction of HIF-1α was observed when comparing the AVA10 treated cells with the 
control (p=0.03) (top). 
qPCR analysis shows an induction of GLUT-1 expression in B16F10 cells treated with the high dose of 
bevacizumab (AVA20) in comparison to no treatment. Expression is demonstrated in normalized fold 
(bottom).
AVA1= equivalent human dose: 1.25 mg/ 5.46 ml; AVA10= 10 times the equivalent human dose: 12.5 mg/ 5.46 







GLUT-1 expression in B16F10 cells treated with bevacizumab in comparison to control, but 
only when treated with the highest dose (Figure 5). 
Validation in human UM cell lines and primary cultures
In vitro uveal melanoma cell proliferation
In order to determine whether the mechanism observed in murine B16F10 cells was relevant 
to the human situation, the in vitro tests were repeated using human UM cell lines and 
primary cell cultures. Following treatment with bevacizumab, human UM cell lines showed 
a dose-dependent decrease of proliferation under normoxic as well as hypoxic culture 
conditions (Figure 6). Four primary tumor cell cultures displayed a greater variability: in 
Figure 6. Bevacizumab inhibits proliferation of uveal melanoma cell lines in vitro.
Proliferation of UM cell lines was measured by WST-1 assay after exposure to three different doses of 
bevacizumab during one, three or six days, under normoxic and hypoxic conditions. Cell density is expressed 
as absorbance (optical density, OD). A dose-dependent decrease of proliferation after treatment with 
bevacizumab occurs under hypoxic as well as normoxic conditions. (Mel 285 normoxia day 1 p=0.0012, all 
other cellines/treatments p<0.0001). AVA1= equivalent human dose: 1.25 mg/ 5.46 ml; AVA10= 10 times the 
equivalent human dose: 12.5 mg/ 5.46 ml; AVA20= 20 times the equivalent human dose: 25 mg/ 5.46 ml; CO= 
control group: culture medium.
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two cultures inhibition of proliferation was observed while two other cell cultures appeared 
resistant and did not show an effect (data not shown). 
In vitro VEGF-A mRNA expression after bevacizumab treatment
Treatment of two UM cell lines with bevacizumab under hypoxic conditions led to an induc-
tion of VEGF-A mRNA (Figure 7). Exposure of UM cells to bevacizumab at normal oxygen 
levels showed the same trend, but was less substantial (data not shown).
In primary UM cell cultures, the effect of bevacizumab on proliferation had been variable: in 
the two cell cultures which had shown reduced proliferation, bevacizumab induced VEGF-
A expression (Figure 8) with a maximum fold increase of 3.36 and 2.48 (cultures two and 
three). The two other cultures which continued to proliferate in the presence of bevacizumab 
showed a high VEGF-A expression that was not affected by treatment.
In vitro GLUT-1 mRNA expression after bevacizumab treatment under hypoxic conditions
To confirm involvement of HIF-1α in the response to bevacizumab, GLUT-1 expression 
was analyzed. An induction of GLUT-1 expression was present following treatment of UM 
cell lines with bevacizumab (Figure 7). GLUT-1 expression in primary cell cultures was 
significantly correlated with decrease in VEGF-A expression (correlation coefficient 0.974, 
P= 0.0002. Figure 8).
Discussion
Anti-VEGF agents have proven to be potent therapeutic agents in ophthalmology for the 
treatment of Age-related Macular Degeneration (AMD), diabetic macular edema and neo-
vascular glaucoma 47,48,52-54. In UM, bevacizumab (Avastin®) is especially interesting because 
of a potential dual use: it is currently used in uveal melanoma patients to treat macular 
edema due to radiation retinopathy but may potentially be used to treat the primary uveal 
melanoma (UM) or its metastases. 
We set out to determine the effect of intraocular injections of bevacizumab as a treatment 
for intraocular tumors in mice. Unexpectedly, an acceleration of intraocular tumor growth 
in response to anti-VEGF-A occurred. Previously, Yang et al. had shown a decrease of tumor 
size in the eye and a reduction in the number of metastases when bevacizumab was given 
systemically 38. The difference in outcome may be due to a concentration effect, or it may be 
that direct contact with the vessel wall is important: in Yang’s study, bevacizumab reached 
the tumor through the intravascular route, while we treated the tumor locally. 
There has been some discussion concerning whether humanized bevacizumab can ef-






96 Figure 7. Bevacizumab induces VEGF-A and GLUT-1 mRNA expression in uveal melanoma cell lines.
mRNA expression was measured with qPCR after exposure to different doses of bevacizumab under hypoxic 
conditions for 24 hour. Expression is shown in normalized fold. Treatment with bevacizumab induced 
VEGF-A and GLUT-1 mRNA.
AVA1= equivalent human dose: 1.25 mg/ 5.46 ml; AVA10= 10 times the equivalent human dose: 12.5 mg/ 5.46 
ml; AVA20= 20 times the equivalent human dose: 25 mg/ 5.46 ml; CO= control group: culture medium.
Figure 8. mRNA expression of VEGF-A differs in primary uveal melanoma cell cultures treated with 
bevacizumab but correlates with GLUT-1 mRNA expression.
mRNA expression was measured with qPCR under hypoxic conditions and after 24 hours of different 
doses bevacizumab treatment. Expression is demonstrated in normalized fold. Two cell cultures show a 
clear induction of VEGF-A expression after treatment with bevacizumab (culture two and three). GLUT-1 
expression in UM cell cultures corresponds to the VEGF-A expression (bottom); correlation coefficient 0.974, 
P= 0.0002. 
AVA1= equivalent human dose: 1.25 mg/ 5.46 ml; AVA10= 10 times the equivalent human dose: 12.5 mg/ 5.46 
ml; AVA20= 20 times the equivalent human dose: 25 mg/ 5.46 ml; CO= control group: culture medium.
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and mouse VEGF164 protein are 86% similar 
56. In addition, Western blot analysis and ELISA 
analysis by Bock et al demonstrated that a high dose of bevacizumab can bind human as well 
as murine VEGF 57,58. Additionally, we confirmed the effects noticed in the murine cells with 
human UM cell lines and short term fresh UM cultures: bevacizumab induced an upregula-
tion of VEGF-A mRNA expression in B16F10 as well as human UM cells. This was especially 
true when the cells were cultured under hypoxic conditions, suggesting that a certain level of 
ischemia is needed to induce the VEGF-stimulating effect of bevacizumab. 
We observed a relatively high VEGF-A expression under normoxic conditions in the 
B16F10 melanoma cells which suggests some kind of HIF-1α stabilization. This could involve 
the von Hippel-Lindau tumor suppressor (pVHL) that regulates the stability of Hypoxia-
Inducible Factor (HIF)-1α. Loss of pVHL function results in constitutive activation of HIF-
1α and thus VEGF-A expression 59-60. Nonetheless, the observed induction of HIF-1α as well 
as GLUT-1 expression in response to hypoxia suggests that HIF-1α regulation is still intact. 
One possible explanation for the in vivo tumor acceleration of tumor growth could be ves-
sel formation after VEGF-A induction. Surprisingly, we detected no difference in the number 
of vessels between the different treatment groups. We did, however, perceive several anterior 
chamber and tumor hemorrhages in murine eyes treated with bevacizumab that may be a re-
sult of the VEGF-A induction. Originally, VEGF-A was referred to as vascular permeability 
factor (VPF) 61. A rapid increase in vascular permeability occurs when the microvasculature 
is exposed acutely to any number of vascular permeabilizing factors, like VEGF-A, allowing 
for the diffusion of trophic substances to adjacent tumor cells 62. An alternative explanation 
may be that mice were monitored for macroscopic tumor growth for merely eleven days, 
which may be too short for vessels to form. Moreover, the intraocular tumor is limited by the 
size of the anterior chamber of 2 mm which is about the limit to which cells can be supplied 
with oxygen and energy through the diffusion of trophic substances. 
In our in vitro experiments, anti-VEGF-A therapy increased the amount of VEGF-A, 
mimicking hypoxic circumstances, and possibly inducing ‘pseudohypoxia’. This phenom-
enon has been described before in other tumors. Verhoeff et al. for example describe that 
VEGF inhibition by local deposition of pegaptanib decreased tumor hypoxia (GLUT-1 
positive tumor cells) in murine intracerebral glioma 63. This ‘pseudohypoxia’ subsequently 
can activate alternative pro-angiogenic signaling circuits, as was noticed in a murine 
pancreatic neuroendocrine cancer model. In this model, treatment with an antibody that 
specifically blocked VEGFR signaling caused an initial response of tumor stasis followed by 
tumor recurrence afterwards. The relapsing tumor expressed higher levels of mRNAs of pro-
angiogenic factors, and tumor relapse was preceded by hypoxic regions in the tumors in the 
response phase 40. Additionally, more invasion and metastasis was implicated as a response 
to this anti-angiogenic treatment, while histological analysis demonstrated a more invasive 







Recently, a novel set of isoforms has been described, the “VEGFxxxb” isoforms, which 
have the same length as the classical ones, because exon 8 (present in all the formerly known 
isoforms) is substituted by an alternatively-spliced exon of the same size (exon 8b). Several 
reports have demonstrated that VEGF165b may have anti-angiogenic properties 64,65. On the 
other hand, it has been suggested that these isoforms may act as VEGF receptor agonists 66,67. 
We did not study the possible contribution of VEGF165b.
With regard to the results in primary cell cultures we noticed inter-individual differences, 
as not all cultures showed an increase in VEGF-A or GLUT-1 expression after treatment with 
bevacizumab. This may be a reflection of molecular differences between tumors which may 
activate different biochemical pathways. We may be observing adaptive or evasive resistance 
of the tumor cells, after an initial response phase, to adapt or evade therapy by inducing 
mechanisms that reduce dependence on neovascularization, leading to changed tumor 
proliferation. 
The ‘pseudohypoxic’ conditions could be responsible for selection of more malignant 
tumor cells, which are less sensitive to anti-angiogenic treatment and switch to alternative 
malignant pathways that result in proliferation, migration and invasion.
Ischemic conditions caused by anti-VEGF treatment can also lead for instance to recruit-
ment of various bone marrow-derived cells that have angiogenic capacities. Pro-angiogenic 
monocytes induce vessel growth by expression of several cytokines and angiogenic factors. 
Research in glioblastoma multiforme has demonstrated HIF-1α to promote angiogenesis by 
inducing recruitment of mature F4/80+ macrophages in mice treated with bevacizumab. 
Additionally, a clinical study suggests that hypoxia determines survival outcome in patients 
treated with bevacizumab for glioblastoma multiforme 68-70. Since it has been shown previ-
ously that malignant UM tumors in patients with a poor survival have a lot of macrophages 
in their tumor, this mechanism is especially relevant 71. 
In conclusion, we observe an acceleration of UM growth after treatment with bevacizumab 
in mice. We further demonstrate a ‘pseudohypoxic’ effect, through induction of HIF-1α and 
VEGF-A expression, in hypoxic UM cell lines and cultures after treatment with bevacizumab. 
This phenomenon has been described in other tumor types and maybe the consequence 
of tumor adaptive or evasive resistance. The use of bevacizumab for treatment of macular 
edema (due to radiation retinopathy) after irradiation of UM should be considered carefully.
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Chapter 6
Triamcinolone acetonide 
and anecortave acetate 
do not stimulate uveal 
melanoma cell growth
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Purpose: Radiotherapy-induced radiation retinopathy can develop in over 40 % of eyes 
treated for uveal melanoma. Triamcinolone acetonide (TA) and anecortave acetate (AA) 
can be used to treat radiation retinopathy. Whether TA or AA has any effect on potentially 
still viable uveal melanoma cells in the choroid after radiotherapy is unknown. We therefore 
studied the effect of these drugs on the proliferation of uveal melanoma cell lines in vitro. 
Furthermore, as these drugs are supposed to counteract vascular leakage, we determined 
their effect on the expression and production of the pro-angiogenic vascular endothelial 
growth factor (VEGF-A), the anti-angiogenic pigment epithelium derived factor (PEDF) 
and thrombospondin (TSP-1) in uveal melanoma cells. 
Method: Three uveal melanoma cell lines were treated in vitro with TA or AA. Cell prolifera-
tion was measured by counting cells and using the WST-1 assay. VEGF-A and PEDF produc-
tion was measured by ELISA and intracellular expression of angiogenic-associated genes 
including VEGF-A, PEDF, and TSP-1 was determined by real time quantitative RT-PCR. 
Results: We found no effect of TA or AA on tumor cell growth or production of VEGF-A 
and PEDF in any of the three uveal melanoma cell lines tested. Regarding expression as 
measured by RT-PCR, TA had an inhibiting effect on TSP-1 in only one cell line, and no 
effect on VEGF-A or PEDF. AA showed a similar lack of effect.
Conclusion: Since TA and AA do not stimulate uveal melanoma cell growth, it seems to be 
save using these drugs to treat radiation retinopathy after irradiation for uveal melanoma. 
Though, additional experiments using more cell lines or primary tumor cell cultures are 
needed to validate this conclusion. Furthermore, the results of our study suggest that TA 
does not exert its anti-leakage effect through down-regulation of VEGF-A or up regula-
tion of TSP-1 or PEDF in uveal melanoma cell lines; it may be that TA and AA influences 
these pro- and anti-angiogenic factors only under hypoxic circumstances, and this will need 
further investigation.
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Introduction
Uveal melanoma (UM) is the most common primary intraocular tumor in adults, with an 
incidence of approximately 5-7 per 1.000.000 in Caucasian populations 1-4. The 5-year tumor-
related survival rate is about 70-80% 5,6 , and eventually about 50% of patients will die from 
the disease 7,8 . Because the eye lacks lymphatic vessels, the route of dissemination is almost 
exclusively hematogenous. The most common site of metastasis formation is the liver 9,10. 
Predictors of survival for UM patients are identified in histologic cell type, tumor diameter, 
tumor location, age, gender 11 and cytogenetic parameters. Loss of chromosome 3 is one of 
the most significant predictors for uveal melanoma-related deaths 12,13. In case of a primary 
UM, different treatments are available. Enucleation remains a common treatment for large 
tumors. Small and medium-sized tumors with a prominence < 8 mm can be treated with 
proton beam therapy, local resection or radiation 14,15. Radiotherapy is often combined with 
transpupillary thermotherapy, which may also allow treatment of larger tumors 16,17. Radio-
therapy, however, not only damages uveal melanoma cells, but also normal healthy cells 
located in the immediate surrounding of the tumor. Capillary endothelial cells are especially 
sensitive to radiation and presumably die directly or later by mitotic death 18. Capillary endo-
thelial cell loss causes changes in the structure and permeability of the vessels in the affected 
area. This leads to an occlusive microangiopathy, clinically known as radiation retinopathy. 
A variety of sight-threatening manifestations are associated with radiation retinopathy, such 
as macular edema and neovascularization 19. The onset of radiation retinopathy occurs on 
average 26 months after radioactive plaque therapy 20. The cause of this delay is not quite 
clear, though duration of the endothelial cell cycle and delayed mitotic cell death might be an 
explanation 18. After one year, approximately 5% of patients treated by radioactive plaque has 
developed radiation retinopathy and after five years this percentage has risen to about 40% 21.
At this moment, there is no established effective treatment for radiation retinopathy and 
its complications, although laser photocoagulation has shown some beneficial effect 20. A 
first report showed that anti-angiogenic agents such as Avastin™ have a beneficial effect 22.
 Triamcinolone acetonide (TA) is a glucocorticoid that has already been shown to improve 
vision for a few months in patients with macular edema associated with diabetic retinopathy 
23,24,24,25 and in patients with exudative age-related macular degeneration (ARMD) 26. Although 
the causal mechanisms underlying these diseases differ, diabetic retinopathy, exudative 
ARMD and radiation retinopathy share the same sight-threatening complications, such as 
macular edema and neovascularization. A recent study reported a temporary positive effect 
of intravitreal TA injections in a group of 31 patients with radiation maculopathy 27.
While TA might be a suitable drug to treat complications of radiation retinopathy, its effect 
on uveal melanoma cells is unknown. The possibility that there are living uveal melanoma 
cells present in the choroid of eyes treated with radiotherapy cannot be excluded 28; this is 







effect of TA on the proliferation of uveal melanoma cells before using this drug in patients 
with radiation retinopathy. To our knowledge, this has not been investigated previously. 
TA 30-32 has been shown to have an anti-angiogenic effect, though the mechanism through 
which this effect comes about is not clear. The extent of tumor angiogenesis is determined by 
the balance between pro-angiogenic and anti-angiogenic molecules, released by both tumor 
cells and surrounding cells 33. The formation of new vessels is in the first place a process 
involving endothelial cells; tumor cells that lack a sufficient blood supply are most likely 
the incentive of angiogenesis. VEGF-A plays an important role in angiogenesis, regulating 
vasopermeability and the proliferation and migration of endothelial cells 34. VEGF-A seems 
also to be the key mediator in ocular vessel diseases as well as in tumor angiogenesis 35. 
We also studied two inhibitors of angiogenesis, pigment epithelium-derived factor (PEDF) 
and thrombospondin-1 (TSP-1). Various studies have documented that PEDF inhibits an-
giogenesis in the eye 36,37 , whereas TSP-1 has been shown to inhibit cutaneous melanoma 
progression by suppressing tumor vessel formation 38.
One of the disadvantages of TA, however, is that it causes ocular hypertension in about 
30% of the cases 39 and may lead to glaucomatous damage. A new steroid-derived substance, 
anecortave acetate (AA), an angiostatic cortisone, has been developed to be devoid of cor-
ticosteroid side effects such as ocular hypertension 40. Hence, AA may be a good alternative 
to TA. A first study of AA administered in a juxtascleral depot to treat subfoveal choroidal 
neovascularization in age-related macular degeneration showed good results in the preven-
tion of further vessel development 41. We therefore analyzed the effect of both TA as well as 
AA on proliferation, expression and production of pro- and anti-angiogenic factors. 
Material and methods
Cell lines
Three very well described cell lines were selected on the basis of known differences in VEGF-
A production (low, medium, high) to perform our experiments: OCM-1, Mel 285 and 92-1. 
Cell line 92-1 was established in our laboratory 42. Cell line OCM-1 was kindly provided by 
Dr. J. Kan-Mitchell 43. Mel 285 was a generous gift of Dr. B.R. Ksander 44. Cell lines Mel 285 
and 92-1 were cultured in RPMI 1640 (GIBCO, Life Technologies, Breda, The Netherlands) 
to which 10% fetal calf serum, 2% glutamine (GIBCO) and 2% penicilline/streptomycine 
(GIBCO) were added. OCM-1 was cultured in DMEM (GIBCO) with 10% fetal calf serum 
and 2% penicilline/streptomycine (GIBCO). Cultures were passaged every 3-4 days. 
Triamcinolone acetonide and AL-4940 preparations
We used triamcinolone acetonide T6501 (Sigma-ALDRICH, St Louis, USA). The recom-
mended intravitreal dose of TA is 4 mg (0.1 ml) 27. The dose to which the uveal melanoma 
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cells are expected to be exposed in vivo after injection of TA is 1 mg/ml. Unfortunately, due 
to massive TA crystal deposits the maximal tolerated dose in vitro was 0,04 mg/ml. 10 mg 
TA was suspended in 230 μl methanol, producing a 100 mM stock suspension. This stock 
was serially diluted with medium to concentrations of 10 μM and 100 μM. Extra methanol 
was added to the 10 μM suspension to obtain a concentration of 0.1% methanol, similar 
to the 100μM suspension. As control, we used solutions of 0.1% methanol in medium. We 
used AL-4940-06 (9(11)-Dehydrocortisol, Alcon Laboratories, Forth Worth, USA) instead 
of AA, as in vivo AA is rapidly deacetylated into AL-4940 and AL-4940 is therefore the 
predominantly present active form 45. A 10mM stock solution was prepared dissolving 5.4 mg 
AL-4940 in 1.6 ml dimethyl sulfoxide (DMSO). This stock was serially diluted with medium 
to concentrations of 0.1, 1.0 and 10 μM. A solution of 0.1% DMSO was used as control. 
Triamcinolone acetonide and AL-4940 administration
Growth assays were performed in triplicate. For each assay, 64 wells per cell line were filled 
with 1· 104 uveal melanoma cells per well in 1 ml medium, using 24-well- plates. Cells were 
allowed to settle for 24 hours. After 24 hours, the regular medium was replaced by 1 ml of 
one of the following media: 1) RPMI/DMEM (control), 2) RPMI/DMEM with methanol 
(second control), 3) 10 μM TA suspension, 4) 100 μM TA suspension; for the AL-4940 assay: 
1) RPMI (control), 2) RPMI with DMSO (second control), 3) 0.1 μM AL-4940 solution, 4) 
1.0 μM AL-4940 solution, 5) 10 μM AL-4940 solution. Cells were cultured in an incubator at 
37° C and 5.0 % CO2. 
Cell proliferation and cytotoxicity 
Four, six, eight, and ten days after medium replacement, cells were counted or replaced with 
fresh specific media. Cells from four wells of each cell line at one time point were pooled to 
obtain a large enough number of cells to obtain a reliable count. Cell death was determined 
by trypan blue dye-exclusion using a Bürker counting chamber. In addition, cell prolifera-
tion was measured by mitochondrial function using the WST-1 assay (Roche Diagnostics, 
Indianapolis, IN), as previously described 46. In short, 96-well plates were filled with 1250 
uveal melanoma cells per well and either filled with regular medium (control) or 100μM TA 
suspension. Absorbance was measured at 450nm (n=8) on a multiwell spectrophotometer 
(Perkin Elmer, Wellesley, MA). 
VEGF-A and PEDF production 
In the supernatant obtained on day eight, VEGF-A and PEDF concentrations were deter-
mined using commercial solid phase sandwich enzyme-linked immunosorbent assay kits 
(VEGF-A: human VEGF ELISA immunoassay Kit, Biosource, Camarillo, USA. PEDF: PEDF 







Real-Time Quantitative RT-PCR analysis
Several different gene mRNA expressions were analyzed by real time quantitative reverse 
transcriptase–polymerase chain reaction (RT-PCR). RNA was isolated on day 8 in one TA 
assay, using an Rneasy® Mini Kit (Qiagen, Valencia, USA). RNA samples were stored at 
-80°C until further processing, when approximately 1 μg of RNA per sample was reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, USA). The 20μl solu-
tions obtained this way were diluted by adding sterile water up till 100 μl. In 96-wells, 2 
μl of this solution was added to a 15 μl solution of iQ SYBR Green Supermix, forward and 
reverse primers (10μM solutions) for VEGF-A, PEDF, TSP-1, β-ACTIN, HRPT or RPS-11 
and sterile water (volume ratio respectively 10:1:1:8). The primers for all genes under study 
were designed with the Primer Express software (PE Applied Biosystems) (Table 1) 47. A 
quantitative analysis of the samples was then performed for all genes by real time quantita-
tive RT-PCR in a MyiQ iCycler real-time PCR system (Bio-Rad, Hercules CA). To correct 
the sample-to-sample variation when determining gene expression, an accepted method is to 
select a cellular housekeeping gene that serves as an endogenous control, against which the 
target gene expression levels can be normalized 48. RPS-11 (ribosomal protein S11) is a house-
keeping gene that has been recently used to normalize gene expression in uveal melanoma 
cells 47. Beta-Actin (β-ACTIN) is a relatively stable cytoskeletal protein generally thought to 
be present at a constant level in cells, regardless of experimental treatment or technical pro-
cedure 49. Hypoxanthine-guanine phosphoribosyltransferase (HPRT), an enzyme in purine 
metabolism, is reported as a constitutively expressed housekeeping gene 49,50.
The PCR reaction settings were 95°C for 3 minutes, then 40 cycles at 95°C for 30 seconds 
and 60°C for 30 seconds, then 95°C for 1 minute and 60°C for 1 minute. With a control 
assigned Relative Quantity for any sample for all genes is calculated as follows: Relative 
Quantity sample (Gene x) = EGene x 
(CT (Control) – CT (sample)). Where E=Efficiency of primer/ (probe) set, 
CT 
(Control) = Average CT for the sample which has been assigned as a control and CT 
(sample) = 
Average CT for the sample. This is referred to as normalized expression 
51.
Table 1. Primer sequences of the genes studied in the RT-PCR assay 
Primer Forward primer ( 5’-3’) Reverse primer ( 5’-3’)
Endogenous 
controls
RPS11 AAGCAGCCGACCATCTTTCA CGGGAGCTTCTCCTTGCC 
HRPT CGAGATGTGATGAAGGAGATGG GCAGGTCAGCAAAGAATTTATAGC
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Statistical Analysis
Data are expressed as the mean ± SD. Student’s t-test was used to determine whether there 
were statistically significant differences between treatment groups determined in the cell 
viability assay. P < 0.05 was considered statistically significant. 
Results
Influence of TA and AA on uveal melanoma cell proliferation
TA and AA may be potential drugs to treat radiation retinopathy. However harmful side 
effects like proliferation of uveal melanoma cells have to be ruled out. 
Treatment of uveal melanoma cells with TA did not induce cell death as measured by the 
Bürker counting chamber (data not shown). The WST-1 assay demonstrated no significant 
effect of TA treatment on cell proliferation of the uveal melanoma cell lines 92.1, OCM-1 
and Mel285 (P=0.755, 0.844 and 0.487, respectively) (Figure 1). AA showed similar results. 
TA and AA had no toxic effect on uveal melanoma cells, as there were no differences in the 
percentages of dead cells between the different treatments (data not shown).
VEGF-A and PEDF production 
To investigate any direct pro- or anti-angiogenic effects of TA and AA on uveal melanoma 
cells, we studied the influence of these drugs on VEGF-A and PEDF production of three 
uveal melanoma cell lines using an ELISA on culture supernatant. Since cell numbers per 
well differed considerably between some treatments and experiments, we corrected for 
the number of cells by dividing the concentration of VEGF-A or PEDF measured in the 
supernatant by the amount of cells present in the same well. All cell lines produced VEGF-A 
and PEDF, but clear differences were observed in the amounts: OCM-1 produced the highest 
levels of VEGF-A (50 pg/ml/104cells). Cell line 92-1 produced approximately one fifth of this 
amount (10 pg/ml/104cells), while cell line Mel 285 produced the lowest amount of VEGF-A 
(approximately 5 pg/ml/104cells).
Cell line 92-1 produced large amounts of PEDF (2.000 pg/ml/104cells), around 100 times 
the amount produced by cell line OCM-1 (20 pg/ml/104cells). Mel 285 produced very little 
PEDF (3 pg/ml/104cells). Addition of TA or AA to the cell cultures had no effect on either 
VEGF-A or PEDF production (Figure 2a and 2b).
VEGF-A, PEDF and TSP-1 expression
We determined by real time quantitative RT-PCR whether TA or AA had any effect on sev-
eral genes in uveal melanoma cell lines that are associated with angiogenesis. VEGF-A was 
expressed in all cell lines at variable levels. TA treatment had no major (> 1.0 time fold differ-







of TSP-1 expression in Mel285 (difference in times the fold= 1.5-2.9) (Figure 3). TSP-1 was 
hardly expressed in 92.1. AA had no significant effect either on VEGF-A or TSP-1 expression 
(Figure 3). PEDF is very highly expressed in cell line 92-1 and only to a minimal extend in the 
other cell lines. PEDF expression in cell line 92-1 was not effected by TA or AA. 
Discussion
Our results showed no apparent stimulating or inhibiting effect of TA on uveal melanoma cell 
proliferation in the concentrations used in this study 27. The effect of TA on uveal melanoma 
cell lines had not yet been investigated, but the effect of TA on other cell types has been the 
object of some studies. For instance, TA inhibited the growth of retinal pigment epithelium 
Figure 1. The effect of TA on uveal melanoma cell proliferation. 
Cells were treated with four different suspensions; a) RPMI/DMEM (control), b) RPMI/DMEM with methanol 
(second control), c) 10 mM TA suspension, d) 100 mM TA suspension. Cell proliferation was determined by 
a WST-1 assay. No substantial difference is shown between TA treatment and controls in proliferation in the 
uveal melanoma cell lines 92.1, OCM-1 and Mel285 (P = 0.755, 0.844 and 0.487, respectively)
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Figure 2a and 2b. The effect of TA and AA on production of VEGF-A and PEDF. 
Cells were treated with four/five different suspensions; for TA experiments: a) RPMI/DMEM (control), b) 
RPMI/DMEM with methanol (second control), c) 10 mM TA suspension, d) 100 mM TA suspension; for AA 
experiments: a) RPMI (control), b) RPMI with DMSO (second control), c) ) 0.1 mM AL-4940 solution, d) 
1.0 mM AL-4940 solution, e) 10 mM AL-4940 solution. All cell lines produced VEGF-A and PEDF, but clear 
differences were observed in the amounts: OCM-1 produced the highest levels of VEGF-A, while cell line Mel 
285 produced the lowest amount of VEGF-A. Cell line 92-1 produced large amounts of PEDF (>2000 pg/ml). 
Mel 285 produced very little PEDF Addition of TA or AA to the cell cultures had no effect on either VEGF-A 
or PEDF production. 
Figure 3. The effect of TA on expression of VEGF-A and TSP-1.
Cells were treated with four different suspensions; a) RPMI/DMEM (control), b) RPMI/DMEM with methanol 
(second control), c) 10 mM TA suspension, d) 100 mM TA suspension. VEGF-A was expressed in all cell 
lines at variable levels. TA treatment had no major (> 1.0 fold) effect on VEGF-A expression. TSP-1 was not 







(ARPE 19) in concentrations ranging from 1 μM to 2,3 mM, but stimulated growth at a con-
centration of 1 nM 52,53. Another study, using bovine retinal endothelial cells, found that TA 
at a concentration of 115 μM had no effect on growth, concentrations ranging from 230 μM 
to 4,6 mM had an inhibiting effect and concentrations of 6,8 mM and higher were cytotoxic 
54. Likewise, in vitro incubation of retinal pigment epithelial cells (RPE) with corticosteroids 
induced a specific and dose-dependent reduction of cell viability. These toxic events were 
not associated with the anti-inflammatory activity of these compounds but depended on the 
hydro-solubility of their formulation 55. 
While previous studies on RPE cells demonstrated an inhibition of VEGF production and 
expression by TA, we found no effect of TA on VEGF-A production or expression in uveal 
melanoma cells. For instance, TA reduced VEGF expression of retinal pigment epithelial 
(ARPE19) cells under oxidative stress 53 and inhibited cobalt-stimulated VEGF production in 
Müller cells, probably by a destabilization of VEGF mRNA 56. The lack of inhibition of TA on 
VEGF-A production and expression in our study could perhaps be explained by the absence 
of specific stimuli that would up-regulate VEGF-A production and expression, such as 
oxidative stress or cobalt administration. In the study by Sears et al 56, only cobalt-stimulated 
VEGF production was inhibited by TA, while basal VEGF production was not affected. Simi-
larly, another study showed no alteration in VEGF expression by TA in a rat retina when no 
special stress was applied 57.We are currently performing experiments to determine the effect 
of TA and other drugs on uveal melanoma cells under stressful conditions, such as hypoxia. 
PEDF inhibits angiogenesis by inducing apoptosis in endothelial cells that try to form 
new vessels 58,59. Besides the separate levels of VEGF-A and PEDF, the balance between the 
two seems to be decisive in whether or not angiogenesis takes place 60. Yang et al has previ-
ously demonstrated expression of PEDF in uveal melanoma cell lines. Furthermore, they 
demonstrated an inhibitory effect of angiostatin on the ratio of VEGF/PEDF mRNA levels 
in vitro 59. Likewise, Mel 285, 92-1, and OCM-1 all produced PEDF in our experiments. We 
observed no effect of TA on the production of PEDF by any of the uveal melanoma cell 
lines. Therefore, stimulation of production of PEDF by uveal melanoma cells seems not to 
be the anti-angiogenic working mechanism of this drug under normal circumstances. The 
high expression of PEDF by cell line 92-1 was unexpected, since PEDF has been shown to 
work as a tumor growth inhibitor through anti-angiogenic mechanisms 61-63 and cell line 92-1 
was derived from a highly malignant tumor 42. However, there are reports that melanocytic 
tumors have a relatively high expression of PEDF 64. Also, PEDF might have a biphasic ac-
tivity, inhibiting angiogenesis in at normal amounts, but stimulating angiogenesis at high 
concentrations 65. 
 The balance between VEGF-A and PEDF as described earlier, seems also to be 
influenced by thrombospondin (TSP-1). TSP-1 inhibits endothelial cell migration and prolif-
eration and also induces apoptosis 66. In cell line Mel 285, TSP-1 expression was about 2-fold 
inhibited in cells grown in TA compared to the control cells. Previous reports on the effect 
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of TA on the expression of TSP-1 could not be found, though some effects of other cortico-
steroids have been reported. Hydrocortisone up-regulated TSP-1 expression in a glioma cell 
line 67 and dexamethason increased TSP-1 expression in a murine trofoblast-like (MC3T3-E1) 
cell culture 68. The results of Mel 285 do not agree with this, and may indicate an unexpected 
effect of TA. TSP-1 expression of cell line 92-1 was very low, possibly due to inactivation of 
this gene in the same manner as described for hypermethylated p16(INK4a) 69.
Parallel experiments with AA, to eliminate any possible side effects of the glucocortoid 
fraction, showed similar results as with TA. There seems to be no differential effect of this 
angiostatic cortisone compared to TA on potentially still viable uveal melanoma cells in the 
choroid after radiotherapy; both drugs have hardly any effect at all.
The risk of an increase in local recurrences of uveal melanoma by TA or AA in the treat-
ment of radiation retinopathy by direct stimulation of uveal melanoma cell seems to be low. 
Though one has to realize that we based these conclusions on a restricted number of cell 
lines and extrapolation to the in vivo situation is by definition limited. In addition, the clini-
cal dose of TA could not be investigated due to massive crystal deposits. Perhaps a certain 
threshold has to be reached before TA can demonstrate any effect.
Nonetheless, our results suggest that TA does not exert any anti-angiogenic effect through 
influencing basal VEGF-A, PEDF, TSP-1 production or expression in uveal melanoma cells. 
Though, influence of hypoxia and stimulation of these cell lines by VEGF or FGF2 or by 
anti-angiogenic factors is very well possible, and is under investigation.
Furthermore, there are many other pro- and anti-angiogenic factors that could be altered 
by TA. Plasminogen activator inhibitor type-1 (PAI-1) for instance, has been implicated in 
metastasis formation and tumor-associated angiogenesis in uveal melanoma 70, and would 
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Introduction. Uveal melanoma (UM) cells and neurohormone-producing cells both origi-
nate from the neural crest. Somatostatin receptors subtype 2 (SSTR2) are over-expressed in 
several tumours, often from neuroendocrine origin, and synthetic antagonists like octreo-
tide and octreotate are being used as diagnostic or therapeutic agents. We investigated the 
SSTR2 expression in uveal melanoma, and determined whether this expression was related 
to prognosis of the disease. 
Material and Methods. UM cell lines and fresh primary UM samples were tested for SSTR2 
expression by autoradiography (AR) using 125I-Tyr3-octreotate. Furthermore, UM cell lines 
were analyzed for SSTR2 mRNA expression with quantitative PCR.
Results. Using AR, cell surface SSTR2 expression was demonstrated in two metastatic cell 
lines, but no expression was detected in three cell lines derived from primary tumours. How-
ever, all primary and metastatic cell lines showed mRNA expression levels for SSTR2 using 
quantitative PCR. Only three of 14 primary UM demonstrated moderate SSTR2 expression, 
and this expression was not significantly associated with tumour-free survival or any tested 
prognostic factor.
Conclusion. Based on the rare and low expression of SSTR2 found in primary UM specimens 
and in UM cell lines, we conclude that SSTR2 is not widely expressed in uveal melanomas. 
Furthermore, SSTR2 expression was not associated with tumour-free survival and prognos-
tic factors. Therefore SSTR2 is not suited as prognostic marker or therapeutic target in UM. 
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Introduction
Uveal melanoma (UM) is the most common primary intraocular tumour, with an annual 
incidence of 0.7/100.000 in the Western population 1. Although less than 2% of the patients 
have clinically detectable metastasis at presentation, 50% of all patients die due to metastatic 
disease. The median survival after the diagnosis of metastasis is extremely poor. Predictors 
of survival for UM patients have been identified in histologic cell type, tumour diameter, 
tumour location, age, gender 2,3 and cytogenetic parameters. Loss of chromosome 3 is one of 
the most significant predictors for uveal melanoma-related deaths 4-6.
Most of the uveal melanomas are treated by radiotherapy, thus material for histopathologic 
and cytogenetic examination has to be obtained by Fine Needle Aspiration Biopsy (FNAB) 
for example. Shields et al. showed that FNAB provides adequate DNA for genetic analysis of 
uveal melanoma using a microsatellite assay 7. Early and long-term complications following 
intraocular FNAB are rare 8. Nevertheless, one suspected clinical case of extrascleral recur-
rence has been recently reported after diagnostic intraocular transscleral FNAB 9. Therefore 
concern about tumour seeding due to this diagnostic procedure still exist 10, and FNAB is 
consequently not used routinely yet.
Conversely, neurohormone receptors as markers could be detected non-invasive and safe 
using scintigraphy, without the need to take a biopsy.
During embryogenesis, neural crest cells migrate to the diencephalon and to the uvea, 
where they give rise to pigmented melanocytes. Neural crest cells are able to produce 
neurohormones like somatostatin (SST). SST inhibits the release of growth hormone and 
thyroid-stimulating hormone. Its actions are mediated by specific G protein-coupled recep-
tors, which are located in specific target cells of the gastrointestinal tract, the peripheral 
nervous system and several blood vessels 11.
Moreover, SST could be involved in the inhibition of tumour growth 12,13. SST receptors 
(SSTR) have been detected in human neuroendocrine tumours 14-16, human lung tumours 
such as bronchial carcinoids 17 and gastro-entero-pancreatic tumours like insulinomas, 
gastrinomas and ileal carcinoids 18. SST analogues, like octreotide and octreotate, can be 
radiolabelled with radionuclides via a chelator and are currently being used in the diagnosis 
(111In) or therapy (90Y or 177Lu) of patients suffering from SSTR-expressing tumours 19-22. 
Due to the common origin of SST and UM cells, a relation or interaction may be found. A 
relation between eye tissue and neurohormones has already been explored in several stud-
ies 23-25. In a previous study, Ardjomand et al. concluded that expression of SST2 receptors 
(SSTR2) in uveal melanomas is correlated with a better ad vitam prognosis of the patients 
26. Our aim was to further investigate the expression of SSTR2 in uveal melanoma, in order 
to identify specific membrane receptors for diagnostic imaging and therapeutic targeting. 
Primary specimens and uveal melanoma cell lines, derived from primary or metastatic uveal 








Patient and tumour material 
Informed consent was obtained prior to enucleation and the study was performed according 
to the tenets of the Declaration of Helsinki. 
Fresh tumor tissue was obtained within 1 hour after enucleation, according to a standard-
ized protocol. An incision was made through the tumor, leaving the optic nerve intact. A 
sample was taken from the side opposite the optic nerve and divided in three; one part was 
processed for fluorescent in situ hybridization (FISH), one part was fixed in 4 % paraformal-
dehyde overnight and the last part, as well as control tissues (rat brain, rat pancreas), were 
stored in liquid nitrogen for cryopreservation. Five-micrometer paraffin section were cut on 
a microtome (Microm HM 335E), and put on uncoated slides (Menzel Superfrost) humidi-
fied with sterile water for haematoxylin-eosin (HE) and periodic acid-Schiff (PAS) staining. 
Five-micrometer cryosections of frozen tumour samples and control tissues were cut on a 
cryostat (Jung CM3000; Leica, Meyer Instruments, Inc. Houston, USA), and mounted on 
coated slides. Subsequently, the slides were air-dried and stored at –80°C and processed 
as below (see under ‘autoradiography’). Conventional histopathologic examination was 
performed on all tumors and confirmed the origin of each one. 
Cell lines 
Mel 202, 92.1 and OCM-1, primary tumour-derived cell lines, were used as a model for 
human primary uveal melanoma. OMM1 and OMM2.3, skin and liver metastases-derived 
cell lines, were used as a model for human uveal melanoma metastasis. Rpe1 is a normal 
retinal pigment epithelium-derived cell line. OCM-1 was provided by dr. J. Kan-Mitchell, 
Mel202 and OMM2.3 by dr. B. Ksander, 92.1 by dr. M.J. Jager and OMM1 and Rpe1 were 
established in our laboratory 27-31. The SSTR-expressing CA20948 cell line originated from 
the solid CA20948 rat pancreatic tumour and served as positive control for autoradiography 
experiments since ocreotate detect both rodent and human SSTR2, of which the homology 
is more than 90% 19,32. All cell lines were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (GIBCO, 
Life Technologies, Paisley, UK). The cells were passaged once or twice a week using tryp-
sin (0.05%) or trypsin+EDTA (0.02%). Cells were centrifuged at 1,000 rpm for 10 min in 
DMEM, resuspended in 0.1 M DPBS and used to prepare cytospins on coated slides (Menzel 
Superfrost Plus Menzel-Gläser, Braunschweig, Germany) humidified with DPBS using a 
cytofuge (Nordic, Tilburg, The Netherlands). 
Fluorescent In Situ Hybridization Analysis
Dual color FISH was performed on uncultured tumor tissue, by using centromeres, locus-
specific cosmids, P1, or YAC as probes for chromosomes 1, 3, 6, and 8, respectively, as 
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described previously 33. Seven probes were used: p1-79 (mapped to chromosome band 1p36), 
P 3.5 (centromere 3), YAC 827D3 (3q24), cos85 (6p21), and cos52 (6q23) (all from Yusuke Na-
kamura, Tokyo, Japan) and D8Z2 (centromere 8) and ETO (8q22). The probes were validated 
on normal peripheral blood cell metaphase spreads, and 10 metaphases were analyzed for 
each probe. Cutoff limits were less than 3%. The concentration for centromeric probes was 5 
ng per slide; for cosmid, P1, and YAC probes, 50 to 75 ng per slide was used. After hybridiza-
tion and washing, the slides were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) 
and mounted in anti-fade medium (Dabco-Vectashield 1:1; Vector Laboratories, Burlingame, 
CA). Signals were counted in 300 interphase nuclei, according to the criteria of Hopman et 
al. 34. Scoring for deletion (>15% of the nuclei with one signal) or amplification (>10% of the 
nuclei with three or more signals) was adapted from the available literature 35.
Autoradiography
125I-DOTA-Tyr3-octreotate (BioSynthema, St Louis Mo, USA), that has a high affinity binding 
to SSTR2, was used for the autoradiography study 36. The autoradiographic experiments were 
performed on cryosections and cytospins using 10-9M or 10-10M 125I-DOTA-Tyr3-octreotate, 
with or without a blockade of 10-6M unlabelled octreotide (Novartis, Basel, Switzerland), to 
investigate SSTR2 specific binding as described in literature 14,37. After a 1 h incubation at room 
temperature and rinsing with Tris buffer to remove the non-bound radioactive octreotate, 
dried cryosection and cytospin slides were exposed to phosphor-imaging screens (Packard 
Instruments Co., Meriden, USA) in X-ray cassettes. After 24-72 hours, the screens were read 
using a Cyclone phosphor imager and analyzed with OptiQuant 03.00 image processing 
system (Packard Instruments Co., Groningen, The Netherlands). Binding of 125I-DOTA-Tyr3-
octreotate to cytospins and cryosections was expressed in digital light units (DLU)/mm2. 
Net DLU/mm2 represents binding of 125I-DOTA-Tyr3-octreotate (specific binding) minus 
non-specific binding in adjacent sections incubated with 125I-DOTA-Tyr3-octreotate plus 
10-6M octreotide. Net DLU/mm2 was considered positive when > 5000 DLU/mm2.
Quantitative real-time RT-PCR 
SSTR2 mRNA expression was analyzed by real time-reverse transcriptase–polymerase 
chain reaction (real time RT-PCR). RNA was isolated using an Rneasy® Mini Kit (Qiagen, 
Valencia, USA). RNA samples were stored at -80°C until further processing. Approximately 
1 μg of RNA per sample was reverse-transcribed using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, USA). The 20μl solutions obtained this way were diluted by adding sterile 
water up till 100 μl. In 96-wells, 2 μl of this solution was added to a 15 μl solution of iQ 
SYBR Green Supermix, forward and reverse primers (10μM solutions) for SSTR2 or RPS-11 
(control gene) and sterile water (volume ratio respectively 10:1:1:8). The primers had the fol-
lowing sequences: SSTR2 forward 5’- TGCTGGGTCTGCCTTTCTTGG – 3’, SSTR2 reverse 







– 3’, RPS-11 reverse 5’ – cgggagcttctccttgcc – 3’ 38. A quantitative analysis of the samples was 
then performed for SSTR2 and RPS-11 (control gene) expression by real time-PCR in a MyiQ 
iCycler real-time PCR system (Bio-Rad, Hercules CA). The PCR reaction settings were 95°C 
for 3 minutes, then 40 cycles at 95°C for 30 seconds and 60°C for 30 seconds, then 95°C for 1 
minute and 60°C for 1 minute. To correct the sample-to-sample variation when determining 
gene expression, an accepted method is to select a cellular housekeeping gene that serves as 
an endogenous control, against which the target gene expression levels can be normalized 39. 
RPS-11 (ribosomal protein S11) is a housekeeping gene that has recently been introduced to 
normalize gene expression in uveal melanoma cells 40.
Results
Patients and tumour material 
In total, primary uveal melanomas from 14 patients (10 male and 4 female, with a mean 
age of 63 ± 10.1 years) were included in the study. Histopathologic analysis of HE and PAS 
stained paraffin sections was performed on all primary uveal melanomas. The mean tumour 
diameter was 12.6 ± 2.8 mm and their mean prominence was 8.5 ± 2.0 mm. Epithelioid cells 
were found in 10 of 14 cases, while in seven cases vascular loops and/or networks were de-
tected. Furthermore, FISH analysis of all samples was performed; monosomy 3 as well as loss 
of chromosome 1p was found in 10 of 14 cases and gain of chromosome 8q was present in 7 
of 14 cases. After a mean follow-up period of 36.1 ± 13.0 months, five patients had developed 
distant metastases (Table 1). 
Autoradiography 
Fresh primary uveal melanoma samples were tested for expression of SSTR2 by AR using 
125I-Tyr3-ocreotate. In three of the in total 14 primary uveal melanomas a positive albeit 
weak binding was observed (Table 2). Statistical analysis with the Kaplan Meier method and 
log-rank test did not show any significant relation between SSTR2 expression and tumour-
free survival (p=0,76). In the univariate and multivariate Cox-regression analysis, SSTR2 
expression was not significantly associated with tumour-free survival or other important 
prognostic factors (cell type, vascular patterns, tumour diameter, prominence, monosomy 3, 
loss of chromosome 1p and gain of chromosome 8q).
Uveal melanoma cell lines were tested for expression of SSTR2 by autoradiography using 
125I-Tyr3-ocreotate. All cell lines were tested in duplicate.
The positive control rat pancreatic tumour cell line (CA20948) showed a strong binding. 
Cell line 92.1 showed very low binding while none of the other primary UM derived cell 
lines (Mel202, OCM-1) or normal cell line (Rpe1) showed specific receptor binding. Both 
metastatic melanoma cell lines (OMM1, OMM2.3) showed high binding (Fig. 1, Table 3). 
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Table 1 Clinical features of included patients
Sex (male/female) 10/4
Age (mean ± SD , years) 63.0 ± 10.1
Diameter (mean ± SD, mm) 12.6 ± 2.8
Prominence (mean ± SD, mm) 8.5 ± 2.0
Cell type (epitheliod/non-epitheliod) 10/4
Vascular loops and/or networks (yes/no) 7/7
Pigmentation (yes/no) 8/6
Metastasis (yes/no) 5/9
Monosomy 3 (yes/no) 10/4
Loss of 1p (yes/no) 10/4
Gain of 8q (yes/no) 7/7
Follow-up (mean ± SD, months) 36.1 ± 13.0


















1 Metastasis present: +, No metastasis:-









Figure 1. Autoradiogram of cytospins with binding to SSTR2
1ste column: incubated cytospins
2de column: negative controls
OMM2.3, B. OMM1, C. Mel202, D. OCM-1, E. Rpe 1, F. CA20948, G. Rat brain.
(a few cell lines are shown in duplicate)









Normal Rpe2 Rpe1 -
Control CA20948 3 ++++
1 Netto Digital Light Units/mm2: <5000: –, 5000-10000: +, 10000-50000: ++, 50000-100000: +++, 
>100000:++++ 
2 Normal retinal pigment epithelium cell line
3 Control cell line from the solid CA20948 rat pancreatic tumor
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Real-time quantitative RT-PCR in cell lines
Expression of SSTR2 mRNA in UM cell lines was evaluated by RT-PCR, with normaliza-
tion of the expression levels to the housekeeping gene RPS-11. All five UM cell lines tested 
expressed SSTR2 mRNA, but the level of expression was quite variable. OMM 2.3 showed a 
two to four times higher expression level of SSTR2 mRNA compared to the other metastases 
derived UM cell line OMM1, and the primary UM cell lines 92.1 and Mel 202. The other tested 
primary UM cell line OCM-1 showed a very low SSTR2 mRNA expression level (Fig. 2).
Discussion
Expression of somatostatin receptors in neuroendocrine tumours has been extensively 
investigated and led to the development of clinically relevant diagnostic and therapeutic 
strategies. Based on common embryonic origin, uveal melanoma could also be a candidate 
for such strategies, as many patients die from metastasized UM. 
In this study, SSTR2 expression was studied in 14 primary UM tumour samples and several 
different uveal melanoma cell lines, either derived from primary or from metastized UM 
tumour samples. Primary tumours were tested at the protein level using in vitro autoradiog-
raphy, cell lines were additionally analyzed on mRNA level. In only three primary specimens 
Figure 2. Expression of SSTR2 in uveal melanoma cell lines.
All five UM cell lines tested expressed SSTR2 mRNA. The expression levels were normalized to the 
housekeeping gene RPS-11. OMM2.3 shows a two to four times higher expression level of SSTR2 mRNA 
compared to OMM1, 92.1 and MEL202. Primary UM cell line OCM-1 had a very low expression level, and can 







moderate SSTR2 expression was demonstrated. One of these was a metastasized melanoma, 
while four other samples of metastasized UM did not express SSTR2.
Furthermore the relation between SSTR2 expression, tumour-free survival and prognostic 
factors was studied, although the number of samples we used was too small to perform reli-
able statistical analysis. With the data obtained thus far, no significant correlation between 
SSTR2 expression and tumour-free survival or any other important prognostic parameter 
could be found. Conversely, Ardjomand et al. detected by using immunohistochemistry 
on paraffin embedded UM tissue, that SSTR2 was expressed in nearly all of the 25 tested 
samples. When the prognosis of these 25 patients was compared with the expression level of 
SSTR2 in uveal melanoma tissue, a positive correlation was found between high SSTR2 and 
a better ad vitam prognosis 26. 
Since Ardjomand et. al used a different approach and techniques to determine SSTR2 
expression, it is difficult to compare our results. An explanation for the differences could be 
that we used cryosections instead of paraffin sections, in antibody versus peptide targeting. 
Furthermore, in immunohistochemistry it is possible to discriminate positive staining in 
individual cells by using antibodies for specific subtypes of somatostatin receptors. In our 
AR experiments, we analyzed tissue cryosections and a peptide analogue that can be applied 
in vivo for PET or SPECT imaging, after labelling with an appropriate radionuclide. In AR 
a certain threshold had to be reached before tissue could be identified as positive; however 
this threshold is low due to the high sensitivity of the phosphor imaging read out system. 
For in vivo imaging this threshold would be much higher. Most of the tumours tested by 
Ardjomand et. al contained between 11 and 80% of SSTR2 expressing tumour cells. If the 
percentage of SSTR2 expressing tumour cells in our tested specimens was within this range, 
these should have been detected using in vitro autoradiography. Furthermore, Ardjomand 
et. al also argued the diagnostic value of SSTR expression, since in only two of four patients 
with UM in their study the affected eye could be visualized by ocreotide scintigraphy. 
Besides primary UM samples, UM derived cell lines, originating either from primary or 
from metastasized UM tumours, were tested for SSTR2 expression. By using the in vitro AR 
technique with cytospins of UM cell line cells, it was found that three primary melanoma 
cell lines showed almost no specific binding of 125I-Tyr3-octreotate, whereas both metastatic 
cell lines showed strong binding. This implied that expression of SSTR2 at the protein level 
could be associated with a bad prognosis and development of metastasis. This clear SSTR2 
expression of the metastatic UM cell line OMM2.3 correlated with a four times higher 
expression level of SSTR2 mRNA compared to the primary UM line 92.1 in quantitative 
real-time RT-PCR. The primary UM cell line Mel 202 also showed a moderately high SSTR2 
mRNA expression, but apparently this mRNA was not transcribed to protein. Apparently the 
correlation between SSTR2 expression at mRNA and protein level seems to be good in cell 
lines derived from metastasized UM, but less in lines from primary UM. Furthermore, there 
is a discrepancy between the SSTR2 expression in cell lines compared to that in primary 
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and metastized uveal melanoma specimens, in which only a small percentage of low SSTR2 
expressing samples was found. Expression of high SSTR2 levels might be favourable for 
deriving an in vitro growing cell line from a UM biopsy. Thus cell lines might not be really 
representative for in vivo circumstances 41.
Considering the low SSTR2 expression of the primary UM samples, we conclude that im-
aging with somatostatin analogues to perform scintigraphy is not feasible in uveal melanoma 
patients. 
Although FNAB has been shown to accurately demonstrate genetic and histologic prog-
nostic factors in the obtained tissue 7, finding another tumour-specific (neurohormone) 
receptor that can be used as an in vivo target for diagnosis (and therapy) is still an attractive, 
non-invasive option to improve the diagnosis of (metastasized) UM using specific radio-
labelled peptide analogues. Metastasis is the single leading cause of death of patients with 
UM. Kaplan-Meier estimates of 5-year melanoma-related mortality range from 26% to 32% 
42. The first site of metastasis is the liver in approximately 90% of patients, but later spread 
to the lungs, bone, and skin occurs frequently 43-45. It remains unknown to which extent 
current treatments for metastasis actually prolong survival compared to no treatment at all 
42,46. It is proposed that patients who develop clinical metastases from uveal melanoma often 
harbour micro metastases for years 47. Targeting tumour-specific receptors might be used 
to treat these (micro) metastases in future when specific analogues are radiolabelled with 
therapeutic β-emitting radionuclides like 177Lu. 
Further investigation targeting other neural-crest derived hormone receptors may thus 
reveal new options. Several studies have shown that vasoactive intestinal peptide (VIP) and 
pituitary adenylate-cyclase-activating polypeptide (PACAP) have tumour-growth promoting 
activities in breast cancer and neuroblastoma for example. Furthermore, VIP and PACAP 
antagonists demonstrated growth-inhibitory properties 48-51. VIP receptors have been found 
to be ubiquitous expressed in all ocular tissues, with highest concentrations occurring in 
the choroid of several different mammals 23. Most uveal melanomas are strongly pigmented. 
Alpha-melanocyte-stimulating hormone is primarily responsible for the regulation of pig-
mentation and could therefore be linked to uveal melanoma 52. 
In conclusion, additional exploration of neurohormone receptors is needed to identify 
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Introduction. Uveal melanoma (UM) is the most common primary intraocular tumor, in 
which still 50% of patients may die due to metastatic disease. Specific targeting of UM for 
imaging and delivery of drugs is urgently needed for improved identification and subsequent 
killing of tumor cells. Ligand-specific antigens that are preferentially expressed by primary 
or metastatic UM cells are ideal targets for tumor-targeting applications. 
Material and Methods. UM cell lines were screened in vitro for tumor-specific peptides 
using a phage-displayed peptide library. Binding and internalization of peptides to cell lines 
was visualized using fluorescein and rhodamine-labeled synthetic peptides and confocal 
microscopy.
Results. Phage display experiments resulted in the identification of three UM-associated 
peptides (UMAPs). After labeling with fluorescein or rhodamine, internalization of these 
peptides in several UM cell lines was visualized by confocal fluorescent microscopy. One 
peptide, UMAP1, was identified multiple times in phages that had bound to metastatic cell 
lines, while UMAP2 showed homology to the insulin-like growth factor 1 receptor (IGF-1R).
Discussion. Three UMAPs were identified by screening phage peptide libraries and shown 
to successfully internalize in targeted UM cells. UMAP1 may have potential for future usage 
for UM-targeted treatment. UMAP2 is especially interesting because of its homology to the 
IGF-1R, which is a bad prognostic marker in UM.
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Introduction
Isolation of tumor-specific ligands has been extensively researched in this last decade, as 
specific tumor agents can be used for in vivo imaging and thus for early detection of tumors 
and micrometastases. In case of uveal melanoma (UM), the most common intraocular 
tumor in adults, these micrometastases are believed to play an important role: in spite of 
an effective treatment of primary UMs by enucleation or radiotherapy, with a local tumor 
control rate of 97% of all treated cases 1-3, still half of all patients may die due to UM-related 
metastatic disease 4,5. The occurrence of metastases has even been described 35-40 years after 
initial diagnosis and treatment of the primary UM tumor 5,6. It has been proposed that dis-
semination occurs several years before identification of the primary tumor and its treatment 
7. Non-invasive detection of dormant micrometastases using specific peptides coupled to a 
fluorescent probe or a radionuclide and subsequent treatment with specific tumor ligands 
that are conjugated to an anticancer drug may improve survival. Specific peptide-based 
agents that achieve apoptosis, or block angiogenesis and proliferation of UM metastatic tis-
sue, would be of great value in sparing healthy tissue. 
For this purpose, various melanoma-derived autoantigens and cell surface receptors 
have been explored in uveal melanoma. Cutaneous melanoma markers such as MAGE are 
not widely distributed in ocular melanoma tissue 8. For histopathologic diagnosis of uveal 
melanoma, antibodies such as S-100 (specific for a protein derived from bovine brain cross-
reacting with melanoma and melanocytes), HBM45 (specific for gp100) and A103, (recog-
nizes the Melan-A/Mart-1 protein) are used 9-11.
Unfortunately, most of these receptors are not UM specific and are also expressed by 
normal cells (melanocytes). Therefore, tartgeting these receptors may cause significant side-
effects.
Phage display is a powerful technique for the isolation of peptides that bind to a particular 
target with high affinity and specificity. In contrast to larger molecules, such as proteins and 
antibodies, small peptides can efficiently penetrate tissues and are relatively easy to synthe-
sise. Several studies describe the successful detection of organ and tumor-specific peptides 
using phage peptide libraries, for example in bladder cancer, brain and kidney tissue 12,13. 
Using phage display, Howell et al. 14 have reported the identification of heptapeptides that 
specifically bind to human tumor melanin, as demonstrated in human metastatic melanoma 
tumor-bearing nude mice. These heptapeptides may be used as a tool in targeted therapy 
for (metastatic) melanoma 14. In addition, phages alone are also known to be highly immu-
nogenic. Treatment of B16-F10 melanoma in mice with tumor specific (selected with phage 
display) phages induced a massive infiltration of neutrophils, which delayed tumor growth 







Using in vitro biopanning on (metastatic and primary) UM cells, we report the identification 
of UM associated peptides (UMAPs) selected from phage display libraries. Additionally, we 
demonstrate the potent binding and internalisation of fluorescein and rhodamine-conjugated 
synthetic peptides in UM cells. 
Material and Methods
Cell Lines 
Four UM cell lines were used as targets in biopanning experiments. Mel270 and 92.1 are 
primary tumor-derived cell lines, while OMM1 and OMM2.5 are cell lines derived from 
metastases. Mel270 and OMM2.5 were provided by dr. B. Ksander (Schepens Eye Research 
Institute, Boston, MA), OMM1 by dr. G.P.M. Luyten (Erasmus University Medical Center, 
Rotterdam, the Netherlands) and 92.1 was established in our laboratory 16-20. All cell lines 
were cultured in complete RPMI 1640 medium containing 10% fetal calf serum and 1% peni-
cillin/streptomycin (GIBCO, Life Technologies, Paisley, UK) at 37°C and 5% CO2 (HERAcell 
240 CO2 Incubator, Thermo Fisher Scientific Inc, USA). The cells were passaged once or 
twice a week using trypsin (0.05%).
 Mel1, a normal melanocyte culture established in our own laboratory, was used for 
pre-adsorption (diminishing tumor aspecificity in subsequent incubation rounds) and as a 
control for internalisation experiments. In addition, HUVECs (human umbilical vein endo-
thelial cells) and SAOS-2 (primary osteosarcoma cells) served as controls in internalisation 
assays.
Biopanning 
M13 phage display libraries containing random hepta- and dodecapeptides fused to the N-
terminus of minor coat protein pIII (Ph.D.-C7C and Ph.D.12 Phage Display Peptide Library, 
New England Biolabs, Ipswich, MA, USA) were used for in vitro experiments. 
Biopanning was performed for three to four rounds, starting with an equal mixture of 1011 
pfu of each library, with and without pre-adsorption on normal melanocytes (Mel1). In case 
of pre-adsorption, the mixed Ph.D.-C7C and Ph.D.12 libraries were first incubated with each 
of the four UM cell lines. The selected phages were amplified and subjected to pre-adsorption 
on a Mel1 cell monolayer, grown in a T25 tissue culture flask (Corning, NY), incubated with 
phages (2x10-11 pfu) for 1 h at 37°C for melanocyte-specific phage depletion. Subsequently, 
the medium, including phages, was transferred to 90-100% confluent UM monolayers in 
T75 flasks and incubated again for 1 h at 37°C. After incubation, cells were washed five times 
with 10 ml of phosphate-buffered saline (PBS) and treated with trypsin (0.05%) for 10 min. 
at 37°C to inactivate non-internalized phages. Subsequently, 10 ml of RPMI was added and 
the cells were harvested in a 15 ml tube and spun down. Cell pellets were washed another 
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3-5 times with PBS. Internalized phages were recovered by lysing the cells in 1 ml of cell 
culture lysis buffer (Promega, Benelux) for 15 min. Phages were precipitated by addition of 
250 µl of a 20% PEG8000/ 2.5 M NaCl solution and overnight incubation at 4°C. Pellets were 
resuspended in 100 µl TBS. The internalized phages were amplified and subjected to another 
round (round 3) of biopanning on their respective cell lines. Round 3 phages were subjected 
to an additional round of pre-adsorption and biopanning (round 4) on their respective cell 
lines. Phages from round 3 and 4 were sequenced.
Phage titering, amplification, and sequencing
Phage titers were determined after each round of selection and amplification by mixing ap-
propriate dilutions of the phage suspension with 100 µl of an overnight culture of E.coli XL-1 
Blue F+ cells. After five minutes of incubation at room temperature, three ml of topagar was 
added and the mixture was plated onto LB agar plates containing kanamycin. Plaques were 
counted after overnight incubation at 37°C. Five to ten plaques were picked after each round, 
amplified and phage DNA was isolated as described by the manufacturer (New England Bio-
labs, Ipswich, MA, USA). Sequencing of phage DNA was performed by automated dideoxy 
sequencing with chain terminator dyes (LGTC, Leiden).
Phages were amplified essentially as described in the manual (New England Biolabs, 
Ipswich, MA, USA).except that XL-1 cells were used. 
Synthetic peptides 
UMAP 1 was synthesized using F-moc chemistry on a peptide synthesizer (LIC, Leiden). The 
lysine-residue was labeled with fluorescein using FITC (Sigma-Aldrich). The peptide was 
purified by HPLC, and analyzed by MALDI-TOF mass spectrometry. Rhodamine-labeled 
UMAP2 and 3, and fluorescein-labeled UMAP3 were purchased from the peptide synthesis 
facility at the LUMC (Leiden, The Netherlands). 
Internalisation assay and Confocal imaging
For internalisation assays, cells were cultured on eight-chamber slides (Nalgen Nunc Int.) to 
~70% confluency. Prior to addition of peptides, medium was refreshed (200 µl RPMI 1640) 
and 50 µl of a 0.2mM solution of peptide in 50% ethanol was added. After 30 min incubation, 
cells were washed 2 times with 200 µl of medium to remove unbound peptides. Images were 
recorded on a Leica SP1 confocal microscope equipped with an Argon laser (488 excitation 








Selection of UM cell-binding peptides 
Two primary and two metastatic UM cell lines were used to select melanoma-specific phages 
from 7- and 12-mer random peptide phage libraries. To assess whether cell-binding phages 
were enriched during the panning experiments, phages eluted after each round of selection 
were amplified and their DNA sequenced.
After three rounds of biopanning, four peptide sequences dominated in the selected phage 
pool in specific cell lines as shown in Table 1. One peptide that was repeatedly amplified (9 
of 10 plaques) from phages targeting the metastatic UM cell lines OMM 1 and OMM2.5, 
consisted of the following sequence: DLNYFTLSSKRE and was named uveal melanoma 
associated peptide 1 (UMAP1). This peptide was identified during biopanning without 
pre-adsorption onto normal melanocytes, and may thus carry melanocyte-lineage and not 
melanoma-specific characteristics. UMAP1 has also been reported in a liver cancer phage 
display experiment as Titanium Oxide binding peptide (www.freshpatents.com).
Two other potentially-interesting peptides, found after pre-adsorption by normal mela-
nocytes, were UMAP2 (YITPYAHLRGGN) from metastatic cell line OMM2.5, and UMAP3 
(ELQVMPIHIAAS) which were selected from both primary UM cell lines 92.1 and Mel270.
The sequence of UMAP2 was identified to be a homologue of the rat insulin-like growth 
factor receptor 21. UMAP3 could not be linked to any known receptor or protein.
Table 1. Identified peptide sequences after biopanning in UM primary and metastatic cell lines.
Peptide Sequence * Label
Cell line of 
origin
Remarks




UMAP 2 YITPYAHLRGGN**(9/9) Rhodamine OMM2.5 Present in round 3 and 4
UMAP 3 ELQVMPIHIAAS (4/17) FITC and 
Rhodamine






Round 3, lost in round 
4 (no clear consensus 
sequence in round 4)
HYSRYNPGPHPL (3/17) n/a 92.1 Round 3 only
SPITISSWFPMP (3/17) n/a 3 & 4 suspicious
SVSVGMKPSPRP (2/17) n./a 3 & 4 aspecific
Umap= uveal melanoma associated peptide , n/a = not applicable.
 * (x/y) x plaques of total y plaques sequenced in rounds 3 and 4 have this sequence for the indicated cell lines. 
**homologous to rat IGF-1 receptor. *** homologous to Titanium Oxide binding peptide SSWSSPITTAAV. 
minor sequences NFMESLPRLGMH (92.1), CNHLNHHLC (92.1), ITSTSPMFATPP (omm1), 
NADNQMTWRHVL (OMM1),
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Two peptides from the PhD-C7C library with the related sequences CLSYLPHKC and 
CFSSHPHVC, named UMAP4 and 5, were isolated from Mel270 and OMM1 cells during 
round 3 only. In general, peptides from the PhD-C7C library were highly underrepresented. 
A peptide with the sequence HYSRYNPGPHPL dominated in the 92.1 pool during round 
3, but was not retrieved in round 4. On a few occasions, peptides with the sequences SPI-
TISSWFPMP and SVSVGMKPSPRP were selected. These peptides were considered aspecific 
because of their homology to a titanium-oxide binding peptide (SSWSSPITTAAV) or to the 
well-known target unrelated peptide (SVSVGMKPSPRP) 22
A total of three peptides were synthesized and either labelled with fluorescein (UMAP 1 
and 3) or rhodamine (UMAP 2 and 3).
Internalization of selected peptides by UM and other cells 
The biopanning method is expected to favor the selection of internalizing phages. We 
therefore investigated whether the synthesized peptides demonstrated internalization in 
UM cells in vitro. UMAP1 showed a fast and efficient penetration in all UM cell lines both in 
the cytoplasm as well as in the nucleus, with high concentrations in the nucleolus (Table 2, 
Figure 1). As expected, also normal melanocytes were penetrated by UMAP1, since no nega-
tive selection against these cells had taken place. UMAP1 was not internalized by SAOS-2 
and HUVEC cells.
All UM cell lines showed a similar mottled distribution of UMAP 2 and 3, which were pri-
marily concentrated in the cytoplasm. UMAP 2 was especially internalized in the OMM2.5 
cell line, from which the peptide was initially selected (Figure 2), and showed less penetra-
tion in the other UM cells. UMAP 3 only moderately penetrated cell lines Mel270, 92.1 and 
OMM2.5, and was not internalized by SAOS-2 and HUVEC cells. Moreover, labelling did 
not influence staining patterns since also fluorescein-labelled UMAP 3 showed a moderate 
mottled internalisation (Figure 3).
Table 2. Internalisation capacities of synthetic labelled peptides.
UMAP 1 UMAP 2 UMAP 3R UMAP 3F
Mel270 + + +/- +/-
OMM2.5 + ++ + +/-
92.1 + + + +/-
OMM1 + - +/- -
- no internalisation,+/- moderate internalisation, + internalisation, ++ excessive internalisation









Figure 1. Internalization of UMAP 1. 
UMAP1 showed penetration of all UM cell lines both in the cytoplasm as well as in the nucleus, with high 
concentrations in the nucleolus (OMM2.5 (top) and Mel 270 (bottom)). UMAP1 was not internalized in 
control cell lines SAOS-2 and HUVEC cells (not shown).
Figure 2. Internalization of UMAP 2. 
UMAP 2 shows a mottled distribution primarily concentrated in the cytoplasm. UMAP 2 was especially 
internalized by OMM2.5 from which the peptide was initially selected. 
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Discussion
In cancer research, phage display libraries have been used widely for the identification of 
tumor-targeting peptides and antibodies. 23 Although UM is the most common intraocular 
tumor in adults, it remains a rare disease and very few reports exist of phage display experi-
ments involving UM. We set out to identify specific UM peptides with good binding and 
internalization capacities and that can be used for in vivo imaging of (micro) metastases and 
as a tool for targeted treatment of UM primary and metastatic disease.
Four peptides were identified and subsequently amplified after several in vitro panning 
rounds. UMAP1 proved to be the most potent peptide, demonstrating excellent internalisa-
tion ability in primary and metastatic UM cell lines. This peptide was also internalized by 
normal melanocytes (due to the lack of counter-selection during biopanning). This is an 
unfavourable event in regard to the effect of targeted therapies on healthy tissue. However, 
the current most widely used treatment for UM related metastatic disease, chemotherapy, 
demonstrates no specificity at all 24. In addition, UMAP1 was not internalized by SAOS-2 and 
HUVEC cells, demonstrating partial selectivity. 
The low specificity of UMAP1 is also evident from its presence in some patents as a titanium 
oxide and antibody-binding peptide (www.frespatents.com). UMAP1 has also previously 
been selected by phage display on human embryonic stem cells 25 and heptocarcinoma cells 26
Figure 3. Internalization of UMAP 3 in UM cell line 92.1







 UMAP2 showed a mild preference for metastatic cell line OMM2.5, from which the pep-
tide was initially selected. Although internalisation was mottled, large amounts of peptide 
were visible in the cytoplasm of almost all cells. The sequence of UMAP2 has been identified 
as a homologue of the rat insulin-like growth factor receptor 21. Interestingly, Economou 
et al described the expression of insulin-like growth factor-1 (IGF-1) in uveal melanoma 
to be associated with a bad prognosis 27,28. IGF-1 binds to the IGF-1 receptor leading to 
phosphorylation of IGF-1R, which then activates key signal molecules involved in tumor 
transformation, maintenance of malignant phenotype, promotion of cell growth, and pre-
vention of apoptosis 29. IGF-1 is mainly produced by the liver, of which the metastatic cell 
line OMM2.5 originated (liver metastases). Since UM almost exclusively disseminate to the 
liver, the expression of IGFR may therefore explain the preferential liver-homing of UM 
cells 5. One would expect to detect a peptide which shows homology with IGF rather than 
its receptor and to have human similarity. However, one should realize that the Ph.D.-12 
phage library does not cover the entire landscape of all possible dodecapeptides (which is 
~4x10e15) so exact homologues to human peptides will be extremely rare in the starting 
quantity of 1x10e11 pfu. Besides, the degree of amino acid homology between rat and human 
IGF receptor is 85% at the C-terminal and 98% at the tyrosine kinase domain 30. In addition, 
heterodimeric hybridization of receptors have been described regarding IGFR and Insulin 
Receptor (IR) 31,32 which are of the same tyrosine kinase family and have a high degree of 
sequence similarity 33. This phenomenon may also explain the binding and internalization of 
UMAP3 with UM cells.
In summary, at least three UMAPs could be identified using phage peptide libraries and 
in vitro panning. In addition, synthetic constructed peptides that corresponded to these 
UMAPs were shown to successfully internalize targeted UM cells. Whether these UMAPs 
can be used clinically for in vivo imaging (radiolabelled) or targeted therapy remains to be 
investigated.
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The RAS/RAF/MEK/ERK pathway is involved in the balance between melanocyte prolifera-
tion and differentiation. The same pathway is constitutively activated in cutaneous and uveal 
melanoma and related to tumor growth and survival. Whereas mutant BRAF and NRAS 
are responsible for activation of the RAS/RAF/MEK/ERK pathway in most cutaneous mela-
noma, mutations in these genes are usually absent in uveal melanoma. We set out to explore 
this pathway and used mitogen-activated protein kinase profiling and tyrosine kinase arrays 
and identified Src as a kinase that is associated with ERK1/2 activation in uveal melanoma. 
However, low Src levels and reduced ERK1/2 activation in metastatasis cell lines suggest 
that proliferation in metastases can become independent of Src and RAS/RAF/MEK/ERK 
signaling. Inhibition of Src led to growth reduction of primary uveal melanoma cultures and 
cell lines and thereby identified Src kinase as a potential target in primary uveal melanoma 
treatment. Metastasis cell lines displayed a more resistant phenotype and indicate that in 
metastases a different approach may be required.
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Introduction
Uveal melanoma (UM) is a rare neoplasm, which arises from melanocytes in the eyes. It 
usually affects people in their sixties with an incidence rate of approximately 6-8 new cases 
per million per year among Caucasians 1,2. Little is known about the molecular pathogenesis 
of UM as compared to cutaneous melanoma (CM). CM and UM share the same embryonic 
origin and similar histological features, but mutations that regulate proliferation and cause 
loss of cell cycle control in CM can hardly be found in UM. Whereas p16-regulated cell cycle 
control is targeted by deletion of chromosome 9p or mutation of CDKN2A in CM, most of 
UM cell lines posses a wildtype p16-encoding gene that is, however, not expressed due to 
epigenetic modification of the CDKN2A gene 3. The same may be true for activation of the 
RAS-RAF-MEK-ERK, or the classical mitogen-activated protein kinase (MAPK) pathway. 
MAPK activation is crucial in the development of melanocytic neoplasia and constitutive 
activation of this pathway has been associated with many different types of cancer 4,5. In 
CM, activation of the MAPK pathway has been shown to occur by a variety of mechanisms, 
including autocrine growth factor stimulation and mutation of the NRAS (20% of cases) 
and BRAF (60% of cases) genes 6-8. BRAF mutations have only rarely been reported in UM 
and activating mutations in NRAS, which are found in 25% of all cancers, have never been 
reported 9-14. However, we and others have found that UM are heterogeneous and that, with 
more sensitive techniques, the percentage of mutant BRAF-positive UM may be higher 15,16. 
The lack of mutations in the majority of cells is in contrast with immunohistochemistry 
and Western blot analysis that have shown activation of ERK1/2 in most UM 13,17,18. Still, 
pharmacological inhibition of MAPK/ERK kinases 1 and 2 (MEK1/2) and genetic targeting 
of BRAF with siRNA resulted in a reduced proliferation of UM cell lines 19,20. This indicates 
that although mutations are absent, the RAS-RAF-MEK-ERK pathway is essential for UM 
growth and suggests that an upstream factor is involved in autonomous UM proliferation. 
Recently, c-Kit was shown to be upregulated in uveal melanoma and involved in an autocrine 
loop that also involved the RAS-RAF-MEK-ERK pathway 20. An incomplete response to 
c-Kit inhibition indicates that additional factors are involved 21. Also the GNAQ gene was 
shown to be mutated in almost half of the uveal melanoma 22. GNAQ is part of the G-protein 
heterotrimer and represents the GTP-binding part that couples GPCR signaling to MAPK 
activation which marks it as a potential therapeutic target. However, targeting downstream 
signaling molecules may be just as effective as they may be shared with other mutant path-
ways. Tyrosine kinase activity profiling in uveal melanoma was used to explore the involved 
kinases. Based on a UM cell line and two related metastasis cell lines which revealed reduced 
ERK1/2 activation in metastases, we were able to identify Src as a crucial upstream tyrosine 
kinase for ERK1/2 activation in primary UM. Unfortunately, metastasis cell lines appeared 









Cell lines and tumor material
Eleven cell lines derived from primary UM (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, 
-290) and UM metastases (OMM-1, -2.3, and -2.5) were analyzed for kinase activity 23-26. 
UM cell lines were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland) supplemented 
with 3mM L-glutamine (Gibco), 2% penicillin/streptomycin and 10% FBS (Hyclone, Logan, 
UT). Primary UM were cultured in Amniochrome Pro Medium (Lonza Group Ltd, Basel, 
Switzerland). All cell cultures were incubated at 37°C in a humidified 5% CO2 atmosphere.
Cell lysates were obtained by lysing cells in M-PER Mammalian Protein Extract Reagent 
(Pierce, Rockford, IL), supplemented with 1% Halt Protease Inhibitor Cocktail, EDTA-free 
(Pierce) and 1% Halt Phosphatase Inhibitor Cocktail (Pierce). Protein concentrations were 
measured by using the BCA Protein Assay kit (Pierce). Cell lysates were also acquired from 
three fresh primary UM samples obtained by enucleation and from three liver metastases of 
three different patients, in which the diagnosis was confirmed.
Phospho-MAPK Array
The Human Phospho-MAPK Array (R&D Systems, Abingdon, UK) was used to simultane-
ously detect the relative levels of nine MAPkinases and nine other serine/threonine kinases in 
cell lines, primary UM and liver metastasis. In this array, capture and control antibodies were 
spotted in duplicate on nitrocellulose membranes. Experiments were carried out according 
to the manufacturer’s guidelines. In short, cell lysates were diluted and incubated with the 
array. After binding of both phosphorylated and unphosphorylated kinases, unbound mate-
rial was washed away. A cocktail of phospho-site specific biotinylated antibodies was used 
to detect phosphorylated proteins via Streptavidin-HRP and chemiluminescence. The X-ray 
films of the blots were scanned and analyzed using the G-boxHR (Syngene, Frederick, MD). 
Control spots with mouse, goat and rabbit antibodies were used for background correction. 
PamGene Tyrosine Kinase Array
Experiments were performed by using a 4-array semi-automated system (PamStation 4, 
PamGene, `s-Hertogenbosch, The Netherlands) designed for processing PamChip-4 arrays. 
The PamChip Tyrosine Kinase Array (PamGene) contains 144 phospho-peptides, immo-
bilized on a porous microarray surface via the peptide N terminus, representing tyrosine 
kinase substrates. Each array was blocked with 0.2% Bovine Serum Albumin, fraction V 
(Calbiochem Immunochemicals, Merck KGaA, Darmstadt, Germany) by pumping it 
through the porous microarray for 30 cycles of 30 seconds. Thereafter, each array was washed 
three times for 8 seconds with 1x ABL Protein Tyrosine Kinase Reaction Buffer solution 
(New England Biolabs, Ipswich, MA). Next, incubation was performed at 30°C with the 
reaction mix, containing 5µg cell lysate, 4µl 100x BSA (New England Biolabs, Ipswich, MA), 
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0.4µl 10mM ATP (Sigma-Aldrich, Zwijndrecht, the Netherlands), 0.5µl 1mg/ml Monoclonal 
anti-phosphotyrosine FITC conjugate (clone Py20, Exalpha Biologicals, Maynard, MA), 
adjusted to 40 µl with distilled H2O. The sample was pulsed back and forth through the 
porous material for 45 cycles, which is coupled to the base of a well to maximize reaction 
kinetics and to reduce analysis time. Every 5 pump cycles, a 16-bit TIFF image was taken with 
a built-in CCD camera. 
Blocking experiments were carried out with Src family-selective tyrosine kinase inhibi-
tors, PP1, PP2 (Biomol international, LP, of Plymouth Meeting, PA) and PP3 (the inactive 
analogue, Calbiochem), at an end concentration of 10µM in line with a large body of litera-
ture. Each particular inhibitor was mixed with lysates of cell lines and tissue together with 
the reaction mix just before incubation on the array.
Acquired data from the PamStation 4 was captured with the supplied software package 
BioNavigator (Version 0.3.1; PamGene). For the purpose of finding differentially phosphory-
lated substrates, the data was imported in the LIMMA package and we applied the empiri-
cal Bayes method 27. Background subtracted data was normalized for differences between 
experiments and substrates and P-values of 0.05 or less were corrected for multiple testing 
using Benjamini and Hochberg correction. Substrates with a corrected P-value of 0.05 or less 
were assumed significant. 
Western blot analysis
Cell lysates (10 µg) were separated on 12.5% SDS-PAGE gels and proteins were transferred to 
Hybond-polyvinyldifluoride membranes (Amersham Biosciences, Buckinghamshire, UK). 
The membranes were blocked with 5% skim milk in PBS-Tween 0.1% solution and probed at 
room temperature for 1 hour with antibodies specific to each antigen: Phospho-Src (Tyr527; 
dilution 1:1000), Phospho-Src Family (Tyr416; dilution 1:1000) and Src (36D10; dilution 
1:1000) antibody (all from Cell Signaling Technology, Hertfordshire, UK). An antibody 
against Actin (Abcam, Cambridge, UK) was used as a loading control. Membranes were 
subsequently incubated at room temperature with horseradish peroxidase-conjugated IgG 
anti-mouse or anti-rabbit secondary antibodies for 1 hour. Supersignal West Femto ECL 
(Pierce) was used to visualize protein bands on the membrane.
siRNA treatment
Sub-confluent cell cultures were grown without antibiotics 24 hours prior to transfection 
in RPMI 1640 medium. A mixture of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 
two different siRNA constructs (40 nM) were incubated in standard medium with reduced 
serum (1%) all in line with the advice of the manufacturer. The siRNA constructs (Stealth) 
were predesigned and validated (~70% knock down) by the manufacturer (Invitrogen). After 








Cell proliferation in response to PP1 (10 and 50µM) was measured by mitochondrial func-
tion using the WST-1 proliferation reagent (Sigma-Aldrich) as previously described 28. This 
assay measures tetrazolium reductase activity in the mitochondria which serves as a measure 
of cell viability. In short, 96-well plates were filled with 1250 uveal melanoma cells per well. 
One (tumor 1-5) or six days (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290, OMM-1, -2.3, 
and -2.5) after treatment, WST-1 reagent was added and absorbance was measured at 450nm 
on a multiwell spectrophotometer. The median and standard error of 8 wells were taken at 
each time and dosage point.
QPCR
The cell lines (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290, OMM-1, -2.3, and -2.5) 
were analyzed for Src gene expression. Primers for Src and the reference gene, β-actin, 
were developed with Beacon Designer software (Premier Biosoft, Palo Alto, CA). Primer 
sequences for Src: 5’-GCTGCGGCTGGAGGTCAAG-3’ (forward) and 5’-AGACATCGT-
GCCAGGCTTCAG-3’ (reverse). Primer sequence for β actin; 5’-CGGGACCTGACTGAC-
TACCTC-3’ (forward) and 5’-CTCCTTAATGTCACGCACGATTTC-3’ (reverse). The PCR 
reaction settings were 95°C for 5 min, then 40 cycles at 96°C for 15 s and 60°C for 45 s. DNA 
melting point of the amplicons were acquired by measuring the fluorescence of SYBR Green 
during a linear temperature transition from 70°C to 97°C at 0.2°C each 10 seconds with 
accompanying software (Bio-Rad, Hercules, CA). 
Results
ERK1/2 activation in uveal melanoma
An antibody array was applied to investigate the mapk pathway in ten um cell lines, three 
primary UM and three UM metastasis. We observed uniform HSP27 phosphorylation with 
the exception of three UM cell lines (OCM1, -3, -8). UM displaying activated ERK1/2 as well 
as phosphorylated HSP27 were most common whereas signals for phosphorylated ERK1/2 
were low in metastasis tissue (MET1-3) and metastatic UM cell lines (OMM1, OMM2.3 and 
OMM2.5) (Fig. 1). Remarkably, two of the metastatic cell lines (OMM2.3, OMM2.5) are 
derived from the same patient as cell line Mel270 but contained far less activated ERK1/2. 
Differential kinase activity in uveal melanoma
Reduction of ERK1/2 activation in metastatic cell lines compared to the primary UM cell 
lines provides a model to identify the underlying mechanism of ERK1/2 activation in the 
absence of BRAF and NRAS mutations. 
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To investigate whether a kinase is differentially activated between primary UM cell lines 
and metastatic UM cell lines we used peptide-based tyrosine kinase arrays 29. The UM cell 
lines displayed a high kinase activity while the metastatic UM cell lines displayed a low 
kinase activity although the same amount of lysate was incubated (Fig. 2A). After normaliza-
tion, we could analyze the kinase data and identify nine substrates that were significantly 
differentially phosphorylated between primary and metastatic UM cell lines (Fig. 2B, Tab. 1). 
Primary UM and metastatic tissue also showed differential phosphorylation of these nine 
peptides though not as clearly as observed in the cell lines (Fig. 2C). 
Candidate kinase: Src
We identified nine peptides derived from eight proteins that were differentially phos-
phorylated between primary and metastatic cell line lysates. based on a literature search 
we identified candidate tyrosine kinases for eight out of nine peptides (Table 1) 30-33. Among 
the candidates, Src and Src family members were most prominent. In order to validate the 
candidacy of Src we performed in vitro inhibition experiments with the Src-kinase specific 
inhibitors PP1 and the PP1 analogue, PP2. We added PP1 and PP2 (10µM) to lysates of pri-
mary UM tissue and of a primary UM cell line and we measured the inhibitory effect of these 
Src inhibitors using the kinase array (Fig. 3A). Seven out of nine substrates that identified 
(A)  (B)
Figure 1. MAPK activation in primary UM and UM metastases was studied with a MAPK antibody array. 
We observed uniform HSP27 phosphorylation in both cell lines and tissue samples except for OCM1, -3 and 
-8 (A). Activated ERK1/2 was normalized with HSP27 and shown to be low in UM metastases (MET1-3) while 







(A)             (C)
(B)
Figure 2. Tyrosine kinase activity was measured with an array of peptide substrates. 
Two representative examples of a UM cell line and a metastatic cell line (A). Analysis with eBayes identified 
nine substrates, representing eight proteins, to be significantly (p=0.01) differentially phosphorylated between 
UM and metastatic cell lines (B). UM (UM1-3) tyrosine kinase activity is high compared to liver metastasis 
(MET1-3) (two representative arrays are shown) (C).
Table 1. Tyrosine kinase substrates on the kinase array that were differentially phosphorylated between 







Adj. P value Kinase
CDK2 P24941 T14/Y15 5.3 0.00005 Lyn
FRK P42685 Y387 6.2 0.0002 unknown
SRC8 Q14247 Y499 4.6 0.006 Src
ENOG P09104 Y43 4.7 0.01 Src
EFS O43281 Y253 3.1 0.01 Src
PLCG1 P19174 Y771 4.2 0.01 Syk, Sky, GFRs
CD79A P11912 Y182/Y188 3.1 0.01 Lyn
PAXI P49023 Y118 4.0 0.02 FAK, Src, Brk
PAXI P49023 Y31 4.3 0.03 FAK, Src, Brk
Tyrosine kinase substrate specificities are included.
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Src in the first screen displayed a significantly reduced phosphorylation when PP1 or PP2 
were added to lysates of UM1 and Mel270 (Fig. 3A). The PLCG1 peptide and one of the 
PAX1 (Y31) substrates did not reach significance but were still phosphorylated at a reduced 
level after PP1 and PP2 treatment. The peptide representing FAK1 Y576/Y577 is a genuine 
substrate for Src that was not detected in the UM cell line comparison but phosphorylation 
was significantly downregulated by PP1 and PP2 treatment. In the control experiment in 
which we added the inactive analogue of PP1 (PP3) to cell lysates, we did not observe a loss 
of kinase activity (not shown).
Kinase activity of metastasis tissue and UM tissue differed marginally (Fig. 2C) and 
incubation with PP1 (10µM) resulted in a decimation of kinase activity similar to the inhibi-
tion that we observed in UM tissue (Fig. 3B). In order to validate Src activity, Mel270 was 
transfected with two siRNA constructs that target Src and reduced kinase activity (Fig. 3B). 
Regulation of ERK1/2 and growth
To investigate whether Src contributes to ERK1/2 activation in Mel270 we analyzed the two 
Src siRNA transfected cell cultures with the MAPK antibody array. Twenty four and 48 hours 
after transfection with Src siRNA we observed a reduced ERK1 phosphorylation whereas 
ERK2 phosphorylation was minimally affected (Fig. 4). 
Whether Src inhibition and consequently a lowered ERK activation in UM cell lines is 
associated with a reduced growth was investigated with the WST-1 viability assay (Fig 5). All 
UM cell lines showed a PP1-dose and time (1 to 6 days) dependent reduction in cell viability 
but the magnitude of the response differed widely. In general, the metastatic UM cell lines 
were less affected by PP1. We also determined the growth inhibition rate of PP1 in cultures 
of five primary UM cell cultures and observed an increased sensitivity to PP1 treatment 
(a)  (B)
Figure 3. UM1 (06-12) and Mel270 treatment with Src inhibitors (PP1/PP2) identified eight substrates with a 
significant reduction in phosphorylation (A). 
Inhibition of EFS peptide phosphorylation by genetic (Src-siRNA) and pharmacological means (PP1) in cell 







Figure 4. ERK1/2 activation in Mel270 24 and 48 hours after transfection with Src siRNA. Phosphorylated 
HSP27 is included as reference signal. 
  (A)     (B)
Figure. 5. UM cell lines and primary cultures were cultured with PP1 (10µM and 50µM). 
After 24 hours and 3 days (UM cultures) and 6 days (cell lines) the viability was tested with the WST-1 assay. 
Two representative cell culture experiments for which all time points and conditions are shown (A). Growth 
inhibition by PP1 (50 µM) after 24 hours and 3/6 days was normalized to the control culture of each individual 
cell line (B). 
Episodic Src activation in uveal melanoma 161
compared to the cell lines. We had to take samples at day 3 of PP1 treatment because hereafter 
massive cell death occurred (Fig 5B). 
Src protein is reduced in metastasis cell line
Src is regulated by phosphorylation of tyrosine residues at position 416 (Y416) and 527 
(Y527). Expression of phosphorylated Src Y416 which is associated with an active conforma-
tion, was low in the metastatic UM cell lines (Fig. 6A). Surprisingly, phosphorylation of 
Y527 that is associated with an inactive conformation, was also low and subsequent analysis 
indicated that Src expression is low in the metastatic UM cell lines. Therefore the difference 
between kinase activity in metastatic cell lines (OMM1, OMM2.3, OMM2.5) and UM cell 
lines (OCM1, OCM3, OCM8, Mel202, Mel270, Mel285, Mel290 and 92.1) seems to be the 
result of a difference in Src expression. 
To investigate the origin of lowered Src expression we performed gene expression analysis 
(Fig. 6B). Src gene expression varied widely in the cell lines and the metastatic cell lines but a 
correlation between protein and gene expression was not observed in UM cell lines. 
(A)  (B)
(C)
Figure. 6. Western analysis of Src in the UM cell lines for activating phosphorylation (Y416) inactivating 
phosphorylation (Y527) and total Src expression (A). 
Src gene expression measured by QPCR varied widely but did not correlate with variation in protein expression 
(B). UM and metastasis tissue all displayed medium Src kinase expression except for UM3 that presents a high 







Western analysis of Src expression in UM and metastasis tissue revealed in only one out 
of three primary UM a very high Src expression whereas all three metastasis tissue displayed 
medium expression of Src protein (Fig. 6C).
Discussion
Constitutive activation of ERK1/2 has often been reported for UM 13,17,18. Using a more 
quantitative approach we distinguished a decrease of active ERK1/2 in metastatic cell lines 
and fresh liver metastasis, suggesting loss of ERK1/2 activation during UM progression. The 
latter is unexpected since ERK1/2 activation is generally associated with mitogen signal-
ing and is known to determine malignant potential in vitro. However, in endometrial and 
breast cancer, ERK1/2 activation has been associated with a good prognosis 34 35. A possible 
explanation is provided by the observation that ERK1/2 is involved in oncogene and stress 
induced senescence 36,37. This mechanism is thought to be an important defense for cells that 
are at risk of neoplastic transformation and needs to be circumvented by tumor cells in order 
to proliferate. Loss of activated ERK1/2 may relieve the associated inhibitory mechanisms 
in a direct manner but also requires for alternative mitogenic signals to take over in UM 
metastasis. 
The metastatic and UM cell lines provide a unique model to identify the mechanisms that 
regulate ERK1/2 activation in uveal melanoma. Previous work already showed that ERK1/2 
phosphorylation in UM depends on the MAPK pathway although mutations in the usual 
suspects (e.g. BRAF and NRAS) are lacking 19. We investigated the possibility of a tyrosine 
kinase with differential activities in UM and UM metastasis to be responsible for ERK1/2 
activation, using an array of kinase activity assays. Src was revealed as differentially activated 
tyrosine kinase and this was supported by incubation with Src specific kinase inhibitors PP1 
and PP2. Moreover, by treating the cell lysates instead of the cell cultures, we minimized the 
secondary effects of the inhibitors. However, PP1 and PP2 affect most of the Src-family of 
tyrosine kinases and the observed reduction of kinase activity therefore does not specifically 
mark Src. Multi-target inhibitors are a problem in molecular analysis but may be beneficial 
in the clinical application since in CM a switch from Src to Yes signaling has been reported 
in brain metastases 38. In order to specifically inhibit Src we targeted the Src gene expression 
with a siRNA approach. We detected a reduced kinase activity in Mel270 upon transfection 
and this was correlated with a reduced ERK1 activation. ERK2 activation appeared unaf-
fected which could be due to the limited efficacy of siRNA treatment or it could indicate 
the activity of another, yet unidentified, kinase. Low Src protein expression in conjunction 
with loss of ERK1/2 activation in metastatic UM cell lines however supports the hypothesis 
that in UM, Src kinase is involved in ERK1/2 activation. Gene expression analysis revealed 
no significant differences between metastatic and UM cell lines and thereby indicated that 
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post-transcriptional mechanisms are most likely involved in Src down regulation. Src is both 
a kinase as well as a client protein for the chaperone HSP90 that is expressed in UM 39. 
Whether HSP90 is reduced in metastases and whether treatment with HSP90 inhibitors 
depends on Src signaling is part of future investigation 40,41. Inhibition of Src kinase activity 
resulted in a strong growth reduction in all UM cultures while in UM cell lines the response 
varied more widely. The genetic background of the cell lines might play a role in the ob-
served variation. However, all UM cell lines displayed Src kinase activity and PP1 sensitivity 
irrespective of c-kit upregulation (Mel270) or BRAF V600E (OCM1) and GNAQ Q209L 
(Mel202) mutation status 20,22. Tissue of UM and UM liver metastasis displayed more or less 
comparable Src levels. Incubation of the lysates with Src inhibitors resulted in comparable 
reduction of kinase activity in UM and metastasis tissue. The possibility that there exist Src 
negative clones in liver metastasis can however not be ruled out on the basis of these data. 
Clinical trials targeting Src kinase activity in uveal melanoma should therefore anticipate on 
this potential risk. 
In conclusion: we have identified differential ERK1/2 activation in UM and metastatic 
UM cell lines. Using tyrosine kinase activity profiling we identified Src as a determinant of 
ERK1/2 activation and showed that Src expression and kinase activity together with ERK1/2 
activation is reduced in UM metastases cell lines. 
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Chapter 10
Src kinase in uveal melanoma is 
associated with monosomy 3 and 
can be inhibited by Dasatinib 










Purpose: Uveal melanoma (UM) leads to metastasis in up to 50% of the patients. Patients 
at risk are readily identified using an array of prognostic markers but an effective treatment 
is lacking. We recently identified Src as an important tyrosine kinase that conveys MAPK 
activation in UM. GNAQ/GNA11 mutations are the common denominators of oncogene 
signalling in UM and Src is a likely downstream kinase. We describe the preclinical analysis 
of Dasatinib, a known inhibitor of Src kinase, in UM. 
Experimental design: Eight tumours were removed, cultured and exposed to Dasatinib 
treatment. Proliferation and MAPK signalling were evaluated. Additionally, 36 UM samples 
were analyzed for Src/ERK signalling, GNAQ/GNA11 mutation status, chromosome 3 and 
known histological prognostic parameters.
Results: Growth arrest was observed in 5 of 8 UM cultures and molecular analysis indicated 
that Dasatinib inhibited MAPK via Src. Treatment efficacy associated with MAPK and Src 
kinase activity as UM cells with the highest Src activity and MAPK activation displayed 
the strongest growth inhibition. Furthermore, treatment responses tended to be better in 
UM cultures with monosomy 3. In the cohort of primary UM, Src expression was highly 
correlated with MAPK activation and monosomy 3. 
Conclusions: We identified the Src family kinase inhibitor, Dasatinib, as a treatment option 
for UM. Dasatinib inhibits UM proliferation and may also inhibit UM progression as an 
association between Src and monosomy 3 was revealed. Consequently, monosomy 3 analysis 
in tumour tissue may suffice both the prognosis and choice of treatment. 
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General introduction
Uveal melanoma (UM) is a rare tumour affecting 7/1.0 million of the Western population 
per year 1. Still, it is the most common tumour in the eye in adults; 30 % of the tumours is 
asymptomatic and only discovered at routine examination 2. This malignancy may ultimately 
lead to metastatic disease in up to 50% of the patients 3. 
UM commonly spreads hematogeneously because there are hardly any lymph vessels pres-
ent in the eye, and most often metastasis of UM are found in the liver. Once liver metastases 
have been detected, life expectancy is a mere 2-6 months on average since hardly any effective 
treatment is available for these patients 4. This highlights the necessity for effective adjuvant 
and clinical treatment options which can be applied in high risk and metastasis patients.
Identifying high risk patients is possible with an array of diagnostic and prognostic mark-
ers. Well-known prognostic factors for UM are an advanced age, tumour thickness/diameter, 
and localization in the ciliary body 5. Besides these histopathological parameters, there are 
also genetic aberrations that are associated with a poor prognosis. Most significantly, loss of 
one copy of chromosome 3 is observed in almost half of the tumours and is associated with a 
poor prognosis 6. The risk associated with monosomy 3 is further modulated by other chro-
mosomal aberrations such as deletion of chromosome 1p and gain of chromosomes 6p and 
8q 7. How these aberrations, besides being a prognostic factor, contribute to the metastasis of 
UM is still unknown but the recent detection of truncating mutations in the BAP1 gene may 
elucidate a possible mechanism 8. 
Recently, two recurrent mutations were identified in the GNAQ and the GNA11 genes. For 
both the GNAQ and the GNA11 gene, a mutation in glutamine-encoding codon 209 has been 
described (Q209), as well as a mutation in R183 (less frequent). Mutations in the GNAQ and 
GNA11 gene were shown to be common in UM with frequencies of respectively 45% and 32% 
9,10. GNAQ and GNA11 encode for Gαq-type subunits of the heterotrimeric G-protein and 
the mutations result in constitutive G-protein activation which mediates intracellular signals 
and activates the Mitogen-activated protein kinase (MAPK) pathway, promoting prolifera-
tion and cell survival 11. Cellular components that couple GNAQ/GNA11 to MAPK signalling 
are most likely the effector IP3 and Src tyrosine kinase 12.
Recently, we showed that in UM, Src expression and Src kinase activity is correlated with 
MAPK activation 13. Whether Src is the intermediate kinase between oncogenic GNAQ/
GNA11 signalling and MAPK activation in UM remains to be shown, but it potentially 
provides an opportunity for pharmaceutical intervention. Treatment of UM cell lines with 
specific MAPK and Src inhibitors has already been shown to reduce proliferation 13, demon-
strating the importance of the MAPK pathway and Src kinase for UM growth. 
Dasatinib is an inhibitor of the Src-family kinases as well as other kinases such as BCR-
ABL, c-Kit, PDGFR-alpha and beta, and ephrin-receptor kinase 14,15. It has been approved 







Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and results 
in remission and improved survival in these malignancies. For several other diseases includ-
ing solid tumours, Dasatinib is still under investigation 16. The single daily oral dose of 100 
mg, and manageable side effects, make Dasatinib an interesting candidate for treatment of 
patients with metastatic disease and/or patients with high risk UM.
We investigated in vitro the efficacy of Dasatinib and analyzed the underlying molecular 
mechanisms in order to identify potential biomarkers. 
Materials and Methods
Patient tumour material and primary cell cultures
Informed consent was obtained prior to enucleation and the study was performed according 
to the tenets of the Declaration of Helsinki. Diagnosis was made based on histopathology 
of the tumor samples. Fresh tumor tissue (n=36), obtained immediately after enucleation of 
the eye, was frozen in liquid nitrogen-cooled isopentane and used to isolate DNA, protein 
lysates or to develop a cell culture (n=8). Histologic sections were prepared from tissues 
fixed in 10% neutral-buffered formalin for 48 hours and embedded in paraffin. Hematoxylin-
eosin-stained 4-μm sections were examined for cell type, largest basal diameter, prominence, 
ciliary body involvement and scleral invasion.
Primary tumour cell cultures
Primary UM cell cultures (n=8) were cultured in Amniochrome® Pro Medium (Lonza Group 
Ltd, Basel, Switzerland) and incubated in an atmosphere with 5% CO2 at a temperature of 
37oC. (HERAcell 240 CO2 Incubator, Thermo Fisher Scientific Inc, USA). The cells were 
passaged once or twice a week using trypsin (0.05%).
PCR
GNAQ/GNA11 genes were amplified with a Polymerase Chain Reaction (PCR). A PCR was 
conducted using chromosomal DNA, isolated from frozen tumours using the QIAamp DNA 
minikit from Qiagen (Germany). The following protocol was used for amplification of exon 
5 of the GNA11 and the GNAQ genes:
94°C, 1min; (96°C, 15sec; 63°C, 15sec; 72°C, 1min) 7X; (96°C, 15sec; 61°C, 15sec; 71°C, 1min) 
8X; (96°C, 15sec; 60°C, 15sec; 72°C, 1min), 36X; 72°C, 1min, end.
The following primers were used CGCTGTGTCCTTTCAGGATGGTG, GNA11 Forward 
and GCCCACCTCGTTGTCCGACT, GNA11 Reverse.
The forward primer for GNAQ: CCCTAAGTTTGTAAGTAGTGCTATATTTATGTTG,
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while the reverse primer was ATGATAATCCATTGCCTGTCTAAAGAACAC. After 
amplification, DNA clean-up was performed using the Nucleospin Extract II columns of 
Macherey-Nagel (Germany) following the manufacturers protocol. For sequencing analysis, 
samples were prepared by adding 10 pmol of reverse primer to the amplified DNA.
Sequencing and Karyotyping
Sequencing for GNAQ c.626A>C (~30%) and GNAQ c.626A>T (~70%) and GNA11 c.626A>T 
(100%) mutations was performed at the Leiden Genomic Technology Center (LGTC) de-
partment of the LUMC. Screening for monosomy 3 with karyotyping in all uveal melanoma 
samples and primary cultures was performed at the Department of Clinical Genetics of the 
LUMC.
Dasatinib treatment
Several Dasatinib (Toronto Research Chemicals Cat# D193600) concentrations were used to 
investigate treatment options in vitro. Dasatinib (stock solution concentration of 20 mM in 
DMSO) was dissolved in Amniochrome® Pro Medium (Lonza Group Ltd, Basel, Switzerland) 
to obtain concentrations ranging from 2 nM to 2 µM and used in experiments as described. 
As control, we used standard Amniochrome® Pro Medium.
Cell proliferation
The effect of Dasatinib on UM cell viability was measured by mitochondrial function us-
ing the water-soluble tetrazolium salt (WST-1) assay (Roche Diagnostics, Indianapolis, IN, 
USA). In short, 96-well plates were filled with 1200 uveal melanoma cells per well, with 
either regular medium (control) or Dasatinib solutions (200nM to 2µM), and placed in an 
incubation chamber (20% O2, 5% CO2, 37°C). After the indicated incubation time (1, 2, or 3 
days) 10ul of WST-1 reagent was added to each well and absorbance was measured at 450nm 
(n=8) on a multiwell spectrophotometer (Perkin Elmer, Wellesley, MA).
PamGene tyrosine-kinase array
To ascertain tyrosine-kinase activity in lysates of UM tissue and primary cultures, the 
PamChip-4 of PamGene B.V. (‘s Hertogenbosch, The Netherlands) was used, as described 
previously 13. In short, this array consists of 144 peptides spotted on a porous carrier. The 
144 peptides are known tyrosine-kinase substrates and phosphorylation of these peptides by 
cell lysates can be monitored because of a generic antibody that recognizes phosphorylated 
tyrosine. Each chip consists of four arrays, so four lysates can be measured at the same time. 
In this experiment, we incubated a control lysate with and without addition of Dasatinib at 








 Cell lysates were obtained by lysing cells of UM cryosamples and primary UM cultures (with 
and without Dasatinib treatment) in M-PER Mammalian Protein Extract Reagent (Pierce, 
Rockford, IL, USA), supplemented with 1% Halt Protease Inhibitor Cocktail, EDTA-free 
(Pierce) and 1% Halt Phosphatase Inhibitor Cocktail (Pierce). Protein concentrations were 
measured by using the BCA Protein Assay kit (Pierce). 
Cell lysates, containing the same amount of protein, were mixed with equal volumes 
of 6× sample loading buffer, boiled for 10 min, cooled on ice, and then analyzed by 10% 
SDS polyacrylamide-gel electrophoresis (SDS-PAGE). Separated proteins were transferred 
to a PVDF membrane (Millipore). Subsequently, the membrane was blocked with Li-Cor 
blocking buffer for 1 h at room temperature and incubated with primary antibodies (rabbit 
anti-Src, rabbit anti-Erk1/2, mouse anti-pErk1/2, rabbit anti-GAPDH (loading control) (Cell 
Signalling, Boston, USA) followed by an infrared labeled secondary antibody (goat anti-
rabbit800 and goat anti-mouse680 (LI-COR, Lincoln, USA). Labeled PVDF membranes 
were scanned with the Li-Cor scanner and quantification of proteins was performed using 
the Li-Cor software.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software (SPSS Inc. Chicago, Illinois, 
USA). One-way ANOVA was used to analyze significant difference in cell proliferation of 
treated and untreated cells. The significance of differences in Src and ERK1/2 expression 
between samples with different histologic and molecular parameters was determined using 
unpaired T-tests. Additionally, all parameters were analyzed for survival and prediction of 
metastatic disease using the Kaplan-Meier analysis, log rank testing, cox regression and 
multivariate analysis. P-values for categorical parameters (associations) were obtained by 
Independent-Samples T Test (t-test for Equality of Means) and for the numerical data by 
Pearson correlation (2-tailed). P < 0.05 was considered statistically significant. 
Results
Inhibition of UM growth by Dasatinib
The application of the experimental Src inhibitors PP1 and PP2 has already shown that Src 
inhibition substantially reduces cell proliferation in UM cell lines 13. The aim of the study 
was to analyze the efficacy of the commercially-available Src kinase-inhibitor Dasatinib in 
primary UM cell cultures. UM cell viability was significantly reduced by Dasatinib in a dose-
dependent manner in five out of eight UM cell cultures (Fig. 1). Three cultures appeared 
Dasatinib resistant and displayed no growth arrest. 
Dasatinib and uveal melanoma 173
MAPK involvement 
In order to investigate the molecular mechanisms by which Dasatinib induces growth 
arrest, we compared MAPK activation (pERK) and Src kinase activity in responders and 
non-responders. Primary cell cultures were exposed to two concentrations of Dasatinib. 
Basal expression of both Src and ERK varied widely in UM tissue cultures but revealed 
no correlation with treatment efficacy. Neither Src nor ERK expression was reduced after 
Dasatinib treatment (Fig. 2a). However, Dasatinib treatment significantly reduced activated 
ERK (pERK) in UM cell cultures (Fig. 2a and b). The degree of pERK down-regulation var-
ied widely and tended to be highest in the responders as compared to the non-responders. 
Furthermore, the degree of ERK activation, prior to treatment, also seemed to be higher in 
the responding cultures (not shown).
Src and pERK expression in primary UM samples 
In order to validate the correlation between Src and MAPK activation, Src and pERK expres-
sion in 36 UM was analyzed (Table 1). Expression levels of Src protein and ERK/pERK were 
quantified with Western analysis. All samples expressed Src (range of 1.17-55.83 integrated 
(A) REsponders
(B) non responders
Figure 1. Cell viability of primary UM cell cultures treated with Dasatinib.
Cell viability was measured at 3 consecutive days. Each time point embodied a control culture and two 
Dasatinib treatments (200 nM and 2 µM). The untreated control culture is set at 100% and in five out of eight 







Figure 2a. ERK/pERK analysis in UM cell cultures treated with Dasatinib.
ERK/pERK analysis of 4 representative UM cell cultures treated for 48 hours with two concentrations of 
Dasatinib. Simultaneous hybridization with total ERK (top) and pERK (middle) specific antibodies allows 
quantification of pERK relative to ERK presence (bottom). Red in the overlay represents high pERK while 
yellow represents reduced pERK and absence of pERK is represented by a green signal.
Figure 2b. ERK/pERK quantification in UM cell cultures treated with Dasatinib.
Activated ERK (pERK) in UM cell cultures after Dasatinib treatment in the responders and the non-
responders. Relative ERK activation (pERK/ERK) is normalized to untreated control cultures. 
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Table 1. Distribution of Src expression and clinical and pathological features of 36 cases of uveal 




N % Src expression Standard Deviation P- value
Gender .10
 Male 18 19,64 10,20
 Female 18 30,97 14,46
Eye .98
 Right 24 25,26 13,59
 Left 12 25,39 14,24
Histopathologic cell type .33
 Spindle 8 21,14 7,99
 Mixed/ Epithelioid 28 26,49 14,72
CB involvement .03
 Not present 21 21,17 10,74
 Present 15 31,10 15,38
Scleral invasion
 None 8 25,92 15,85
 Intrascleral 24 25,73 12,74
 Extrascleral 4 21,49 17,55
Chromosome 3 status .001
 Disomy 3 11 14,21 9,64
 Monosomy 3 25 30,18 12,25
Metastasis .10
 No 23 22,49 12,31
 Yes 13 30,28 14,84
Death .20
 Yes, due to other cause 3 29,37 17,72
 Yes, due to metastasis 11 29,32 16,02
 No 22 22,74 11,77
GNA11 .99
 No 17 25,32 17,00
 Yes 19 25,29 10,16
GNAQ .89
 No 17 24,48 10,46
 Yes 16 23,82 16,34
GNA11/GNAQ status .75
 GNA11 19 25,29 10,16









Age at diagnosis (year) 36 0.41 .01
Tumor diameter (mm) 36 0.19 .26
Tumor thickness (mm) 36 -0.04 .82
Erk expression (SD) 36 0.40 0.02
pErk expression (SD) 36 0.71 <.001
Data indicate the mean ± SD for the categorial parameters and correlation coefficients for the numerical 
variables. 
P-values for categorical parameters (associations) were obtained by Independent-Samples T Test (t-test for 
Equality of Means) and for the numerical data by Spearman correlation (2-tailed).
Figure 3a. Src kinase activity in UM cultures.
Phosphorylation of ENOG and CD79A peptides on the kinase array represent Src kinase activity in UM cell 
lysates and this activity is lost upon incubation with Dasatinib. Kinase activity of treated and untreated lysates 
are plotted for Dasatinib responders (n=3) and non-responders (n=3). 
Figure 3b. Src kinase activity of Dasatinib responder and non-responder.
Representative kinase arrays of UM that were used for in vitro analysis. The cells of the tumor on the left 
responded with growth arrest whereas the cell culture of the tumor on the right did not respond to Dasatinib 
treatment.
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intensity), ERK (range of 0.1-22.0 integrated intensity) and pERK (range of 0.84-13.29 in-
tegrated intensity) at variable levels (Fig 4a). Src expression was not correlated with ERK 
expression but the level of pERK was highly correlated with the level of Src (p<.001) and Src 
level predicts pERK to large degree (correlation coefficient = 0.71) (Table 1). Though ERK 
expression was also found to be correlated with pERK (p= 0.017) only part of the activation 
is predicted by ERK expression (correlation coefficient = 0.40).
Tyrosine-kinase activity
With kinase activity arrays Src activity in response to Dasatinib treatment was analyzed. 
Lysates of Dasatinib-treated UM cells all displayed reduced Src kinase activity, still a cor-
relation with treatment efficacy was observed. UM cultures that responded to Dasatinib 
treatment with growth arrest presented a higher basal Src activity compared to the non-
responding tumor cultures and hence a stronger reduction of kinase activity was observed 
(Fig 3a). Peptides on the kinase array, such as ENOG and CD79A, that are known substrates 
for Src kinase were highly phosphorylated by lysates of the Dasatinib sensitive UM cultures 
(Fig 3b). 
Molecular mechanisms
Known molecular mechanisms in UM were analysed and compared to treatment efficacy. 
GNAQ and GNA11 mutations of Q209 represent early events in UM development that could 
be related to Src activity in UM. However, mutations in GNAQ/GNA11 are very common and 
hence only 2 wiltype tumor cultures were analyzed. The GNAQ/GNA11 wildtype UM were 
found to be present in both the responder and non-responder group. In addition, the GNAQ 
and GNA11 status of primary UM was assessed (n=36) and no correlation was detected 
between GNAQ/GNA11 mutation status and Src/pERK expression. Out of the 36 analyzed 
tumors, 19 displayed the GNA11 mutation and 16 contained the GNAQ mutation while for 
one sample, the sequence analysis failed. 
Monosomy 3 is a late event and strongly correlated with metastasis development. Eight 
primary UM cultures were analyzed for chromosome 3 and all three non-responders dis-
played a normal chromosome 3 karyotype whereas three out of five responders displayed 
monosomy 3. These data suggest that Dasatinib efficacy and ERK activation through Src 
signaling may be correlated with tumor progression, and this was further analyzed using 
primary UM tissue. 
Using 35 UM samples, we observed that the level of Src expression was significantly 
correlated with monosomy 3 (p = 0.0014): the mean Src expression in UM samples with 
monosomy 3 was much higher (mean of 29.87; SEM 2.452) than in UM samples with disomy 
3 (mean of 14.91; SEM 3.249). Analysis for pERK demonstrated a similar trend, as expression 
of pERK was elevated in the UM samples with monosomy 3 (mean of 7.13; SEM 0.60) in com-







difference did however not reach statistical significance (p =0.068) (Fig. 4B). The analysis of 
the total amount of ERK1/2 expression and monosomy 3 revealed neither an association nor 
a trend (mean expression disomy 5.6, monosomy 4.6, p=0.750). 
According to the TNM classification (7th edition) five tumors were stage I, four were stage 
IIA, ten were stage IIB, 14 were stage IIIA, one was stage IIIB, and one was stage IV. Besides 
ciliary body involvement (p=0.03), neither TNM classification, nor other clinical and histo-
pathological parameters demonstrated an association with Src or pERK expression (Table 1).
Figure 4A. Expression of Src, ERK and pERK in primary UM samples.
Representative example of the Western analysis that was conducted on 36 UM samples in order to analyze ERK 
activation and Src expression. 
Figure 4B. Src/pERK expression and chromosome 3 status in UM tissue.
Protein expression levels of Src and pERK were measured and correlated with chromosome 3 status of 35 UM 
using unpaired T-test.
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Prognosis
Patient data and survival were updated till September 2010 and the mean follow-up at the 
time of analysis was 43 months (range, 3-121). During this period, 14 patients died, 11 due to 
metastatic disease. Two patients with metastasis were still alive at the end of follow-up and 
no patients were lost to follow up. According to Kaplan-Meier analysis and log rank testing, 
ciliary body involvement (hazard ratio 3.31, p<0.05), TNM classification (stage IV; hazard 
ratio 28.2, p<0.05) and monosomy 3 (hazard ratio 7.17, p<0.05), were significantly associated 
with a decreased survival. Src and pERK expression was not correlated to prognosis. 
Discussion 
Src has previously been identified in UM cell lines as an important kinase involved in UM 
growth via the activation of MAPK signaling. Based on this, preclinical analysis with Dasat-
inib was performed, a Src family-kinase inhibitor that is used in the treatment of leukemia.
Using 8 primary UM cell cultures, we tested whether UM cell growth could be inhibited 
using Dasatinib. In about 60% of the UM cultures, cell proliferation was reduced after treat-
ment with Dasatinib whereas in the remaining cultures, proliferation appeared unaffected. To 
investigate the underlying mechanism, MAPK activation in response to Dasatinib treatment 
was analyzed. In cell cultures that responded to Dasatinib with growth arrest, ERK activation 
(pERK) appeared to be higher prior to treatment and was also more strongly reduced upon 
Dasatinib treatment, compared to the non-sensitive cell cultures. To investigate the molecu-
lar mechanism of Dasatinib induced growth inhibition, the response was compared with the 
molecular characteristics of the UM. Tumors with GNAQ and GNA11 wildtype genotypes 
were detected in both the responders and the non-responders and could not distinguish 
the treatment groups. Monosomy 3 was however only detected in the responders while the 
non-responders all contained two copies of chromosome 3. This may indicate that a modifier 
of Src signaling is located on chromosome 3. 
We also determined Src and MAPK activation status in 36 UM samples obtained after enu-
cleation. A very strong correlation was detected between Src expression and ERK activation 
(pERK), supporting the notion that Src is associated with MAPK-driven UM proliferation 
and survival. Furthermore, we evaluated the possibility that Src upregulation and MAPK 
activation is due to somatic mutations in the heterotrimeric G protein alpha-subunit (GNAQ 
and GNA11) gene 10-13. GNAQ/GNA11 mutations are the first oncogenic mutations in UM and 
were shown to occur in about 78% of tested primary UM samples 9,10. In our UM cohort we 
detected an even higher abundance of GNAQ and GNA11 mutations (>90%) and hence we 
could not detect an association with Src mutation status and MAPK activation because a 







early event and underlines the importance of secondary lesions as possible determinants of 
metastatic disease and elevated Src/MAPK activation. 
Subsequent comparison of chromosome 3 status with Src and MAPK activation status in 
the primary tumors, and, in support of our in vitro analysis, revealed a significant association 
between Src expression and monosomy 3 (p= 0.0014). Src protein expression was approxi-
mately two-fold higher in monosomy 3 UM samples compared to disomy 3 UM samples. 
Monosomy 3 has been established as one of the most important molecular markers in UM 
patient survival and actually represents a late event in UM development 6,17,18. This association 
supports in vitro data that suggest the presence of a Src modifier on chromosome 3. Recently, 
somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) 
on chromosome 3p21.1 which was significantly associated with metastatic occurrence 8. BAP1 
has been shown to possess tumor suppressor activity and mutations have been reported in 
some forms of cancer 19,20. BAP1 mutation is a late event which may determine malignant 
conversion and should be analyzed for its role in Src/MAPK activation. 
Previously, we reported a decreased Src activation in metastatic cell lines compared to 
primary UM cell lines 13. However, in the same study residual Src activity was shown in UM 
metastasis tissue. Further analysis regarding the discrepancy between metastatic tissue and 
metastatic UM cell lines with regard to Src activity should be performed as loss of Src activity 
could be a potential cause of Dasatinib treatment resistance.
Uveal melanoma metastasizes almost exclusively to the liver and most current treatment 
options focus on this site 3. Currently, conventional metastasis treatment including (systemic 
or intra-hepatic) chemotherapy or partial hepatectomy, provides no significant prolonga-
tion of survival compared to no treatment 4. We propose the use of chromosome 3 status, 
ERK activation and Src kinase expression level of the primary UM and related metastases 
as a tool to select patients eligible for treatment with Dasatinib. In the future, prophylactic 
treatment of high risk patients could be an additional possibility hence biomarker analysis 
should be performed on both patients treated locally and patients treated with enucleation. 
Assessment of monosomy 3 by fine-needle-aspiration biopsy has been shown to be feasible 
in patients undergoing brachytherapy 21. However, biopsies would only be clinically relevant 
if successful treatment options for metastases patients would become available. 
In summary, we have shown that in selected UM, Dasatinib inhibits cell growth in vi-
tro. The UM cultures that respond to Dasatinib treatment, differ in MAPK and Src kinase 
activity compared to non-responding primary UM cultures. Moreover, with monosomy 3 
we may have revealed the underlying mechanism and hence we propose Dasatinib as a pos-
sible therapy for UM and we suggest monosomy 3, Src expression and MAPK activition as 
potential biomarkers for early adjuvant treatment.
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Summary and general discussion
Medical care of uveal melanoma has many aspects, as it involves treatment of the primary 
tumor, dealing with the complications of ocular radiation therapy, and the prevention and 
treatment of metastatic disease. In this thesis, I set out to analyze the efficacy and safety 
of some already available treatment modalities and subsequently explored new therapeutic 
options to reduce complications of current treatments and prolong survival.
It would be ideal if pre-clinical analysis in a laboratory setting (in vitro and in vivo) could 
be used to predict which treatment will have the best outcome. Knowledge of molecular 
mechanisms and pathways may allow efficient patient selection and help to prevent undesir-
able side effects.
In this discussion, I will first describe anti-angiogenic therapy and subsequently consider 
targeted therapy, which will be divided in cellular targeting and molecular targeting of tumor 
cells.
VEGF-regulated tumor angiogenesis in uveal melanoma
In general oncology, anti-angiogenic therapy has been explored extensively under the as-
sumption that a tumor cannot grow beyond the limits of oxygen and nutrient diffusion 
(about 1-2 mm), unless (tumor)angiogenesis occurs 1. Prevention of the formation of new 
vessels is expected to stop tumor growth. The clinical course of UM is often slow, implicating 
dormancy, which has been associated with an avascular phase. Change of this angiogenic 
phenotype, which is known as the ‘angiogenic switch’ and due to an alteration in the bal-
ance of inhibitory and stimulatory factors, may be associated with the induction of vessel 
growth and tumor proliferation 2,3. VEGF is an important pro-angiogenic factor which is 
produced by tumor as well as adjacent cells and regulates vasopermeability and proliferation 
and migration of endothelial cells 4. VEGF is especially upregulated in ischemic tumor areas 
due to Hypoxia-Inducible Factor (HIF)-1α stabilization 5. We therefore analyzed the regula-
tion of expression of VEGF in combination with the HIF-1α pathway in uveal melanoma 
cells in vitro (Chapter 4). Hypoxic conditions strongly induce VEGF mRNA expression in 
uveal melanoma cell lines and primary uveal melanoma cultures, although hypoxia did not 
increase cell proliferation. On the contrary, UM cell proliferation was significantly reduced 
under hypoxic conditions in comparison to UM cells in a normoxic environment. This indi-
cates that VEGF cannot independently increase uveal melanoma growth through a possible 
feedback loop. However, it is likely that VEGF induction may play a role in the development 
of new vessels.
In several tumors including colon carcinoma, soft tissue sarcomas and gastric cancer, se-
rum VEGF levels have been found to be an indicator of metastases 6-8. We therefore extended 
our analysis by determination of VEGF expression in primary UM in order to determine a 







of primary tumor tissue varied widely and did not predict survival nor was it correlated with 
the presence of bad prognostic factors. The importance of VEGF production was shown by 
testing serum from UM patients: we detected a significantly higher level of VEGF in sera 
of patients suffering from UM-related metastatic disease compared to UM patients without 
metastases and ‘healthy people’. This has been confirmed in subsequent clinical studies 9 and 
in an experimental UM metastatic mouse model 10. The high amounts of VEGF in the sera of 
patients with UM metastases suggest that VEGF plays a role in the growth of metastases, and 
the use of VEGF-inhibiting agents as treatment should therefore be considered. 
Pharmacologic effects of anti-angiogenic treatment in uveal melanoma
Anti-angiogenic treatment which mainly targets VEGF has been used in the treatment of 
colorectal, lung and renal cancer 11-13, rendering a possibility for uveal melanoma treatment 
(Chapter 2 and 3). We therefore analyzed the anti-melanoma effect of bevacizumab (Avas-
tin), the first approved monoclonal antibody against VEGF that has been used for treatment 
of metastases in colorectal cancer. When we injected bevacizumab intraocularly to treat a 
murine melanoma present in the anterior chamber, we, unexpectedly, found an acceleration 
of intraocular tumor growth (Chapter 5). In addition, following bevacizumab treatment, 
these anterior chamber tumors demonstrated more intraocular and intratumoral hemor-
rhages; however, no difference in vessel amount could be ascertained. In vitro treatment with 
bevacizumab stimulated expression of VEGF mRNA expression in murine melanoma as well 
as in human uveal melanoma cells. Combined, our in vivo/vitro results suggest that high 
VEGF levels caused tumor growth acceleration and hemorrhages by increasing vascular 
permeability 14. These ‘adverse’ effects of bevacizumab have been described before: in mice 
bearing intracerebral glioma, anti-VEGF treatment with pegaptanib (Macugen) increased 
GLUT-1 expression (a glucose transporter upregulated by HIF-1α similar to VEGF) 5. This 
‘pseudohypoxia’ has been shown to increase tumorigenesis in other types of cancer cells: 
anti-VEGFR treatment of mice bearing pancreatic neuroendocrine tumors resulted in an 
initial tumor stasis followed by tumor recurrence. The relapsing tumor expressed high levels 
of mRNAs for pro-angiogenic factors while demonstrating several hypoxic regions 15, and 
treated mice developed more invasive tumors and metastatic lesions 16. Bevacizumab has 
now been in clinical use since 2004 and treatment often prolongs overall survival of cancer 
patients by a few months, without really curing metastatic disease 17. However, the FDA has 
recently prohibited the use of bevacizumab (monotherapy) for metastatic breast cancer, since 
several studies have revealed that VEGF inhibitors eventually may promote tumorigenesis 
and metastatic dissemination in this malignancy 16,18. 
Ophthalmologists have been using bevacizumab for several indications, though not for the 
treatment of ocular tumors. Anti-VEGF treatment has been used in ocular diseases which are 
characterised by vessel leakage and neovascularisation, such as age-related macula degenera-
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tion and diabetic retinopathy. Regarding uveal melanoma, bevacizumab is frequently utilized 
for the treatment of radiation retinopathy. ‘Off-label’ use of intravitreal bevacizumab to treat 
macular edema and neovascularization in radiation retinopathy often demonstrates a decrease 
of macular edema and an improvement of visual acuity 19-21. Still, the use of VEGF inhibitors in 
uveal melanoma-bearing eyes should be considered carefully, since the possibility that there 
are living uveal melanoma cells in eyes treated with radiotherapy cannot be excluded 22,23: a 
possible effect on micrometastases which could be present in the eye or systemically has never 
been investigated. An alternative for treatment of radiation retinopathy consists of intraocular 
steroid injections. Triamcinolone acetonide (TA) is a glucocorticoid that has already been 
shown to exhibit a temporary positive effect in patients with radiation maculopathy 24. TA 25-27 
has been shown to have an anti-angiogenic effect, though the mechanism through which this 
effect comes about is not clear. We analyzed the effect of TA on UM cell growth and VEGF 
expression in vitro (Chapter 6). Our results show no apparent stimulating or inhibiting effect 
of TA on uveal melanoma cell proliferation or on VEGF mRNA and protein expression. One 
of the disadvantages of TA, however, is that it causes ocular hypertension in about 30% of the 
cases 28 and may lead to glaucomatous damage. A steroid-derived substance, anecortave acetate 
(AA), which is an angiostatic cortisone, has been developed to be devoid of corticosteroid 
side effects such as ocular hypertension. Hence, AA may be a good alternative to TA. A first 
study of AA administered in a juxtascleral depot to treat subfoveal choroidal neovasculariza-
tion in age-related macular degeneration showed good results in the prevention of further 
vessel development 29. In our experiments, AA did not induce cell proliferation or affect VEGF, 
pigment epithelium derived factor (PEDF; pro-angiogenic factor) or trombospondin-1 (TSP-1, 
anti-angiogenic factor) expression in vitro, similar to TA. In addition, AA has been found 
to significantly reduce tumor growth in intraocular tumor-bearing mice 30. Tumor inhibition 
was presumably due to the angiostatic properties of AA because the compound did not affect 
tumor cell proliferation in vitro as was confirmed in Chapter 6. It is therefore regrettable that 
AA is not a marketed drug. 
Anti-VEGF treatment is valuable in many ocular diseases. As tumor angiogenesis plays 
a role in uveal melanoma growth, it is probably also important in metastases, and systemic 
administration has been shown to reduce metastatic out growth in experimental models 
31. Studies are needed to determine the use of anti-VEGF drugs for single or combination 
therapy for prevention or treatment of metastases in UM patients.
Tumor-specific targeting
One of the main challenges in cancer treatment is selective and potent delivery of drugs to 
tumor cells. This motivated us to search for ligands that are selective for uveal melanoma. 
These ligands may be used as a diagnostic tool and/or used for targeted therapy of primary 
and (micro) metastatic uveal melanoma. Our first approach was to isolate uveal melanoma 







migrate to the diencephalon and to the uvea, where they give rise to pigmented melanocytes. 
Neural crest cells are able to produce neurohormones like somatostatin (SST). SST inhibits 
the release of growth hormone and thyroid-stimulating hormone by binding to specific G 
protein-coupled receptors 32. 
SST analogues, like octreotide and octreotate, can be radiolabelled and are currently being 
used in the diagnosis and therapy of patients suffering from SSTR-expressing tumors 33-36. 
In Chapter 9, expression of SSTR2 on uveal melanoma cell lines was analysed by autoradi-
ography using radio labelled-ocreotate. Cell lines created from primary UM cells showed 
very low or no receptor-specific binding. By contrast, cell lines obtained from metastatic 
melanoma cells showed high binding. In addition, a two- to four-times higher mRNA ex-
pression level of SSTR2 was demonstrated in metastatic cells compared to primary UM cells. 
These result implicate a possible association between SSTR2 expression and UM malignancy. 
Unfortunately, analysis of primary UM tissue revealed an overall low expression level of 
SSTR2, and no association with known histologic and genetic prognostic markers or with 
survival. We therefore conclude that SSTR is not a valuable tool to further investigate for use 
in uveal melanoma. 
As an alternative approach to select uveal melanoma selective peptides, we subsequently 
used phage peptide libraries. Phage display is a powerful technique for the isolation of pep-
tides that bind to a particular target with high affinity and specificity. In contrast to larger 
molecules, such as proteins and antibodies, small peptides can efficiently penetrate tissues 
and are relatively easy to synthesize. Several studies describe the successful detection of 
organ and tumor-specific peptides using phage peptide libraries 37,38. Using phage display, 
Howell et al. identified heptapeptides that specifically bound to human tumor melanin, as 
demonstrated in nude mice that carried human metastatic melanoma tissue. These hepta-
peptides could be used as a tool in targeted therapy for (metastatic) melanoma 39. In Chapter 
8 we describe the identification of uveal melanoma associated peptides (UMAPs). In the 
future, these UMAPs may be used clinically for in vivo imaging of micro metastases. It has 
been proposed that patients who develop clinical metastases from uveal melanoma often 
harbour micro metastasis for years 40. UMAPs radiolabelled with radionuclides could be 
used in scintigraphy to detect such micro metastases. In addition, the same peptides labeled 
with therapeutic β-emitting radionuclides, may be used in targeted therapy and prevent or 
decelerate the occurrence of ‘full-blown’ metastatic disease.
In our study, UMAP1 proved to show excellent internalisation ability in primary and 
metastatic UM cell lines. This peptide was also internalized by normal melanocytes due to 
the lack of a negative selection with normal melanocytes. Other control cells such as SAOSH 
and HUVEC cells did not internalise UMAP1, demonstrating a partial selectivity. 
UMAP2 showed a strong preference for metastatic cell line OMM2.5 and the sequence of 
UMAP2 has been identified as a homologue of the rat insulin-like growth factor receptor 
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41. Interestingly, Economou et al demonstrated the expression of insulin growth factor-1 
receptor (IGF-1R) in uveal melanoma to be associated with a bad prognosis 42-44. Besides 
representing an opportunity for targeting UM cells, UMAP2 may be used to study the 
mechanisms that are involved in proliferation and progression; for instance IGF-1R signaling 
couples to MAPK signaling that is responsible for proliferation and survival signaling. The 
lack of tumor-specificity of the UMAPs that we identified made us focus on other targeted 
therapies.
Oncogenic pathways involved in uveal melanoma and treatment options
The RAS-RAF-MEK-ERK, or classical mitogen-activated protein kinase (MAPK) pathway, 
is essential in the development of melanocytic neoplasia and constitutive activation of this 
pathway has been associated with many different types of cancer 45,46. Knowledge of these 
pathways and the molecular mechanisms that underlay aberrant signaling is required to 
predict treatment efficacy and/or failure. Recently, mutations have been discovered in the 
GNAQ and GNA11 gene, which encode Gαq-type subunits of the heterotrimeric G-protein. 
These mutations occur in 77 % of uveal melanomas 47,48, and result in constitutive G-protein 
activation which mediates intracellular signals and activates the MAPK pathway 49. This 
discovery has created a great interest in these pathways, as interference may be used thera-
peutically. 
A molecule that links GNAQ/GNA11 to MAPK signaling as well as IGF-1R signaling is Src 
tyrosine kinase 50. We identified Src as a crucial upstream tyrosine kinase, based on analysis 
of several UM cell lines which revealed ERK1/2 activation in primary UM cell lines (Chapter 
9). 
In addition, metastatic tissue displayed considerable Src kinase activity, most likely resem-
bling the in vivo condition (Chapter 9). Src kinase was efficiently inhibited by incubation 
with Dasatinib. In Chapter 10, we further analyze the Src and MAPK activation in primary 
uveal melanoma. Using primary UM cell lines, we observed that Src is associated with the 
MAPK pathway resulting in UM proliferation and survival, and this was confirmed by a 
significant correlation between Src/ERK expression levels and ERK activation (pERK). In ad-
dition, we evaluated the possibility of Src upregulation and MAPK activation due to GNAQ/
GNA11 mutations. In our primary UM samples we detected a high occurrence of GNAQ and 
GNA11 mutations (>90%) but no association with Src and MAPK activation. The mutation 
of these genes in UM development appears to be an early event and indicates the importance 
of secondary lesions as possible triggers of elevated Src and MAPK activation. We further 
analyzed whether there was an association with the presence of monosomy 3, which is one of 
the most important prognostic markers in UM patient survival and may actually represent a 
late event in UM development 51-53. In agreement, we did find a significant association between 
Src expression and monosomy 3. Based on the apparently pivotal role of Src in MAPK-driven 







tion of cell growth in 60% of UM cell cultures treated with dasatinib; a commercially available 
tyrosine kinase inhibitor of the src-family kinase. Further analysis revealed that basale Src 
kinase activity and ex vivo reduction after incubation with Dasatinib was much higher in the 
sensitive cultures in contrast to the non-responding cells. In addition, all three non-responders 
displayed a normal chromosome 3 karyogram whereas three out of five responders displayed 
monosomy 3. Based on this pre-clinical evaluation, optimal treatment selection should include 
evaluation of primary and metastastic tumor tissue for basal Src kinase activity of the cells and 
testing ex vivo cultured cells for reduction of expression of kinase activity after incubation with 
specific drugs, using for example kinase arrays. In addition, determination of chromosome 3 
status could be of value, but this remains to be ascertained by others as well. Tyrosine kinase 
inhibitors, such as Dasatinib, are interesting due to their ability to target multiple kinases 
and therefore have a wide application in several different malignancies. Unfortunately, this 
promiscuous nature may also cause “off-target” effects demonstrated in several clinical trials 
54,55. Tumor cell targeting with specific ligands and of specific cellular components, such as Src, 
which play an important role in uveal melanoma tumorigenesis may provide new treatment 
options and reduce adverse side effects.
Conclusion and future prospects
UM is a disease with many faces: ophthalmologists treat the primary tumor, but the patient 
faces the problem of developing metastases, which are often deadly after a short period. 
Collaboration with geneticists, biochemists, and oncologists is of the greatest importance to 
develop an effective approach to prevent or treat metastases. Recent insight, as described in 
this thesis, indicates the need for knowledge-based treatment of UM. The ‘pseudohypoxic’ 
and tumor promoting effects of bevacizumab as described in this thesis is especially relevant. 
Bevacizumab is frequently used off-label to treat macular edema in UM patients suffering of 
radiation retinopathy, without the knowledge of possible effect on still viable UM cells. The 
FDA has recently prohibited the use of bevacizumab (monotherapy) for metastatic breast 
cancer, and future (clinical) experiments should be performed to establish the clinical safety 
in case of UM.
We further observed that specific peptides, such as UMAP1, which can successfully be 
internalized by targeted UM cells, have demonstrated potential for UM-targeted treatment. 
These peptides have to be investigated in vivo, to ascertain whether they are a viable clinical 
tool. Labeling the peptides with radionuclides, and demonstrating specificity for UM cells 
are some of the challenges which have to be overcome. Another aspect in the patient-specific 
treatment of UM is the in vitro analysis of primary UM samples to predict treatment re-
sponses. In case of Dasatinib, we describe treatment responses associated with monosomy 
3 and ‘kinase’ activity in different primary UM samples. In vitro and ex-vivo pre-clinical 
analysis in association with genetic testing for specific gene mutations will be of future 
relevance. 
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De medische zorg van oogmelanomen kent vele aspecten; behandeling van de primaire tu-
mor, het omgaan met de complicaties van radiotherapie, en de preventie en behandeling van 
metastasen. In dit proefschrift is gezocht naar de werking en veiligheid van een aantal reeds 
beschikbare behandelmethoden. Ook zijn nieuwe therapeutische mogelijkheden onderzocht 
om complicaties van de huidige behandelingen te verminderen en de overleving van patiën-
ten te verbeteren. Dit proefschrift beschrijft het mechanisme van tumor vaatnieuwvorming 
in oogmelanomen en de effecten van de behandeling die dit tegen moet gaan. Verder wordt 
er ingegaan op de mogelijkheden om oogmelanomen op cel en moleculair niveau te behan-
delen. 
Behandeling van tumor vaatnieuwvorming in oogmelanomen
Het remmen van tumor vaatnieuwvorming is uitgebreid onderzocht als mogelijke therapie 
voor kanker met de vooronderstelling dat tumorgroei beperkt wordt door diffusie van 
zuurstof en voedingsstoffen. Het remmen van vaatnieuwvorming zal naar verwachting de 
groei van tumoren stoppen. Het klinische verloop van oogmelanomen is vaak traag en wordt 
in verband gebracht met een vaatarme groeifase. VEGF is een belangrijke vaatgroei factor, 
die wordt geproduceerd door de tumor en aangrenzende cellen. VEGF is vooral aanwezig 
in zuurstof arme gebieden en daarom onderzochten we de regulatie van VEGF expressie 
in oogmelanoom cellen (Hoofdstuk 4). Onder zuurstofarme omstandigheden neemt VEGF 
expressie toe en de tumorgroei neemt af. 
In een aantal tumoren waaronder darmkanker en maagkanker, zijn VEGF niveaus in het 
bloed een goede indicator van de aanwezigheid van uitzaaiingen. En ook in het oogmela-
noom is VEGF in het bloed van patiënten die lijden aan uitzaaiingen aanzienlijk verhoogd in 
vergelijking met patiënten zonder uitzaaiingen en ‘gezonde mensen’. De grote hoeveelheden 
VEGF in het bloed van patiënten met uitzaaiingen suggereert dat VEGF een rol speelt in de 
groei van metastasen, en het gebruik van VEGF-remmende middelen als behandeling moet 
daarom worden overwogen.
Hoofdstuk 3 beschrijft het effect van een VEGF neutraliserend antilichaam (Avastin; beva-
cizumab ) op oogmelanomen. In een diermodel vonden we, geheel onverwacht, een versnel-
ling van de intraoculaire tumorgroei na behandeling met bevacizumab, en dit ging gepaard 
met bloedingen van de tumor (Hoofdstuk 5). Mogelijk dat de paradoxale VEGF verhoging 
die we in oogmelanoom cellen zien na bevacizumab behandeling, tumor vaatdoorlaatbaar-
heid en daarmee tumorgroei, verhoogt. Deze ‘ongewenste’ effecten van bevacizumab zijn al 
eerder beschreven en de FDA heeft onlangs het gebruik van bevacizumab (monotherapie) 
voor gemetastaseerde borstkanker verboden, omdat diverse studies hebben aangetoond dat 









Onderwijl gebruiken oogartsen bevacizumab voor verschillende indicaties, maar niet 
voor de behandeling van oculaire tumoren. Anti-VEGF behandeling wordt gebruikt bij 
oogaandoeningen die worden gekenmerkt door vaatlekkage en vaatnieuwvorming zoals 
leeftijds- gerelateerde macula degeneratie en diabetische retinopathie. Bij oogmelanomen 
kan bevacizumab gebruikt worden voor de behandeling van bestralingsretinopathie. Toch 
moet het gebruik van VEGF-remmers in ogen behandeld voor een oogmelanoom zorgvul-
dig worden afgewogen, omdat de mogelijkheid dat er nog levende oogmelanoomcellen in 
het oog aanwezig zijn, niet kan worden uitgesloten. Een alternatief voor de behandeling van 
bestralingsretinopathie bestaat uit intraoculaire corticosteroïdinjecties. Triamcinolonaceto-
nide (TA) is een glucocorticoïd dat een tijdelijk positief effect vertoont bij patiënten met 
bestralingsmaculopathie. Onze resultaten tonen aan dat er geen stimulerend of remmend 
effect van TA op oogmelanoom celproliferatie of op VEGF expressie is (Hoofdstuk 6). Één 
van de nadelen van TA, echter, is dat het oogdrukstijging veroorzaakt in ongeveer 30% van 
de gevallen en kan leiden tot glaucomateuze schade. Een afgeleide stof, anecortave acetaat 
(AA), is ontwikkeld om de bijwerkingen zoals oculaire hypertensie te verminderen. In onze 
experimenten geeft AA vergelijkbare resultaten als met TA (Hoofdstuk 6 ). 
Anti-VEGF behandeling is waardevol in vele oogziekten. Als tumor vaatnieuwvorming 
een rol speelt in oogmelanoom groei, is het waarschijnlijk ook belangrijk in metastasen, en 
systemische toediening heeft aangetoond dat de groei van uitzaaiingen in experimentele mo-
dellen verminderd. Studies zijn nodig om een mogelijke rol voor het gebruik van anti-VEGF 
geneesmiddelen bij de preventie of behandeling van uitzaaiingen in de oogmelanoompati-
enten te bepalen.
Tumor specifieke peptiden 
Één van de belangrijkste uitdagingen in de behandeling van kanker is selectieve en effectieve 
aflevering van geneesmiddelen aan tumorcellen. Oogmelanoom specifieke peptiden kun-
nen worden gebruikt als een diagnostisch hulpmiddel of voor een gerichte behandeling. In 
tegenstelling tot grotere moleculen, zoals eiwitten en antistoffen, kunnen kleine peptiden 
efficiënt weefsels penetreren en zijn relatief makkelijk te synthetiseren.
Oogmelanoom-selectieve peptiden kunnen op basis van embryonale oorsprong veronder-
steld worden. SSTR2 wordt geexpresseerd door cellen uit de neurale lijst waartoe oogmela-
nocyten ook behoren en in Hoofdstuk 7, is de expressie van SSTR2 op oogmelanoom cellen 
geanalyseerd. Oogmelanoom cellen vertoonden een zeer lage SSTR2 expressie en daardoor, 
nauwelijks receptor-specifieke binding door het bijbehorende hormoon, terwijl cellen van 
oogmelanoom uitgezaaiingen een hoge expressie en hormoonbinding vertoonden. Dit 
suggereert een mogelijk verband tussen SSTR2 expressie en oogmelanoom progressie. Uit 
analyse van klinische en moleculaire kenmerken bleek echter geen relatie met uitzaaiingen. 
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Een andere benadering om tumorspecifieke peptiden te identificeren is door random 
peptiden te screenen voor oogmelanoom penetrerend vermogen. In Hoofdstuk 8 wordt de 
identificatie van oogmelanoom geassocieerde peptiden (UMAPs) beschreven. In de toe-
komst kunnen deze UMAPs klinisch gebruikt worden om micro-uitzaaiingen op te sporen. 
Daarnaast kunnen dezelfde peptiden worden gebruikt in gerichte therapie om metastasen te 
voorkomen danwel te vertragen. Of deze peptiden klinisch gebruikt kunnen gaan worden is 
afhankelijk van de specificiteit waarmee oogmelanomen gedetecteerd en behandeld kunnen 
worden. Voorlopige analyse op cellen laat een beperkte mate van specificiteit zien maar al-
leen analyse in een diermodel kan hier uitsluitsel over geven. 
UMAP2 vertoonde een sterke voorkeur voor de cellen van het gemetastaseerde oog-
melanoom. De sequentie van UMAP2 werd geïdentificeerd als een homoloog van de rat 
‘ insulin-like growth factor receptor’ (IGF-1R) waarvan al aangetoond is dat de expressie 
in oogmelanomen geassocieerd is met uitzaaiingen. IGF-1R is bovendien betrokken bij 
tumorgroei; IGFR signalering verloopt via de mitogeen-activated protein kinase (MAPK) 
route. UMAP2 is daarmee ook uitermate geschikt om de mechanismen die betrokken zijn 
bij celgroei en tumorprogressie te bestuderen. 
Tumor signalen en behandelingopties
Activering van de RAS-RAF-MEK-ERK, of klassieke mitogeen-activated protein kinase 
(MAPK) route, is in verband gebracht met melanomen en vele andere soorten kanker. Ken-
nis van deze route en de moleculaire mechanismen die ten grondslag liggen aan activering 
van deze route is nodig om de werkzaamheid van behandelingen te voorspellen. Voor oog-
melanomen worden mutaties in het GNAQ en GNA11-gen verantwoordelijk gehouden voor 
MAPK activering en deze mutaties komen voor in een overgrote meerderheid. Src kinase 
is een mogelijk tussenstation voor mutaties en MAPK activering. In Hoofdstuk 9 wordt de 
rol van Src bij oogmelanoom beschreven en hoe dit samenhangt met tumorgroei. Op basis 
van de belangrijke rol van Src in de MAPK proliferatie, is remming van Src overwogen als 
behandeloptie. Het commercieel beschikbare Dasatinib, een tyrosine kinase remmer van 
de Src-kinase familie, kan de oogmelanoom celgroei inhiberen in 60% van de geteste cel-
culturen (Hoofdstuk 10). Verdere analyse wees uit dat basale Src kinase-activiteit en verlies 
van chromosoom 3 voorspellend zijn voor het behandelingseffect. Tyrosine kinase-remmers, 
zoals Dasatinib, zijn interessant vanwege hun vermogen om op meerdere kinasen gericht 
te zijn en hebben dus een brede toepassing in verschillende maligniteiten. Helaas kan dit 
ook leiden tot “off-target”-effecten aangetoond in verschillende klinische studies. Tumorcel 
'targeting' met specifieke liganden tegen specifieke cellulaire componenten, zoals Src, die een 
belangrijke rol speelt bij oogmelanomen, bieden nieuwe behandelingsmogelijkheden en de 
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